PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Free Radic Biol Med. Author manuscript; available in PMC 2010 June 15.
Published in final edited form as:
PMCID: PMC2797369
NIHMSID: NIHMS147427

Oxidative Risk for Atherothrombotic Cardiovascular Disease

Jane A. Leopold, M.D. and Joseph Loscalzo, M.D., Ph. D.

Abstract

In the vasculature, reactive oxidant species including reactive oxygen, nitrogen, or halogenating species, and thiyl, tyrosyl, or protein radicals, may oxidatively modify lipids and proteins with deleterious consequences for vascular function. These biologically active free radical and non-radical species may be produced by increased activation of oxidant-generating sources and/or decreased cellular antioxidant capacity. Once formed, these species may engage in reactions to yield more potent oxidants that promote transition of the homeostatic vascular phenotype to a pathobiological state that is permissive for atherothrombogenesis. This dysfunctional vasculature is characterized by lipid peroxidation and aberrant lipid deposition, inflammation, immune cell activation, platelet activation, thrombus formation, and disturbed hemodynamic flow. Each of these pathobiological states is associated with an increase in the vascular burden of free radical species-derived oxidation products and, thereby, implicates increased oxidant stress in the pathogenesis of atherothrombotic vascular disease.

Keywords: Reactive oxidant species, oxidant stress, antioxidant enzymes, oxLDL, HDL, atherosclerosis, shear stress, immunomodulation

Introduction

Atherosclerosis and its attendant morbidity and mortality remain a global health issue with more than 17.5 million worldwide deaths attributable to the cardiovascular complications of this disease [1]. The common risk factors for developing atherosclerotic cardiovascular disease, hyperlipidemia, hypertension, tobacco use, diabetes mellitus, and family history, alone or in combination, are associated with a pathophysiological vascular phenotype. As such, the dysfunctional vasculature becomes susceptible to lipid deposition, thrombus formation, immune cell infiltration, inflammation, and aberrant hemodynamic profiles. At a mechanistic level, a number of hypotheses have been advanced to unite these features; central to these theories is the tenet that increased oxidant stress perturbs vascular homeostasis to promote atherogenesis.

The importance of oxidant stress in atherothrombotic cardiovascular disease is highlighted by the observation that increased markers of oxidant stress have been shown to predict coronary heart disease. The F2-isoprostanes, formed by the free-radical catalyzed peroxidation of phospholipid-bound arachidonic acid and released into the circulation, are considered reliable markers of oxidant stress [24]. Elevated levels of F2-isoprostanes have been detected in patients with coronary heart disease risk factors, including hyperlipidemia, diabetes mellitus, hypertension, tobacco use, and obesity [59]. Furthermore, levels of both urinary and plasma F2-isoprostane have been shown to correlate with the number of coronary artery disease risk factors present [10, 11]. In a matched case-control study of 93 coronary heart disease patients and 93 control subjects, urinary F2-isoprostane levels were elevated in patients compared to control subjects (139 vs. 77 pmol/mmol creatinine, p<0.001), and multivariate analysis revealed that individuals with F2-isoprostane levels in the highest tertile had a 30.8-fold increased risk of coronary heart disease [10]. In a similar case-control study of 50 patients with angiographically significant epicardial coronary artery disease compared with 54 patients with insignificant atherosclerosis, plasma levels of F2-isoprostanes were increased significantly in patients with coronary artery disease (9.4 ± 4.6 vs. 6.2 ± 3.4 µmol/mol arachidonate, p<0.001). Multivariable analysis adjusted for Framingham Risk Score revealed that F2-isoprostane levels remained an independent predictor of angiographic coronary artery disease risk (OR = 9.7, 95% CI: 2.6 – 36.9, p=0.016) [12]. Interestingly, the methodology used in this study allowed for the simultaneous measure of specific fatty acid oxidation products, including individual hydroxy-octadecadienoic acids (HODEs) and hydroxy-eicosatetraenoic acids (HETEs). Measures of these markers revealed no significant difference between cases and controls with respect to 9-HODE and 13-HODE levels; however, there was a significant increase in 9-HETE in patients with coronary artery disease (8.7 ± 3.9 vs. 6.8 ± 3.6 µmol/mol arachidonate, p=0.011), and 9-HETE levels were also shown to predict angiographic disease (OR = 4.8, 95% CI: 1.3 – 17.1, p=0.016) [12].

Nitrated protein tyrosine residues also predict coronary heart disease risk. In a case-control study of patients with coronary artery disease, nitrotyrosine levels were found to be significantly higher in patients with coronary artery disease than in controls (9.1 vs. 5.2 µmol/mol tyrosine, p<0.001), and individuals with the nitrotyrosine levels in the highest quartile were found to have an increased risk of disease (OR = 6.1, 95% CI: 2.6 – 14.0, p<0.001), even after adjustment for Framingham Risk Score (OR = 5.4, 95% CI: 2.0–14.3, p<0.001) [13]. Baseline serum levels of lipid hydroperoxides were also found to be an independent predictor for the development of major adverse cardiovascular events in a study of 634 individuals followed over three years (HR = 2.23, 95% CI for relative risk; 1.44–3.44, p<0.0003) [14]. Thus, atherosclerosis and the risk for developing disease are associated with increases in several indices of systemic oxidant stress; however, it should be recognized that these studies merely define a correlation between indices of oxidant stress and atherothrombotic vascular disease and do not establish oxidant stress as a causative determinant for atherosclerosis.

Oxidant stress broadly defines the redox state achieved when there is an imbalance between antioxidant capacity and reactive oxidant species (ROS), such as reactive oxygen, nitrogen, or halogenating species, and free radical species such as thiyl, tyrosyl, or protein radicals. Within the cell, ambient levels of some ROS are utilized as signaling molecules to maintain basal cellular functions. In contrast, when reactive oxidants and free radicals are generated in the absence of a physiological stimulus, small molecule antioxidants are depleted, or antioxidant enzymatic systems are overwhelmed, there is a net increase in biologically active ROS and oxidant stress ensues. In blood vessels, oxidant stress has deleterious consequences for basal vascular function that have been associated with atherosclerosis. It is, therefore, not surprising that the cellular mechanisms that result in vascular redox imbalance leading to an increase in oxidant stress have been implicated in the pathogenesis of atherothrombosis.

Oxygen-derived radicals

In biological systems, a diverse array of free radical and non-radical reactive species may be generated, which, under pro-atherogenic conditions, may lead to lipid and protein modification to accelerate the disease process. Basal oxidative cellular metabolism, through the activation of enzymes that produce superoxide anion (O2•−) and/or as a byproduct of mitochondrial respiration, generate a number of oxygen-derived free radical species of importance to atherogenesis.

Superoxide anion is a one-electron reduced product of molecular oxygen that may be protonated to form a hydroperoxyl radical (HOO: pKa = 4.69 for HOO [left arrow over right arrow] O2•− + H+) [15]. Hydroperoxyl radicals have been shown to initiate lipid peroxidation in the absence of free transition metal ions as demonstrated in EtOH/H2O-fatty acid dispersions by the abstraction of a bis-allylic H from polyunsaturated fatty acids [16, 17]. Using a stopped flow technique, the rate constants for the reaction of HOO and linoleic, linolenic, and arachidonic acids were found to be 1.2 × 103 M−1s−1, 1.8 × 103 M−1s−1, and 3.0 × 103 M−1s−1, respectively [18]. Superoxide may spontaneously dismutate to oxygen and the nonradical oxidant hydrogen peroxide (H2O2) in aqueous environments at a rate of ~2 × 105 M−1s−1 at pH 7.4 or undergo enzymatical dismutation by the superoxide dismutases (SOD), which at physiological pH, increase the reaction rate over the spontaneous dismutation of O2•− ~10,000-fold [1922].

Superoxide may react with other free radicals such as nitric oxide (NO) to form peroxynitrite anion (ONOO), or react with non-radical derivatives by abstracting H from a −C-H, −O-H, or −S-H moiety that exists in the non-radical species. These reactions typically involve low-molecular-weight antioxidants and enzyme cofactors, nucleic acids, lipids, proteins, and sugars [2326]. At neutral pH, O2•− may also oxidize [4Fe-4S] clusters in enzymes to release Fe(II) allowing for the reduction of H2O2 to form a hydroxyl radical (OH) through Fenton chemistry [2729]. The OH is a potent oxidant [E0’ (OH, e/H2O) = 2.31 V, vs. NHE at pH 7.0] that reacts with organic compounds at a diffusion-limited rate (k = ~108–1010 M−1s−1); samples of the lipid-rich core of atherosclerotic lesions obtained at autopsy confirmed that these specimens were able to generate OH in the presence of H2O2 and ascorbate [3032].

Reactions between these oxygen-derived free radicals and non-radical species may also participate in chain reactions as occurs with lipid peroxidation. Here, a free radical such as OH will abstract H from a carbon of a fatty acyl side chain leaving the remaining carbon radical accessible to molecular oxygen to form a lipid peroxyl radical (LOO). This newly generated LOO is itself highly reactive and propagates the chain reaction by reacting with nearby lipid moieties (L-H) to yield L and LOOH; the newly generated L, in turn, reacts with molecular oxygen to yield another LOO and propagate the chain reaction [18].

Lipid peroxidation may also be initiated by ONOO. Studies performed with soybean phosphatyidylcholine liposomes incubated with ONOO demonstrated malondialdehyde and conjugated diene formation that was not dependent upon Fe2+/Fe3+ to initiate or enhance lipid peroxidation [33]. Further study with human low-density lipoproteins (LDL) exposed to the ONOO (0.125 – 1 mmol/L) or the ONOO-generating agent sydnonimine (0.5 or 1 mmol/L) revealed that ONOO promoted lipid peroxidation, increased the formation of F2-isoprostanes, and converted the lipoproteins to more negatively charged forms [34, 35].

Nitric oxide-derived radicals

Nitric oxide is a heterodiatomic free radical that is a key determinant of vascular homeostasis. In the vasculature, NO-derived reactive nitrogen species react with aromatic amino acids, lipids, and thiols resulting in lipid and protein modification [3640]. The terminal oxidation product of NO is nitrite (NO2), formed in a series of reactions that generates the intermediate N2O3, a mild oxidant [calculated E0’ (N2O3/NO, NO2) = 0.8 V, vs. NHE at pH 7.0] which nitrosates thiols and other nucleophiles [4144] Nitric oxide also reacts with oxygen (autooxidation) to form nitrogen dioxide (NO2); the kinetics of NO2 formation are second order with respect to NO and first order with respect to oxygen (k = 7 × 106 M−2s−1), indicating that oxidation of NO is strongly dependent upon its concentration [4447]. In addition, head space gas analysis of helium-swept reaction mixtures has also demonstrated that NO2 may be formed by leukocyte peroxidases utilizing H2O2 and NO2 as substrates [48]. Nitrogen dioxide is a highly reactive species, and has been shown to abstract hydrogen atoms from unsaturated lipids, as well as participate in addition and abstraction reactions with cyclohexane, methyl oleate, linoleate, and linolenate [4952].

The reaction of NO with O2•− occurs in a nearly diffusion-limited manner (k = 6.7 × 109 M−1s−1) to yield ONOO [53]. Peroxynitrite may be protonated to form peroxynitrous acid (ONOOH), which has a pKa ~ 6.8 and may account for up to approximately 20% of total ONOO at physiological pH [54, 55]. In the trans-configuration, ONOOH is a highly reactive and strong oxidizing species; however, ONOOH undergoes rapid homolytic cleavage with a half-life of 1.9 sec at pH 7.4 to yield NO2 and OH, which participate in oxidation, nitrosation, and nitration reactions [56, 57]. Peroxynitrite also reacts readily with CO2 to generate a nitrosoperoxycarbonate anion adduct (ONOOCO2) that is unstable and rearranges to form a nitrocarbonate anion or generates NO2 and carbonate anion as a pair of caged radicals that may escape the solvent cage as free radicals. Nitrocarbonate anion, in turn, may undergo hydrolysis to yield nitrate (NO3) and carbonate [58]. As the concentration of plasma CO2 is high (~ 1.3 mM), the reaction rate of CO2 with ONOO is approximately 60-fold faster than that of the reaction of ONOO with thiols [58, 59]. The reaction between ONOO and either O2•− or NO has been suggested to be thermodynamically feasible with a calculated Gibbs free energy [ΔrxnG°’ (kcal/mol)] of −36 and −27, respectively, for the reaction at pH 7.0 and 25°C [54, 60]. Evidence also suggests that O2•− or NO-mediated consumption of ONOO may be indirect and a consequence of the reaction of the ONOOH homolytic cleavage products NO2 and OH with NO leading to the formation of N2O3 and HNO2, respectively, and with O2•− to yield O2NOO, and OH and O2, respectively [61]. Peroxynitric acid (HO2NOO/O2NOO) is unstable and decomposes to HO2 and NO2 with NO2 reacting with itself in water to form NO2, NO3, and H+ [62]. Peroxynitrite may also react with H2O2 to form NO2 and H2O [63].

Nitric oxide may also react with other peroxyl radicals react to form lipid peroxynitrite compounds (LOONO) in reactions that are near diffusion-limited (k = 1 – 3 × 109 M−1s−1) [37, 64]. Experimental evidence also indicates that NO may react with H2O2 to generate OH; however, in this study it was not determined if NO reacted directly with H2O2 or if an intermediate yielded OH by homolysis [65]. In aqueous solutions, NO may also react with OH itself at a diffusion-controlled rate (k = 1 × 1010 M−1s−1) to generate HNO2 [66].

Reactions between NO-derived radical species and proteins or lipids lead to post-translational modification(s) that influence function and have been associated with atherosclerosis [6770]. In particular, the presence of 3-nitrotyrosine is evidence of reactive nitrogen species-mediated modifications that occur under conditions of oxidant stress. Tyrosine nitration may occur via the addition of NO2 to a tyrosyl radical; the reaction between NO and a tyrosyl radical to form 3-nitrosotyrosine, which is oxidized via the intermediacy of an iminoxyl radical to yield 3-nitrotyrosine; and/or by the addition of a nitrating species similar to NO2+ to the aromatic ring of tyrosyl residues [71]. Early studies using monoclonal and polyclonal antibodies revealed extensive 3- nitrotyrosine immunostaining and protein tyrosine nitration in fatty streaks in coronary arteries of young subjects at autopsy and in human atherosclerotic plaques [72]. Later studies using gas chromatography/mass spectrometry analysis of LDL isolated from human atherosclerotic lesions revealed that 3-nitrotyrosine levels were 90-fold greater than that observed in human plasma LDL [73]. Following these seminal studies, 3-nitrotyrosine formation has been detected in human macrophages and vascular smooth muscle cells of excised carotid plaques [74]; in atherosclerotic human coronary artery or peripheral arterial vessels [75]; in high-density lipoproteins (HDL) isolated from human atherosclerotic intima [76]; in plasma from patients with abdominal aortic aneurysms [77]; and in plasma from patients with ischemic stroke [78]. While ONOO was initially believed to be the sole source of protein tyrosine nitration and 3-nitrotyrosine formation in vivo, it is now recognized that 3-nitrotyrosine may be formed as a result of neutrophil myeloperoxidase (MPO)-mediated oxidation of NO2 to NO2, peroxidase(s) or heme/hemoprotein-catalyzed reactions/Fenton chemistry, and/or MPO-generated hypochlorous acid (HOCl)-induced generation of nitryl chloride (ClNO2) [3739].

Unsaturated fatty acids react with NO-derived species via the addition of NO2 across the double bond to generate carbon-centered radical species known as nitro-fatty acids [64, 79]. Although nitro-fatty acids have been detected in plasma, urine, and tissues from healthy and hypercholesterolemic individuals, the exact mechanism by which nitration of fatty acids occurs in vivo remains unknown [7981]. It has been suggested that nitration may occur via NO2 reacting with unsaturated lipids or LOO to yield lipid derivatives that are of the nitro-allylic, nitroalkene, dinitro, or nitro-hydroxy forms [49, 82]; peroxidase-mediated or Fenton-induced oxidation of NO2 to NO2 [48, 68, 83]; interaction with ONOO or ONOOH via oxidation, nitrosation, or nitration reactions; and/or electrophilic addition reactions with NO2+ [84, 85]. Nitrated lipids, such as nitroalkenes, may undergo aqueous decay and release NO (independent of thiols), isomerize to a nitrite ester with N-O bond cleavage, or undergo one-electron reduction to generate an enol group and NO [86, 87]. Nitroalkenes may also participate in Michael addition reactions with cysteine and histidine residues in proteins and with the thiolate anion of glutathione (GSH) to initiate reversible post-translational modification(s) of proteins [88, 89].

In vivo, nitroalkene and nitrohydroxy nitro-fatty acids are the predominant species formed [90]. In plasma, following the administration of the exogenous nitro-fatty acid, nitro-9-cis-octadecenoic acid, it was found that this nitro-fatty acid was adducted rapidly to GSH or thiol-containing proteins, underwent reversible release from GSH, and after 90 minutes was predominantly localized to the muscle and liver compartments [91]. These nitro-fatty acids have been shown to mediate a number of inflammatory and vascular cell signaling processes [79, 92, 93]. Although nitro-fatty acids, such as nitrolinoleic acid (LNO2) and nitro-hydroxy arachidonic acid derivatives, induce NO-dependent guanylyl cyclase-mediated vasodilation, other biological actions attributed to nitro-fatty acids do not result from activation of this signaling pathway and have been attributed, in part, to activation of PPAR-γ and inhibition of NF-kB [81, 86, 9294]. Nitrolinoleic acid and nitrated oleic acid inhibit neutrophil activation, O2•− synthesis, and degranulation by limiting proinflammatory STAT signaling [95, 96]. Nitroarachidonic acid has also been shown to limit the deleterious effects of macrophage activation by decreasing transcription and expression of the inducible form of nitric oxide synthase (iNOS) in an NO-independent manner [97]. Leukocyte recruitment and adhesion to the vessel wall are also inhibited by LNO2, which decreases CD11b and vascular cell adhesion molecule-1 (VCAM-1) expression [92, 95]. Platelet function is modulated by nitro-fatty acids, and LNO2 has been shown to decrease thrombin-induced aggregation by increasing platelet cAMP levels [98]. Interestingly, LNO2 has been shown to exert some of its vasoprotective effects via upregulation of the antioxidant enzyme heme oxygenase-1 (HO-1) mRNA and protein levels in both an NO-dependent and -independent manner; the NO-independent effects result from activation of the ERK pathway and eIF2α to increase transcription and translation [99, 100]. Nitrolinoleic acid also inhibits vascular smooth muscle cell proliferation by enhancing nuclear translocation of the transcription factor Nrf2 [101]. Thus, nitro-fatty acids represent a novel class of endogenous mediators with vasoprotective effects that are generated by lipid nitration under pathophysiological hypoxic or ischemic conditions.

Thiyl and tyrosyl radicals

Thiyl radicals (RS) may be formed by the OH, ONOO, and/or by Fe3+-mediated one-electron oxidation of thiols, such as GSH or cysteine residues in proteins [102104]. Thiyl radicals may also be derived from other sulfur-containing moieties, including disulfide, thioester, or thioether functionalities, under conditions of oxidant stress [105107]. Once formed, RS react not only with themselves and oxygen but also oxidize biological electron donors, including ascorbic acid, NADH, and ferricytochrome c; react with tocopherol species (limiting their availability for reaction with unsaturated fatty acids); and react across carbon-carbon double bonds [108113].

Evidence for the in vivo formation of RS was demonstrated in rats administered the spin trap 5,5-dimethyl-1-pyrroline (DMPO) and given oxidized linoleic or linolenic acid via direct injection into the stomach. Analysis of bile samples revealed that a DMPO-RS adduct, identified as DMPO-GS, was formed presumably due to a reaction between the oxidized fatty acids with biliary GSH [114]. In human plasma isolated from healthy adult volunteers, incubation of the samples with ONOO (0.5 mM) and the spin trap α-phenyl-N-tert-butyl nitrone (PBN) (50 mM) resulted in the detection of an EPR spectrum that was nearly identical to that obtained for a PBN-albumin-RS radical adduct following ONOO-mediated oxidation of bovine serum albumin [115, 116].

The importance of RS to atherogenesis results from their ability to participate in reversible addition reactions to double bonds and to abstract hydrogen atoms from bisallylic carbon-hydrogen bonds. Thiyl radicals induce cis-trans isomerization of double bonds in monounsaturated and polyunsaturated fatty acids through a radical intermediate where the carbon-carbon bond is capable of rotation [117121]. The RS adds to the double bond, induces rotation of a carbon-carbon bond, and subsequently ejects an RS by β-scission to perpetuate the cycle [122]. The RS-mediated isomerization process is random with respect to the position of the double bond within the structure, and, as the trans-conformation is preferred energetically by 0.6–1 kcal/mol, at equilibrium the trans-olefin will predominate (80% vs. 20% cis isomer) [117, 118, 121124]. The kinetics of cis-trans isomerization are determined by the rotation barrier, which itself is dependent upon the thiol structure but independent of the choice of RS [121]. In the case of polyunsaturated fatty acids, cis-trans isomerization proceeds via the formation of intermediate mono-trans isomers followed by RS addition to yield di-trans isomers [118]. When present, trans-fatty acids in membrane lipids alter the physical properties of the phospholipid bilayer resulting in decreased fluidity and permeability [112, 125].

Trans-isomers of unsaturated fatty acids are a component of the Western diet as they occur naturally in dairy products and beef fat, or are formed during the partial hydrogenation of vegetable oils. Intake of these food products results in the absorption of geometrical isomers of C18 unsaturated fatty acids that may be converted to long chain fatty acids or incorporated into lipids [126128]. Trans-fatty acids may also be formed in vivo. In rats fed a diet devoid of trans-fatty acids, analysis of membrane lipids isolated from different tissues revealed the presence of trans-fatty acids indicating that endogenous formation had occurred. When rats were subjected to CCl4 poisoning to induce CCl3 and CCl3O2 radical formation in vivo, there was a fourfold increase in plasma lipid trans-fatty acid content suggesting that free radicals participate in the endogenous formation of trans-fatty acids [129, 130].

Increased intake of trans-fatty acids has been associated with an elevated risk of cardiovascular disease; however, the contribution of endogenously formed trans-fatty acids to disease risk has not been evaluated to date [131]. Mechanistically, the adverse effects of dietary trans-fatty acids have been attributed to increased total and LDL cholesterol with a concomitant decrease in HDL cholesterol [132, 133]; increased levels of lipoprotein(a) and triglycerides [134]; elevated plasma levels of the inflammatory markers, tumor necrosis factor-α, tumor necrosis factor receptor 1, interleukin-6, and C-reactive protein [135, 136]; increased soluble intercellular adhesion molecule-1 (ICAM-1), VCAM-1, and plasma E-selectin levels [135]; and, impaired endothelium-dependent vascular reactivity assessed by brachial artery flow-mediated dilation [137].

Thiyl radicals also have a propensity to initiate lipid peroxidation by abstracting hydrogen atoms from bis-allylic methylene groups of fatty acids to yield pentadienyl radicals. These radicals, in turn, may react with oxygen to generate peroxyl radicals. Early studies using pulse radiolysis to generate RS revealed the absolute rate constants for the reactions between cysteinyl RS and linoleic (18:2), linolenic (18:3), and arachidonic (20:4) acids in water/alcohol mixtures to be 1.3–16 × 106 M−1s−1, and these rates were increased with both the number of bis-allylic functions and the polarity of the solvent [138]. In studies performed with other RS, including RS derived from GSH, the rate constant range for the reaction with fatty acids containing between 2 and 6 double bonds was determined to be 0.3–7.5 × 107 M−1s−1 [139]. Further characterization of the hydrogen abstraction reaction from bis-allylic centers estimated that the carbon-hydrogen bond dissociation energy was 75–80 kcal/mol [140]. Thiyl radical reactivity with polyunsaturated fatty acids was also found to be determined by the distance between the reactive –S center and the ionic group in the attacking molecule, the number of ionic functions in RS, and the lipophilicity of the attacking RS [139].

Experimental evidence supports the role of RS in lipid peroxidation in complex biological systems. For example, in monkey arterial smooth muscle cells, ROS generation and oxidation of LDL was found to be L-cystine-dependent and required micromolar concentrations of Cu(II) or Fe(III). This oxidatively modified LDL was taken up and degraded by mouse peritoneal macrophages to a greater extent than that observed for non-modified LDL. These findings demonstrated that sulfur-containing amino acids support ROS generation resulting in modification of lipoproteins and, therefore, may play a role in atherogenesis [141]. This conclusion is further supported by the observation that trans-isomers of arachidonic, linoleic, or oleic acid residues were also found to be present in membrane phospholipids isolated from human monocytic leukemia cells following incubation with thiol compounds, including β-mercaptoethanol, GSH, or 3-(mercaptoethyl)quinazoline-2,4(1H,3H)dione [142].

Tyrosyl radicals are generated by the one-electron oxidation of L-tyrosine in reactions with OH and transition metal ions, as well as by reaction with ONOO derivatives, and by MPO and H2O2 [143145]. Tyrosyl radicals readily combine to form o,o’-dityrosine and react with O2•− at a rate (1.5 × 109 M−1s−1) that is approximately 3-fold faster than that for dimerization to occur (0.45 × 109 M−1s−1) [146, 147]. Tyrosyl radicals generated by MPO are highly reactive and have been shown to damage proteins by forming o,o’-dityrosine crosslinks. Studies performed with human neutrophils demonstrated that the MPO-H2O2 system was able to generate protein-bound dityrosine with free L-tyrosine independent of free metal ions [143, 148]. In a chloride-free system, the major product of L-tyrosine oxidation by MPO was determined to be dityrosine with lesser amounts of pucherosine and trityrosine formed; however, at physiological concentrations of L-tyrosine and Cl, the amphipathic aldehyde p-hydroxyphenylacetaldehyde was determined to be the major product of the neutrophil MPO-H2O2 system. This aldehyde was shown to modify proteins covalently via a reduced Schiff base mechanism involving the aldehyde and lysine residues’ Nε-amino moieties [149, 150]. Tyrosyl radicals generated by MPO have also been implicated in the initiation of lipid peroxidation. In vitro studies of LDL oxidation by activated human neutrophils, which contain abundant MPO and H2O2, revealed that lipid peroxidation occurred only in the presence of free L-tyrosine implying that tyrosyl radical formation by MPO was necessary for the initiation of lipid peroxidation [151]. Tyrosyl radicals have also been shown to play a role in LDL oxidation in vivo and in atherogenesis. Analysis of LDL isolated from human vascular tissue demonstrated that o,o’-dityrosine levels were 100 times greater than that observed in circulating LDL [152]. Similarly, o,o’-dityrosine formation was found to be increased 11-fold in atherosclerotic fatty streaks and 6-fold in advanced atheromas compared to normal aortic tissue, indicating that tyrosyl radical formation was capable of protein damage in vivo [152].

Sources of ROS

In vascular cells, circulating inflammatory cells, and platelets, free radicals and non-radical reactive species may be generated from reactions between O2•− and/or NO and other free radicals, lipids, and proteins. In these cell types, O2•− is synthesized by the enzymes NADPH oxidase, MPO (which also synthesizes reactive halogenating species) xanthine oxidase, lipoxygenases, and uncoupled nitric oxide synthase(s), and as a byproduct of mitochondrial respiration (Fig. 1). Within the cell, some level of O2•− is required to maintain cellular homeostasis; however, when these O2•−-generating sources remain activated after a physiological stimulus has abated, the continued production of O2•− alters cellular redox homeostasis resulting in increased oxidant stress. As such, there is evidence to support a role for the activation of the aforementioned sources of O2•− in the pathogenesis of atherosclerosis.

Figure 1
Vascular cell determinants of superoxide generation and redox state

NADPH oxidases

The NADPH oxidases are a family of multicomponent enzymes that assemble upon stimulation in the cell membrane, and are a predominant source of vascular cell O2•− formation. These enzymes utilize NADPH as an electron donor to reduce molecular oxygen to O2•−, have low levels of ambient activity, and in vascular cells, are differentiated by their subunit composition. NADPH oxidase is comprised of up to three cytosolic subunits (p40phox, p47phox, and p67phox), a regulatory G-protein (Rac1 or Rac2), and a membrane-bound cytochrome b558 reductase domain, consisting of two proteins (p22phox and gp91phox); homologs of the gp91phox in vascular cells have been termed Nox [153158]. Although there is no crystal structure of the Nox enzymes, they contain 6 transmembrane domains, and domains III and IV contain 2 histidine residues that span 2 asymmetrical heme groups. The −COOH terminus resides in the cytoplasm and contains the NADPH and flavin adenine dinucleotide binding domains. Thus, to generate O2•−, an electron is transferred from NADPH to flavin adenine dinucleotide, to the inner heme, to the outer heme, and then to oxygen [159163]. Vascular endothelial cells have been shown to contain Nox1, Nox2, Nox4, and Nox 5 and predominantly generate O2•− that is released to the extracellular compartment, while vascular smooth muscle cells express Nox1, Nox4, and Nox5 and synthesize intracellular O2•− and H2O2 [164167]. Regulation of NAD(P)H oxidase activation occurs via phosphorylation of p47phox. In p47phox, intermolecular interaction between two tandem SH3 domains limit p47phox binding to p22phox; however, once p47phox is phosphorylated, it may interact with the cytoplasmic tail of p22phox and facilitate the full assembly of NAD(P)H oxidase [168]. Once the enzyme is assembled, it is active and O2•− is generated by transfer of electrons from cytosolic NADPH to oxygen in the luminal or extracellular space. The Km of the Nox2 subunit for NADPH has been reported to be 40–45 µM [169].

Vascular NAD(P)H oxidase-derived O2•− production is augmented by stimuli with pathophysiological relevance for atherosclerosis, including tumor necrosis factor-α and inflammatory cytokines, angiotensin II, aldosterone, bone morphogenetic proteins, and oscillatory shear stress [170-176]. Superoxide levels produced by NAD(P)H oxidase may also be influenced by heritable polymorphisms with functional effects on enzyme activity. To date, the association between the C242T polymorphism of the p22phox subunit and atherosclerotic risk has received the greatest attention. One analysis of 201 patients with coronary artery disease compared with 201 control subjects revealed that this variant was protective with respect to atherosclerosis (OR = 0.49, 95% CI: 0.28, 0.87, p=0.015) [177]. Similarly, another study 3,085 subjects with established atherosclerosis compared with 2,163 control subjects confirmed that the C242T polymorphism was associated with a decreased risk of atherosclerosis [178]. This protective effect may be attributed, in part, to the finding that basal and stimulated vascular NAD(P)H oxidase-mediated O2•− production is decreased ~30% in individuals with the C242T polymorphism compared to controls [179]. In contrast, two polymorphisms in the promoter region of p22phox, −675 A/T and −930 G/A, were associated with elevated NAD(P)H oxidase expression and activity, and increased carotid intima-media thickness; the −930 G/A polymorphism was also found to have an interaction with tobacco use [180, 181].

In atherosclerosis, evidence demonstrates that NAD(P)H oxidase expression and activity are elevated. Increased expression of the NAD(P)H oxidase subunits p22phox, p47phox, and p67phox, calcium-dependent Nox5, and O2•− production have been found in coronary arteries isolated from patients with established atherosclerosis, and saphenous veins and internal mammary arteries obtained from diabetic patients [182184]. Similarly, enhanced expression of the p22phox and gp91phox subunits has been shown to correlate with both the degree of coronary artery atherosclerotic lesion severity and plaque cross-sectional area [167, 185].

Despite these observations, data to support a causal role for NAD(P)H oxidase in atherosclerotic lesion formation remain controversial, and studies performed in mouse models with genetic deletion of NAD(P)H oxidase subunit(s) have yielded conflicting results. For example, gp91phox−/− mice develop the same degree of atherosclerosis as control mice, and when crossed with apolipoprotein E knockout (apoE−/−) mice, deletion of gp91phox had no influence on vascular atherosclerotic burden [186]. In contrast, genetic deletion of p47phox, an activator of Nox2, appeared to influence atherogenesis: p47phox/apoE double knockout mice have a marked reduction in atherosclerosis compared to apoE−/− mice, in part, due to a decrease in monocyte/macrophage-mediated oxidation of LDL [187, 188].

Myeloperoxidase

Myeloperoxidase, which is expressed abundantly in neutrophils and monocytes, is a basic (pI > 10) heme protein that utilizes chloride as a substrate and H2O2 as a cosubstrate to generate reactive oxidants and radical species that oxidatively modify lipids and proteins [189, 190]. Immunohistochemical and biochemical analyses have demonstrated that MPO and its oxidation products are present within human atherosclerotic lesions [72, 191, 192]. Among the MPO-derived oxidants, HOCl is a potent chlorinating oxidant; importantly, MPO is the only known pathway for synthesizing reactive chlorinating species in humans [192194]. Myeloperoxidase has also been shown to use other free radicals and low-molecular-weight compounds as substrates, including NO2, tyrosine, ascorbate, urate, catecholamines, estrogens, and serotonin [148, 195199]. In human plasma, it has also been shown that MPO catalyzes the oxidation of NO to NO2 by a mechanism that involves the MPO-mediated formation of a substrate radical, which, in turn, reacts with NO [200202].

Regulation of MPO peroxidase activity is dependent, in part, upon NO levels [200, 203]. Under anaerobic conditions, it was found that NO binds to MPO-Fe(III), which is catalytically active, with kon = 1.07 µM−1s−1 and koff = 10.8 s−1, while NO was found to bind to MPO-Fe(II) with kon = 0.1 µM−1s−1 and koff = 4.6 s−1, suggesting that following heme reduction, there is a conformational change that modifies the accessibility of NO to the heme pocket [200]. Furthermore, NO was found to modulate MPO peroxidase activity by two mechanisms: low levels of NO reduce Compound II of the enzyme to the Fe(III) form while high levels of NO lead to inhibition of MPO by forming the nitrosyl complex, MPO-Fe(III)-NO [200, 201, 203]. As such, it has been suggested that MPO may serve as a catalytic sink for NO and limit its bioavailability [201].

The MPO-derived oxidant, HOCl, mediates chlorination of amines and unsaturated lipids, oxidation of thiols and thiol esters, and oxidative bleaching of heme groups and iron sulfur centers [193, 204206]. The formation of 3-chlorotyrosine, a stable chlorination product, has been detected in LDL isolated from human atherosclerotic aortas, and levels were found to be 30-fold higher than those measured in LDL from healthy donors [192]. Nitrotyrosine may also be formed through MPO-dependent pathways, including the reaction of NO2 with HOCl to generate nitryl chloride (Cl-NO2) and NO2 [67, 68, 195, 207]. Similarly, other oxidation products derived from MPO have been demonstrated in human atherosclerotic tissues. Acrolein, an aldehyde formed by threonine exposed to MPO-derived oxidants, was shown to modify lysine residues covalently in human atherosclerotic plaques [208]. The MPO-mediated oxidation of serine results in formation of the glycoaldehyde, carboxymethyllysine, an intermediate in advanced glycosylation end-product generation, which has been detected in atherosclerotic lesions [209]. In addition, Schiff base adducts between p-hydroxyphenylacetaldehyde, a tyrosine oxidation product, and the ε-amino moiety of protein lysine residues and amino lipids have been identified in human atherosclerotic lesions [150, 210].

Lipoproteins exposed to MPO-generated tyrosyl radicals demonstrate o,o’-dityrosine formation, protein cross linking, and lipid peroxidation, and these modifications have been found in lipoproteins isolated from human atheroma [72, 73, 143, 151]. HOCl oxidizes lysine residues in apolipoprotein B-100 (apoB-100) of LDL and converts LDL into an high-uptake form [211, 212]. Exposure of LDL to MPO-HOCl-NO2 also promotes apoB-100 protein nitration, and effectively initiates lipid peroxidation in serum [207, 213, 214]. These nitrated LDL species are converted into NO2-LDL that is recognized by the scavenger receptor CD36 and are avidly taken up and degraded by macrophages, resulting in foam cell formation and cholesterol deposition [214216]. Other studies have identified oxidized phospholipids, characterized by an sn-2 acyl group with a terminal γ-hydroxy(or oxo)-α,β-unsaturated carbonyl, as high affinity ligands for the macrophage scavenger receptor CD36, on both NO2-LDL and other oxidized forms of LDL [217, 218].

MPO-catalyzed oxidation of thiocyanate (SCN), which is present in human plasma and elevated in smokers, induces protein carbamylation at sites of inflammation and may have relevance to atherogenesis. The oxidation products of SCN include hypothiocyanous acid (HOSCN), a weak oxidant, and trace amounts of cyanate (OCN) [219, 220]. Cyanate may react with protein nucleophilic groups through carbamylation, possibly leading to functional impairment. MPO-carbamylated lipoproteins have atherogenic properties and have been associated with coronary artery disease; in a case-control (1:2) study performed in 450 subjects, individuals with plasma concentrations of homocitrulline (ε-carbamyllysine) in the highest quartile were found to have a 7–8–fold higher risk of having clinical or angiographic evidence of atherosclerotic vascular disease compared to those in the lowest quartile [221].

In the vasculature, MPO-mediated consumption of NO may contribute to a pathophysiological phenotype that facilitates atherothrombogenesis. Levels of MPO-derived HOCl contribute to a prothrombotic phenotype and have been shown to induce endothelial cell apoptosis and detachment [222]. MPO-derived lipid oxidation products increase expression of P-selectin to enhance platelet adhesion and increase tissue factor activity [222, 223]. MPO has also been implicated in the transition of a stable plaque to a vulnerable plaque, as HOCl activates matrix metalloproteinase-7 (MMP7) via oxygenation of a thiol residue in the enzyme’s cysteine switch; however, there is also dynamic homeostatic control of MMP7 activity as oxidative modification of tryptophane and glycine residues located in the catalytic domain of MMP7 decrease proteolytic activity [224].

Statins have been shown to downregulate MPO mRNA expression by 60-fold in human monocytes compared to levels in untreated cells by blocking geranylgeranylation of rhoA GTPase [225]. In statin-treated human transgenic MPO mice, MPO mRNA levels were reduced significantly, and this reduction correlated with a reduction in MPO activity [225]. Statins have also been shown to lower systemic levels of protein-bound nitrotyrosine: in hypercholesterolemic patients without evidence of atherosclerosis, atorvastatin decreased plasma levels of protein bound nitrotyrosine, chlorotyrosine, and dityrosine by 25%, 30%, and 32%, respectively [13, 226].

Epidemiological studies have found that individuals with total or near total deficiency of MPO, which occurs in the Caucasian population with a frequency of ~ 1 in every 2000–4000, are less likely to develop coronary artery disease [227]. Individuals with a −463G/A promoter polymorphism that results in a 2-fold decrease in MPO expression have decreased angiographic evidence of coronary artery disease, nonfatal myocardial infarction, and cardiac death [228, 229]. In contrast, individuals with elevated levels of MPO have an increased risk of angiographically documented coronary artery disease. In one study, individuals with MPO levels in the highest quartile were 15–20-fold more likely to have coronary artery disease compared with those in the lowest quartile [230]. Serum MPO levels have also been shown to predict independently endothelial dysfunction in humans (OR = 6.4, 95% CI: 2.6 – 16.0, p=0.001 for highest vs. lowest quartile), to predict future risk of coronary artery disease in healthy individuals with LDL cholesterol < 130 mg/dL (OR = 1.52, 95% CI: 1.21–1.91) or HDL > 50 mg/dL (OR = 1.59, 95% CI 1.24–2.05), and to be significantly associated with recurrent ischemic events in patients with acute coronary syndromes [231233].

Xanthine oxidase

Xanthine oxidase catalyzes the oxidation of hypoxanthine to xanthine and uric acid in a reaction that involves a one-electron transfer to oxygen to yield O2•− [234237]. Xanthine oxidase also catalyzes hydroxylation of N-heterocyclic and aldehyde substrates, as well as functions as an NADH oxidase [238241]. The enzyme exists as a homodimer, and each subunit possesses four redox centers: a molybdopterin site, a single flavin adenine dinucleotide site, and two Fe2S2 sites [242, 243]. Xanthine oxidase circulates in plasma at levels reported to be 0–4200 mU/L and is expressed only by vascular endothelial cells in the vessel wall [244246]. In the endothelium, xanthine oxidase exists as two isoforms, dehydrogenase and oxidase [247]. While only the oxidase isoform generates O2•−, isoform switching is mediated irreversibly by proteolysis or by reversible oxidation of Cys535 and Cys992, indicating that isoform activity is redox-sensitive [248, 249]. Under physiological conditions, the enzyme exists mainly in the dehydrogenase form; however, in the setting of hypoxia, the oxidase isoform predominates [250, 251].

Although increased expression and activity of xanthine oxidase have been demonstrated in atherosclerosis and serum uric acid has been shown to be an independent predictor of cardiovascular mortality, evidence implicating xanthine oxidase in atherogenesis in humans has been largely indirect [184, 252]. Inhibition of xanthine oxidase activity with oxypurinol has been shown to improve impaired vasodilation and vascular reactivity in individuals with hypercholesterolemia and coronary artery disease [253]. In these patients, increased circulating levels of xanthine oxidase may contribute significantly to vascular oxidant stress as studies performed in hypercholesterolemic rabbits revealed that hypercholesterolemia stimulates the release of xanthine oxidase from the liver to increase circulating xanthine oxidase activity two-fold [254]. Similarly, patients who underwent coronary artery bypass grafting surgery and were treated with allopurinol demonstrated decreased histological evidence of myocardial ischemia-reperfusion injury compared to untreated patients; in addition, patients with an acute myocardial infarction who received allopurinol prior to primary angioplasty had improved left ventricular function post-procedure and at 6 months [255, 256]. Recently, investigators have provided more direct experimental evidence to link xanthine oxidase activation with the development of atherosclerosis. In atherosclerotic apoE−/− mice, inhibition of xanthine oxidase activity with tungsten attenuated vascular O2•− production, improved endothelial function and vascular reactivity, and prevented the development of atherosclerosis [257].

One plausible explanation for the difficulty in implicating xanthine oxidase with atherogenesis is that the enzyme may function as a NO3 and NO2 reductase at the molybdopterin site and generate atheroprotective NO, especially under hypoxic conditions [258262]. A second rationale has been exposed by population-based phenotyping studies that have identified significant interindividual and interethnic differences in xanthine oxidase activity, with Caucasians having approximately 20% lower activity than other groups [263]. Furthermore, while several genetic polymorphisms have been identified, only the A69901C variant has been associated with carotid atherosclerosis in a study of 953 hypertensive subjects and 1,818 individuals from Japan [264]. Interestingly, it has been shown that xanthine oxidase expression and O2•− production are upregulated by NAD(P)H oxidase, suggesting that factors that regulate activity of this oxidase may also influence xanthine oxidase [265].

Lipoxygenases

The lipoxygenases are non-heme iron-containing dioxygenases that promote atherosclerosis by generating oxidatively modified, biologically active lipids. Lipoxygenases catalyze the stereospecific insertion of oxygen into polyunsaturated fatty acids, yielding unsaturated hydroperoxy fatty acid derivatives, including prostaglandins, thromboxanes, and leukotrienes [266, 267]

Expression of 12/15-lipoxygenase has been detected in human atherosclerotic plaques, and using chiral phase HPLC, lipoxygenase-mediated oxidation of linoleate and cholesteryl hydroperoxy-octadecadienoate isolated from human atherosclerotic plaques was confirmed by the high degree of observed stereospecificity of oxidation [268270]. In apoE−/− and LDLR−/− mice, genetic deletion of 12/15 lipoxygenase was associated with a decrease in vascular oxidant stress, macrophage foam cell formation, monocyte adhesion to the endothelium, and atherosclerosis [271275]. Interestingly, genetic studies in humans do not confirm this association between 12/15-lipoxygenase expression and atherosclerosis. In two large community-based populations (1,809 subjects, 1,734 controls in the Coronary Artery Risk Development in Young Adults Study; 12,974 participants in the Atherosclerosis Risk in Communities study), the T560M polymorphism, which results in a 20-fold reduction in the catalytic activity of 12/15-lipoxygenase, was associated with a 1.31–1.62-fold increased risk of atherosclerosis suggesting that near deletion of enzymatic activity did not protect against atherosclerotic vascular disease [276]. In contrast, increased 12/15-lipoxygenase activity, as occurs with the −611A/G promoter polymorphism, was associated with carotid plaque (OR = 4.01, 95% CI: 1.39, 11.53, p=0.0005) when examined in 556 individuals with coronary heart disease; however, the association was not found in 1,111 community-based individuals [277].

The enzyme 5-lipoxygenase (5LO), which synthesizes the proinflammatory leukotrienes, leukotriene B4, leukotriene C4, leukotriene D4, and leukotriene E4, has been linked to atherosclerosis [278287]. Early studies in the atherosclerosis resistant CAST mouse model identified 5-LO in the chromosome 6 region that was found to be a major locus for atherosclerosis susceptibility. When this locus was bred into atherosclerosis susceptible B6 mice (known as CON6 mice) and subsequently crossed with LDLR−/− mice, the mice demonstrated decreased atherosclerotic lesion formation on an atherogenic diet compared to LDLR−/− on a similar diet [288]. Further studies performed in 5LO−/− mice bred onto an LDLR−/− background demonstrated a 26-fold decrease in atherosclerotic lesion formation compared to LDLR−/− mice, similar to what was observed in CON6 mice, and that 5LO was abundantly expressed in atherosclerotic plaques and appeared to colocalize with macrophages [289].

In human atherosclerosis, 5LO expression was confirmed in plaques isolated from the aorta, carotid, and coronary arteries at different stages of atherosclerosis. Here, 5LO was localized to macrophages, dendritic cells, foam cells, mast cells, and neutrophilic granulocytes, and the number of 5LO expressing cells in the plaque was increased in advanced lesions [290]. Interestingly, 5-LO expression was found predominantly in activated macrophages, and cells expressing 5-LO were localized to the shoulder region of atherosclerotic plaques [290, 291]. Similarly, plaque analysis of endarterectomy specimens obtained from patients with carotid atherosclerosis revealed that 5-LO expression, leukotriene B4 production, and leukotriene A4 hydrolase expression were increased in unstable as compared to stable plaques, and this was associated with an increase in MMP2 and MMP9 expression and activity as well as decreased collagen content [286, 287, 291].

Further support for the role of 5LO in atherosclerosis was provided by several studies that related polymorphisms of the 5LO promoter or 5-lipoxygenase activating protein (FLAP) with an increased risk of atherosclerosis. In a study of 470 healthy individuals enrolled in the Los Angeles Athersoclerosis Study, 6% of the study cohort was identified as carriers of a variant genotype (increased or decreased number of GC-boxes in tandem in the promoter) with racial and ethnic differences in expression; the highest rates of variant genotypes were observed in Asian or Pacific Islanders and African-Americans as compared to Hispanics and non-Hispanic Caucasians. In this study population, presence of the 5LO polymorphism was associated with an increase in carotid intima-media thickness (80 ± 19 µm; 95% CI: 43 – 116, p<0.001). Furthermore, carriers of the 5LO polymorphisms were found to have increased intima-media thickness that was associated with increased intake of arachidonic acid and linoleic acid, a finding that was not observed in noncarriers [292].

Polymorphisms in the gene encoding FLAP have been associated with the presence of xanthomas in familial hypercholesterolemia as well as an increased risk of myocardial infarction and stroke. In 945 patients with heterozygous familial hypercholesterolemia, the rs9551963 polymorphism was associated with an increased risk of xanthomas (OR = 1.52, 95% CI: 1.11–2.07, p=0.01), while the rs17222842 polymorphism was found to be protective (OR = 0.62, 95% CI: 0.43–0.90, p=0.01) [293]. In a genome-wide linkage analysis of 296 families in Iceland, including 713 individuals with myocardial infarction, a four SNP haplotyope in the FLAP gene, HapA, was found to be associated with myocardial infarction (RR = 1.8, adjusted p=0.005); HapA had a frequency of 15.8% in affected individuals compared to 9.5% in controls. In this population, HapA was also found to be associated with an increased risk of stroke (RR = 1.7, p=000095). Neutrophils isolated from individuals with a history of myocardial infarction demonstrated increased production of leukotriene B4 following stimulation with ionomycin compared to neutrophils from controls. To confirm that these findings were not unique to the Icelandic population, a similar genetic analysis was performed in 753 individuals from the United Kingdom with myocardial infarction and 730 controls. In this population, the HapA haplotype was not associated with myocardial infarction; however, the investigators identified a second 4 SNP haplotype, HapB, that was associated with an increased risk of myocardial infarction (RR = 1.95, p=0.00037) [294]. These findings were also confirmed in a Scottish population of 450 patients with ischemic stroke [295].

A haplotype in the leukotriene A4 hydrolase gene, HapK, has also been described. In an Icelandic population, this haplotype was associated with an increased risk of myocardial infarction and additional cardiovascular disease (RR = 1.45, p = 0.0091). A replication study performed in Atlanta, Cleveland, and Philadelphia revealed that self-described European Americans, 27% of whom carried at least one copy of HapK, were at increased risk of myocardial infarction (RR=1.19, p=0.006); however, African-Americans, of whom only 6% were carriers, were found to be at significantly increased risk (RR = 3.57, p= 0.000022) [296].

Further support for the contribution of 5-LO and FLAP to atherosclerotic vascular disease was provided by a study of apoE/LDLR double knockout mice treated with MK-866, an inhibitor of FLAP. In these mice, MK-866 treatment decreased aorta atherosclerotic lesion size and lesion cross-sectional area, and increased plaque stability by increasing collagen and smooth muscle cell content while limiting macrophage infiltration [297]. Clinically, a randomized, prospective, placebo-controlled crossover study of the FLAP inhibitor (DG-031) was carried out in patients with myocardial infarction who were found to carry at-risk polymorphisms in the FLAP or leukotriene A4 hydrolase genes. In this study, 191 patients were identified as carriers of polymorphisms in either gene; 87% with a FLAP polymorphism, 13% with a leukotriene A4 hydrolase polymorphism. Treatment with DG-031 (750 mg/d) resulted in a 26% decrease in ionomycin-stimulated neutrophil production of leukotriene B4 (95% CI: 10% – 39%, p=0.003) and a 12% reduction in neutrophil myeloperoxidase release (95 % CI 2% – 21%, p=0.02) [298].

Endothelial nitric oxide synthase

The endothelial isoform of nitric oxide synthase (eNOS) catalyzes the oxidation of L-arginine to L-citrulline and NO. The enzyme exists as a dimer with both reductase and oxygenase domains, and produces NO via electron transfer from the cofactor NADPH through flavin adenine dinucleotide and flavin mononucleotide to heme where substrate L-arginine is oxidized to form NO and L-citrulline. When L-arginine or the cofactors NADPH or 5,6,7,8-tetrahydrobiopterin (BH4) are not sufficient, eNOS “uncouples” and reduces oxygen to yield O2•− in preference to its oxidizing L-arginine to yield NO [299]. Similarly, release of zinc from the zinc-thiolate moiety of eNOS by ONOO results in disulfide bond formation between eNOS monomers, and uncoupling of the enzyme to generate O2•− [300].

Although eNOS is atheroprotective, overexpression of eNOS in apoE−/− mice resulted in decreased NO, elevated levels of vascular O2•−, and increased atherosclerotic lesion formation [301]. This finding was attributed to a relative deficiency in BH4, leading to eNOS uncoupling; dietary supplementation with BH4 restored NO levels and diminished vascular oxidant stress [301]. In a GTP cyclohydrolase I transgenic mouse model, characterized by increased synthesis of BH4 and limited BH4 oxidation, eNOS uncoupling was prevented both in the absence of vascular disease and in experimental atherosclerosis [302, 303]. When this mouse model was crossed with an apoE−/− mouse that overexpressed eNOS, there was a reduction in vascular oxidant stress and atherosclerotic lesion formation, demonstrating the importance of cofactor supply to prevent eNOS uncoupling [304]. Recently, a novel haplotype of GCH1, the gene encoding GTP cyclohydrolase I, was identified and found to be associated with reduced enzymatic activity [305, 306]. The relationship between this haplotype, defined by 3 single nucleotide polymorphisms (rs8007267G>A in the promoter region, rs3783641A>T in intron 1, and rs10483639C>G in the 3’ untranslated region) and vascular biopterin levels, oxidant stress, and vasodilation was examined in arterial and venous segments obtained from 347 patients with coronary artery disease at the time of elective coronary artery bypass grafting. Here, it was found that homozygous carriers of the haplotype had significantly lower plasma and vascular BH4 and total biopterin levels compared to heterozygous or noncarriers of the haplotype. Vascular O2•− production was increased significantly and endothelium-dependent vascular reactivity was decreased significantly in vascular segments from homozygous carriers compared to heterozygous or noncarriers of the haplotype. Thus, GCH1 haplotype appears to regulate vascular BH4 levels with consequences for eNOS coupling [307]. Other investigators have identified a C243T polymorphism in the 3’-UTR that was associated with NO production, baroreflex coupling, and systolic and diastolic blood pressure levels [308]. C-reactive protein, which is associated with endothelial dysfunction and atherosclerosis, was shown to produce its adverse vascular effects, in part, by uncoupling eNOS through decreased GTP cyclohydrolase I expression resulting in BH4 deficiency [309]. In addition, the compound AVE9488 was found to limit atherosclerosis in apoE−/− mice by stimulating eNOS promoter activity, and, therefore, eNOS expression, concomitant with increasing vascular content of BH4 to prevent eNOS uncoupling [310].

Clinically, eNOS uncoupling has been associated with hypertension, diabetes mellitus, hypercholesterolemia, and atherosclerosis, suggesting that the association between eNOS cofactor supply, eNOS uncoupling, and eNOS-mediated O2•− production defined in animal models may also be operative in human disease [311314]. In fact, in explants of saphenous veins and internal mammary arteries obtained from patients undergoing coronary artery bypass grafting surgery, high vascular levels of BH4 were associated with decreased eNOS-derived O2•− production and improved endothelium-dependent vascular reactivity [315]. When these explanted tissues were incubated with 5-methyltetrahydrofolate to scavenge ONOO or 5-methyltetrahydrofolate was infused in vivo prior to vessel harvest, there was a further increase in vascular BH4 levels and the BH4/total biopterin ratio, and diminished eNOS-mediated O2•− production. The eNOS dimer/monomer ratio was also increased, resulting in enhanced eNOS activity and NO levels [316].

Inducible nitric oxide synthase

In atherosclerosis, vascular smooth muscle cells, monocytes, macrophages, and dendritic cells all express iNOS. Induction of iNOS may occur following exposure to inflammatory cytokines, including interleukin-1β, interferon-γ, and tumor necrosis factor-α. In contrast to eNOS, iNOS binds Ca2+/calmodulin tightly and does not require an increase in intracellular Ca2+ for activation [317].

The presence of iNOS localized to macrophages and vascular smooth muscle cells has been documented in human atherosclerotic plaques [318320]. In these vascular atheromas, iNOS expression was detected as early as the fatty streak stage and was present in advanced atheromas coinciding with evidence of protein nitration [319]. Moreover, iNOS expression was found to colocalize with oxidized lipid and protein derivatives found in atherosclerotic plaques [321]. Further evidence for the role of iNOS in atherosclerosis is derived from studies in animal models. In the apoE−/− mouse, iNOS expression was detected in macrophages and vascular smooth muscle cells of developing plaques [322]. Although genetic deficiency of iNOS itself did not influence atherosclerotic lesion size in diet-induced atherosclerosis, several studies performed in iNOS/apoE double knockout mice show a reduction in atherosclerotic plaque formation [323326].

To determine the association between iNOS-derived NO and ONOO formation in atherosclerosis-prone mouse models, 3-nitrotyrosine accumulation and BH4 oxidation were assessed in apoE−/− mice fed a Western diet. Here, 3-nitrotyrosine and dihydrobiopterin (BH2) levels were found to be low in 3-week old apoE−/− mice but increased significantly in 27-week old mice fed a Western diet. In contrast, apoE-iNOS double knockout mice fed a Western diet demonstrated a reduction in tissue 3-nitrotyrosine accumulation indicating that 3-nitrotyrosine expression in this model was, in part, associated with iNOS-derived NO. Similarly, increased BH2 levels associated with Western diet feeding were decreased in double knockout mice, indicating iNOS likely played a role in oxidation of BH4 [327].

In a streptozotocin-induced diabetic rat model, electron paramagnetic resonance spectroscopy detected OH formation and LOO radicals generated by uncoupled iNOS. Treatment of the rats with L-arginine decreased O2•− generation and ONOO production resulting in decreased LOO formation. As diabetes progressed in this animal model, there was an associated rise in iNOS protein expression, and iNOS colocalized with 3-nitrotyrosine and 4-hydroxynonenal formation. Thus, iNOS-mediated OH production likely also contributes to atherogenesis by initiating lipid peroxidation in experimental diabetes [328].

Mitochondria

During oxidative phosphorylation, mitochondria generate O2•− at several sites within the electron transport chain. As electrons are transferred from NADH through Complexes I–IV to generate ATP, 0.2–2.0 % of the electrons leak to form O2•−, primarily via Complex I and Complex III [329]. Within the mitochondria, O2•− may be produced within the mitochondrial matrix and the intermembrane space, and it has been suggested that mitochondrial membranes produce ~ 24 nmol/O2•−/min per gram of tissue [329, 330]. The majority of O2•− is converted to H2O2 by manganese superoxide dismutase (Mn-SOD), localized to the matrix, to maintain an estimated intramitochondrial steady-state concentration of O2•− of 8 × 10−12 M or greater [331]. Mitochondrial dysfunction has been linked to atherosclerosis, and aortic specimens obtained from patients with atherosclerosis show a greater degree of mitochondrial DNA damage than that observed in the absence of atherosclerosis [332]. Mitochondrial DNA damage has been shown to precede atherosclerosis and to correlate with the extent of disease in apoE−/− mice [332]. The mechanistic role of O2•− in mitochondrial DNA damage was determined when Mn-SOD) activity was inhibited in a murine atherosclerosis model: when Mn-SOD activity was deficient, there was evidence of increased mitochondrial DNA damage and accelerated atherosclerosis [332]. It has also been shown that oxidized lipids colocalize with mitochondria in vitro and that oxidized LDL (oxLDL) increases mitochondrial O2•− formation, suggesting another mechanism by which mitochondrial dysfunction may be associated with atherosclerotic lesion formation [333, 334]. Finally, deficiency of complex I, NADH:ubiquinone oxidoreductase, is the most common enzymopathy associated with oxidative phosphorylation and is associated with an increase in O2•− generation as a result of decreased complex I activity [335].

Vascular antioxidant enzymes

To limit the deleterious effects of reactive free radical and non-radical species and their pathophysiological sequelae, the intracellular redox state is balanced by small molecule antioxidants that include GSH, α-tocopherol, ubiquinones, and ascorbic acid, as well as antioxidant enzymes that modulate the intra- and extracellular reactions of oxidizing metabolites. The enzymes that comprise this antioxidant defense system are extensive and include the SODs, which dismutate O2•− to H2O2 and oxygen; catalase, which catalyzes the decomposition of H2O2 to water and oxygen; the glutathione peroxidases, which utilize GSH to reduce H2O2 and fatty acyl peroxides to water and lipid alcohols, respectively; glutathione reductase, which reduces oxidized glutathione or glutathione disulfide to GSH; glutathione-S-transferases, which glutathiolate oxidants to decrease their oxidizing potential; thiol-disulfide oxidoreductases, which preserve the thiol redox state of proteins; peroxiredoxins, which catalyze the reduction of H2O2 to water; HO-1, which degrades free heme to carbon monoxide (CO) and biliverdin; paraoxonases, which limit oxidation of LDL; and glucose-6-phosphate dehydrogenase, which is the principal intracellular source of NADPH, a key reducing equivalent and cofactor for other antioxidants (Table 1)(Fig. 1).

Table 1
Key Vascular Antioxidant Enzymes, Genotypes, Post-translational Modifications, and Vascular Disease Risk

The importance of these antioxidants in modulating the oxidative risk for atherothrombotic vascular disease is revealed when the aforementioned antioxidant enzymes have diminished catalytic activity. This insufficiency may occur as a result of decreased enzyme expression or activity as a consequence of a heritable polymorphism, or in a significant oxidizing environment where oxidative modification of the enzyme alters its functional properties. As a result of decreased activity of these antioxidant enzymes, a pro-oxidative environment is created that favors the development of atherosclerotic lesions.

Superoxide dismutases

Once formed, O2•− is dismutated enzymatically to H2O2 and oxygen by the SOD family of antioxidant enzymes, which include intracellular SOD (Cu,Zn-SOD), extracellular SOD (EC-SOD), and mitochondrial Mn-SOD, also referred to as types I, III, and II, respectively [336342]. These enzymes catalyze the dismutation of O2•− with a rate constant of 2.3 × 109 M−1s−1 that is 10,000 times faster than the spontaneous dismutation of O2•− [22, 343]. Cu,Zn SOD requires Cu2+ and Zn2+ for catalytic activity and resides in the cytoplasmic compartment of cells, although some enzymatic activity has been detected in the nucleus, lysosomes, and peroxisomes, as well as the intermembrane cisterns of the mitochondria [336, 337]. EC-SOD resides in the extracellular matrix, requires Cu2+ and Zn2+ for catalytic activity, and contains an intrasubunit disulfide bridge (Cys107-Cys189) that is necessary for enzymatic activity [338, 339, 344]. In the mitochondria, Mn-SOD dismutates O2•− released into the matrix, and is a pH sensitive enzyme with a loss of activity observed as pH rises [340343].

Among these SODs, a common human gene variant in the heparin-binding domain of EC-SOD has been linked to cardiovascular disease risk. The R213G polymorphism results in a decreased affinity for heparin without a purported effect on specific enzymatic activity. This polymorphism has been linked to increased body weight and triglycerides in a Swedish population study of 4,925 randomly selected 74-year old subjects, increased mortality from ischemic heart disease and cerebrovascular events in patients with diabetes on renal replacement therapy, and a 2.3-fold increased risk of ischemic heart disease in a nested case-control study that included 1,912 individuals from a Danish population [345347]. In experimental rat models, overexpression of R213G EC-SOD as compared to native EC-SOD failed to limit vascular O2•− and ONOO levels, decrease blood pressure, or improve impaired endothelium-dependent vasodilation under basal conditions or in the setting of increased inflammation, suggesting a mechanistic basis for the observations in humans [348, 349]. Clinical studies have also shown a decrease in EC-SOD activity in aged individuals, African-Americans with hypertension, patients with vasospastic angina, thoracic aortic aneurysm patients, and in calcific aortic stenosis; however, genotyping was not performed in these studies, and, thus, it remains unknown if decreased SOD activity may be attributable to a heritable polymorphism [350354].

A functional polymorphism has also been identified in the signal sequence of MnSOD (Ala16 to Val) that results in structural alterations to the mitochondrial targeting domain, implying that its decreased antioxidant potential may be a consequence of limited post-transcriptional transport to the mitochondria. A study of 989 individuals revealed that those who harbored this variant had an increased carotid intima-to-media thickness and were at increased risk for coronary artery disease and acute myocardial infarction [355, 356].

Increased vascular oxidant stress may also lead to a functional decrease in SOD activity through oxidative posttranslational modification of the enzyme. In an angiotensin II-infused rat model, Mn-SOD was subject to tyrosine nitration and accounted for ~20% of the total pool of nitrated proteins; this resulted in a 50% decrease in Mn-SOD activity in the absence of a decrease in protein expression [357]. Similar findings were observed in the kidney of diabetic apoE−/− mice. In these studies, it was found that Tyr34 was exquisitely sensitive to nitration, and this posttranslational modification may result in a decrease in activity as this residue is located in the active site of the enzyme [358]. Mass spectrometry revealed that Tyr45 and Tyr193 were also nitrated following exposure of the enzyme to ONOO [359]. Other studies have reported that when CuZn-SOD was exposed to ONOO, nitration of Trp32 occurred, leading to a 6-nitrotryptophan modification with a corresponding 15% decrease in enzymatic activity [360, 361].

Catalase

Catalase is located primarily in peroxisomes where it exists as a tetramer of four identical subunits that each contains a heme at the active site. Catalase reduces H2O2 to H2O in a reaction that occurs at the diffusion limit of H2O2 [362, 363]. During this reaction, the heme iron of catalase is oxidized by H2O2 resulting in the formation of an oxyferryl group with the porphyrin (Por) π radical and conformational conversion to Compound I (Por+•−FeIV=O). Compound I subsequently reacts with a second molecule of H2O2 to yield water and oxygen with return of the enzyme to the resting conformational state (Por−FeIII). A second state of catalase, Compound II (Por−FeIV=O), is formed by the reduction of Compound I; Compound II does not participate in the reduction of H2O2 but may revert to Compound I, albeit slowly. Catalase also binds NADPH to limit oxidative inactivation of the enzyme by H2O2 (i.e., formation of Compound II) and to facilitate tetramer formation [364367].

Heritable catalase deficiency is an autosomal recessive disorder and reported solely in families of Japanese, Hungarian, or Swiss origin. These individuals have no overt phenotype with the exception of oral ulcers reported in Japanese individuals with acatalasemia. In a Hungarian cohort of 30 patients compared with 29 family members with normal catalase activity, several polymorphisms (G insertion at exon 2, GA insertion at exon 2, or T→G substation at intron 7) were associated with a 12.7% incidence of familial diabetes mellitus, elevated levels of plasma homocysteine, and lower levels of folate, suggesting an adverse risk profile for cardiovascular disease [368, 369]. Despite these findings, a recent analysis of 420 patients with type 1 and type 2 diabetes mellitus patients did not find an association between these polymorphisms and disease state, regardless of the degree of glycemic control [370].

Under conditions of oxidant stress, catalase has been shown to undergo tyrosyl nitration leading to a decrease in enzyme activity that results from oxidative modification of Cys377 to form a cysteic acid [371, 372]. Catalase is also subject to chlorotyrosyl modification in the presence of MPO and to protein carbonyl formation through the actions of oxidant species on lysine, arginine, proline, or threonine residues with a resulting decrease in intrinsic catalase activity [372, 373].

Glutathione peroxidases

The glutathione peroxidases (GPx) are selenocysteine-containing enzymes that catalyze the reduction of H2O2 and lipid hydroperoxides to H2O and lipid alcohols, respectively, in a reaction that utilizes GSH as a reducing cosubstrate [374377]. The glutathione peroxidases may also function as ONOO reductases [378, 379]. There are 5 known forms of GPx: cellular GPx (GPx-1), gastrointestinal GPx (GPx-2), plasma GPx (GPx-3), phospholipid GPx (GPx-4), and sperm GPx (snGPx).

The importance of the GPx family of antioxidant enzymes in limiting the oxidative risk for atherothrombosis is increasingly recognized. Evidence from genetically modified mouse models has confirmed the role of GPx in vascular redox homeostasis. GPx-1- deficient mice demonstrate endothelial dysfunction and have spontaneous neointima formation, increased periadventitial inflammation, and collagen deposition surrounding the coronary arteries [380, 381]. When GPx-1−/− mice were crossed with apoE−/− mice to examine the influence of GPx-1 deficiency in atherosclerosis, decreased GPx-1 activity was associated with increased atherosclerotic lesion formation, increased vascular oxidant stress, and decreased NO levels as compared to apoE−/− mice with normal GPx-1 activity [382]. When these double knockout mice were made diabetic, increased atherosclerotic lesion formation was associated with elevated levels of adhesion molecules, receptors for advanced glycation end products, and proinflammatory and profibrotic markers [383]. Conversely, overexpression of GPx-4, which reduces oxidized phospholipids, cholesterol hydroperoxides, as well as proinflammatory lipid peroxides generated by lipoxygenases and cyclooxygenases, has been shown to decrease vascular oxidant stress and the progression of atherosclerosis in apoE−/− mice [384]. The central role of GPx-4 in modulating vascular redox tone was elucidated recently. Studies performed in a GPx-4 conditional knockout mouse model revealed that inhibition of GPx-4 resulted in activation of 12/15-lipoxygenase to initiate lipid peroxidation and stimulate apoptosis-inducing factor-mediated cell death [385, 386].

Clinical studies have shown that erythrocyte GPx-1 activity is an independent predictor of adverse cardiovascular events in individuals without traditional risk factors for atherosclerosis. In one study of 636 individuals with suspected coronary artery disease, individuals with the highest level of GPx-1 activity had the lowest risk of cardiovascular events a (HR = 0.29, 95% CI: 0.15, 0.58, p<0.001) compared to individuals with the lowest levels of enzyme activity [387]. In a second study of 508 patients with documented coronary artery, carotid, and/or peripheral arterial disease followed for a median of 6.5 years, those individuals with the lowest levels of erythrocyte GPx-1 activity were more likely to experience a cardiovascular event than those with the highest levels (HR = 2.3; 95% CI: 1.4, 4.0 for lowest vs. highest GPx-1 activity, p=0.002 adjusted) [388].

Deficient GPx-1 activity may be acquired, as occurs in hyperhomocysteinemia, which has been shown to decrease expression of GPx-1 via an effect on translation, or associated with a heritable polymorphism [389, 390]. A Pro198Leu variant that decreases GPx-1 activity by 40% has been associated with increased carotid intima-media thickness, peripheral arterial disease, and the prevalence of cardiovascular disease [391]. This polymorphism has also been associated with increased coronary artery calcification in diabetic patients, and an increased risk of coronary artery disease and thoracic aortic aneurysm [392394].

As a large number of oxidant factors that mediate atherosclerotic risk are circulating in plasma, recent attention has focused on GPx-3, or plasma GPx, and its role in modulating oxidant stress. Deficient GPx-3 activity has been associated with increased platelet activation, decreased platelet NO responsiveness, and cerebrovascular arterial thrombosis [395]. Molecular examination of the GPx-3 promoter revealed seven polymorphisms within the promoter that are tightly linked and form two novel haplotypes. The H2 (less prevalent) haplotype was associated with decreased GPx-3 transcriptional activity, was more prevalent among patients with stroke and cerebral venous thrombosis, and conveyed an approximate two-fold increased, independent risk of thrombotic stroke in young patients [396, 397].

Glutathione-S-transferases

The glutathione-S-transferases (GSTs) are xenobiotic-metabolizing enzymes that detoxify reactive electrophiles, such as those contained in tobacco smoke, to limit their oxidizing capabilities. The GSTs are dimeric cytosolic enzymes that catalyze the conjugation of an active xenobiotic to GSH, an endogenous water-soluble substrate. Each dimer contains 2 active sites, which function independently, and each has a ligand binding site for GSH that is specific as well as an electrophilic binding site that is less specific [398]. The N-terminus contains a catalytically essential cysteine, serine, or tyrosine residue that interacts with GSH to lower the pKa to 6–7 from its baseline value of 9 [399, 400]. These enzymes may catalyze Michael additions to α,β-unsaturated ketones as well as epoxide ring-opening reactions and nucleophilic aromatic substitutions to yield GSH conjugates, as well as reduce hydroperoxides to form GSSG [401, 402]. Once the GSH conjugate is formed, it is eliminated via several transporters, including the broad-specificity anion transporter of dinitrophenol S-GSH conjugates, ATP-dependent GS-X pump, P-glycoprotein, and the multidrug resistance-associated protein [403408]. In addition to their catalytic role in detoxification, GSTs have also been found to possess selenium-independent peroxidase activity with hydroperoxides; steroid isomerization capacity; and bind and transport bilirubin, heme, bile salts, and steroids, in a process that is associated with a decrease in enzymatic activity [409411].

Several studies have found an association between GST polymorphisms that decrease enzymatic activity and atherosclerosis. In fact, in 75 patients with established atherosclerosis, elevated levels of plaque DNA damage, as well as levels of the inflammatory markers C-reactive protein, fibrinogen, and adhesion molecules, were detected in individuals with the GSTM1*0 null allele [412, 413]. A meta-analysis revealed that smokers with the GSTM1*0 allele were at increased risk for coronary artery disease (OR 2.3; 95% CI: 1.4, 9.0), as were individuals with a GSTT1*1 null allele (OR 2.5; 95% CI: 1.3, 4.8) [414, 415]. Interestingly, smokers with angiographically documented coronary artery disease were more likely to harbor the GSTT1*1 allele than smokers who did not have significant disease [416]. In addition to genetic polymorphisms influencing GST activity, GST is subject to tyrosine nitrosation and carbonylation (by reactive aldehydes) with a concomitant reduction in enzyme activity, although the precise functionalities subject to these posttranslational modifications have not yet been identified [417, 418].

Heme oxygenase

Heme oxygenase catalyzes the oxygen-dependent regiospecific metabolism of heme to Fe(II), CO, and biliverdin, which, in turn, is converted to bilirubin via biliverdin reductase. Heme oxygenase exists as two isoenzymes: the inducible isoform HO-1 and the constitutive isoform HO-2. These isoenzymes similarly metabolize heme; however, HO-2 contains heme regulatory motifs that are absent in HO-1, and its primary function has been suggested to be the generation of CO to serve as a signaling molecule [419422]. The observation that HO-1 is induced by oxidant stress has led to consideration of this enzyme as an antioxidant. The antioxidant properties attributed to HO-1 result from its ability to degrade the heme moiety released by destabilized or denatured proteins bearing it and, thereby, limit LDL oxidation [423]; to generate vasoprotective levels of CO that limit cell proliferation and inflammation, and stimulate vasodilation, predominantly through cGMP-independent effects on Ca2+-dependent potassium channels [424427]; and to increase levels of bilirubin, which itself is a free radical scavenger that inhibits NADPH oxidase enzyme assembly and activity to decrease O2•− production [428, 429]. HO-1 is induced by 1-palmitoyl-2-isoprostanoyl-sn-glycero-3-phsophorylcholine and linoleyl hydroperoxide contained within oxLDL, and its expression has been detected in early fatty streaks as well as advanced atherosclerotic lesions [430433]. Induction of HO-1 through ROS-responsive transcription factor(s), such as Nrf-2, results in increased levels of bilirubin and CO to decrease oxidant stress, and has been shown to limit atherosclerotic lesion formation and vein graft failure in mouse models of hypertension and cardiac hypertrophy [434436].

A number of studies have examined HO-1 polymorphisms and their association with atherothrombotic vascular disease. Recent studies have focused on a (GT)n repeat in the HO-1 promoter and found that as the repeat lengthened, ROS were less effective at inducing HO-1 expression [437]. In fact, in 110 patients with established coronary artery disease, and presumably increased systemic oxidant stress, the ability to induce HO-1 in peripheral monocytes was negatively correlated with the degree of atherosclerosis [438]. Studies have also shown that short repeats (<25 GT) were associated with a decreased risk of restenosis in 472 patients with peripheral arterial disease following peripheral intervention (HR = 0.46, 95% CI: 0.24, 0.87, p=0.016), while a study of 323 patients with successful coronary artery stenting procedures revealed that long repeats (>25 GT) were associated with an increased risk of restenosis (OR = 3.74, 95% CI: 1.61, 8.70, p=0.002) as well as major adverse coronary and cerebrovascular events [439, 440]. In 263 diabetic patients, those with long repeats (> 27 GT) had lower levels of serum bilirubin and an increased risk of cardiovascular disease after controlling for conventional coronary heart disease risk factors (OR 2.81; 95% CI 1.22, 6.47, p=0.015), compared to individuals with short repeats (< 27 GT) [441].

Heme oxygenase activity is also regulated at the posttranscriptional level. Heme oxygenase-1 may undergo tyrosine nitration or sulfhydryl oxidation in the presence of ONOO, although neither modification has been proven conclusively [442]. In contrast, HO-2 activity may be regulated by oxidative modification. HO-2 contains an intramolecular disulfide bond that links Cys265 of one heme regulatory motif with Cys282 of a second heme regulatory motif; this covalently linked conformation binds heme tightly. When this disulfide bond is reduced, elevated levels of free heme are detectable in cells. Therefore, reduction of the disulfide bond would likely increase cellular heme, decrease enzyme activity, and decrease atheroprotective levels of CO and bilirubin [443].

Glucose-6-phosphate dehydrogenase

Glucose-6-phosphate dehydrogenase (G6PD) is the first and rate-limiting enzyme in the pentose phosphate pathway and the principal source of intracellular NADPH. NADPH is utilized as a reducing equivalent to maintain thiol redox balance and as a cofactor by other antioxidant enzymes. The G6PD gene is highly polymorphic with a large number of recognized functional variants [444]; G6PD deficiency is the most common enzymopathy worldwide with more than 440 biochemical variations owing to ~120 different mutations. The majority of described mutations are single or double missense mutations that have arisen owing to selective pressure for decreased G6PD activity in the malaria belt to render erythrocytes more susceptible to oxidative damage [445]. As a result, erythrocytes parasitized with plasmodium species are cleared by the reticuloendothelial system at a faster rate than those with normal G6PD activity [446].

The central role of G6PD in modulating the cardiovascular redox milieu has been demonstrated by our group. G6PD limits oxidative injury in vascular endothelial cells, smooth muscle cells, and cardiomyocytes and has been associated with a decrease in angiogenesis and worsening indices of left ventricular function following ischemia-reperfusion injury in a G6PD-deficient mouse model [447450]. In addition to genetic G6PD deficiency, G6PD deficiency may also be acquired. For example, G6PD activity was decreased in the kidneys of diabetic rats with a normal G6PD genotype and reduced by 80% in mice with a normal genotype that were fed a high fat diet rich in polyunsaturated fats [451, 452]. In the setting of hyperaldosteronism, G6PD expression and activity were decreased leading to increased vascular oxidative stress, decreased NO, and impaired vascular reactivity in mice with a normal G6PD genotype [453]. Clinically, G6PD deficiency has been linked to an increased risk for hypertension, gestational hypertension, preeclampsia, and diabetes, all of which are associated with vascular endothelial dysfunction [454457].

Oxidative modification of lipids

Although the aforementioned studies implicate increased activation or dysfunction of individual ROS-generating or antioxidant enzymes, respectively, in the pathogenesis of atherosclerosis, it is more likely that functional alterations occur in several enzymatic systems concurrently to render a pro-oxidant vascular redox milieu. The accumulation of biologically active free radicals and their ability to oxidize a range of target molecules provide support for the role of oxidant stress in the pathogenesis of atherothrombosis. Prevailing cholesterol theory dictates that oxidant stress is a mechanistic necessity for atherogenesis; the oxidative modification hypothesis contends that only oxLDL are taken up by macrophages to form foam cells and serve as the nidus for the developing atherosclerotic plaque [458, 459]. For this reason, we now turn to a discussion of the role of ROS in lipoprotein oxidation as a precursor to atherothrombotic vascular disease.

Low-density lipoproteins

During the process of LDL oxidation, ROS target polyunsaturated fatty acids that contain bis-allyllic hydrogens to oxidize them (Fig. 2). These oxidized fatty acids degenerate to form a number of reactive low-molecular-weight aldehyde species, which, in turn, react with the ε-amino groups of lysine residues of apoB-100 to modify the surface charge of LDL particles [212, 460]. Proteomic analysis of apoB-100 and oxLDL has also identified histidine and tryptophan residues as targets for oxidative modification [461]. In the presence of MPO-derived reactive nitrogen species, human LDL particles are also subject to tyrosine nitration of apoB-100, rendering these nitrated LDL species proatherogenic and capable of initiating lipid peroxidation [214]. Once peroxidation of phospholipids present in the outer layer of LDL occurs, the particle promotes a conformational change in apoB-100 such that it is displaced from the LDL particle’s hydrophobic zone into the aqueous phase, leading to increased nonreceptor-mediated capture of the oxLDL particle by vascular cells [460].

Figure 2
Oxidant stress and lipid peroxidation

LDL may undergo oxidation of particle components other than apoB-100; for example, minimally oxidized forms of LDL were found to contain polyoxygenated cholesteryl ester hydroperoxides. Moreover, evidence exists that minimally oxLDL is formed in vivo and has been identified in extracts of atherosclerotic lesions isolated from apoE−/− mice [462]. Minimally oxLDL has been shown to activate macrophages and induce cell membrane ruffling and spreading via CD14. Toll-like receptor 4 also binds to minimally oxLDL leading to the secretion of the proinflammatory cytokines, including monocyte chemotactic protein-1, tumor necrosis factor-α, and interleukin-6, to enhance monocyte binding to endothelial cells and induce platelet shape change and aggregation [463465].

Following oxidative or nitrosative modification, LDL is taken up by macrophages via scavenger receptor pathways resulting in the formation of cholesteryl ester-rich foam cells. Similarly, endothelial cells also take up oxLDL via the lectin-like oxidized LDL receptor-1 [466]. Intracellular endothelial accumulation of oxLDL results in diminished NO production, increased expression of leukocyte adhesion molecules, promotion of a prothrombotic surface, and synthesis of smooth muscle cell mitogenic factors [466468]. This results, in part, from oxLDL-mediated NADPH oxidase activation to increase endothelial cell oxidant stress; carbonylation and nitration of proteins, including the epidermal growth factor receptor and eNOS; and increased proteasomal degradation of eNOS [469]. These functionally-deficient endothelial cells, together with atherogenic macrophage-derived foam cells, facilitate atherosclerotic lesion formation as confirmed by the presence of oxLDL in human atherosclerosis. Immunohistochemical analysis of atherosclerotic plaques demonstrates abundant staining for apoB-100, which is absent in human arteries without evidence of atherosclerosis [470]. Furthermore, therapies aimed at reducing oxLDL in preference to LDL have been shown to decrease experimental atherosclerosis: gene transfer of LOX-1 to the livers of apoE−/− mice decreased plasma oxLDL levels and inhibited atherosclerosis progression without influencing total cholesterol or LDL levels [471]. Interestingly, there is also evidence to suggest that macrophages may take up nonoxidized LDL, which subsequently undergoes oxidative modification to form oxLDL within the cell. In vitro studies have demonstrated that macrophages take up acetylated LDL, which is shuttled to lysosomes that serve as the intracellular site for lipid particle oxidation [472].

Oxidized LDL may exit the subendothelial space and has been measured in blood, where it has been reported to account for 0.001% of the total LDL in normal individuals and to increase as high as 5% of total LDL in patients with an acute myocardial infarction [473476]. The presence of circulating oxLDL has been supported by the detection of plasma autoantibodies to oxLDL, and the observation that human plasma possesses immunoreactivity to oxLDL epitopes [477479]. Elevated plasma levels of oxLDL, which presumably reflect the vascular burden of oxLDL, correlate with incident metabolic syndrome, peripheral arterial disease, acute coronary syndromes, angiographically documented coronary artery disease, and stroke [480483].

High-density lipoproteins

High-density lipoproteins (HDL) derive their atheroprotective functions from their ability to reverse transport cholesterol from the vasculature to the liver; however, components of HDL are subject to oxidative modification to generate oxidized lipoprotein particles that are dysfunctional, proinflammatory, and paradoxically promote atherosclerotic lesion formation [484487]. In vitro studies have shown that metal ions, ROO and OH, aldehydes, tyrosyl radicals, lipoxygenase, and HOCl oxidize HDL, while in vivo it has been suggested that HDL oxidation results from exposure to MPO, O2•−, H2O2, ONOO, and lipoxygenases [485, 486, 488497]. Once oxidized, HDL exhibits an increase in fluidity that is associated with impaired reverse cholesterol transport and anti-inflammatory properties as well as cytotoxicity towards cells [487, 489, 498503].

High-density lipoprotein particles are heterogeneous and composed of free cholesterol, phospholipids, and apolipoproteins that surround a triglyceride- and cholesteryl ester-rich core. High-density lipoprotein particles also carry enzymes with antioxidant properties, including paraoxonase-1 and lecithin:cholesterol acyltransferase (LCAT) [504506]. Within the HDL particle, these antioxidant enzymes serve to limit free radical oxidation of circulating LDL and HDL particles as well as those particles resident in the vessel wall. In fact, plasma HDL is the predominant carrier of lipid hydroperoxides that are reduced to their corresponding hydroxides when apolipoprotein A-1 (apoA-1) methionyl residues are modified to methionine sulfoxide [493495].

Under basal conditions, HDL maintains reverse cholesterol transport by enhancing apoA-1-mediated cholesterol efflux from macrophages via the ATP-binding cassette (ABC)A1 and esterification of cholesterol by LCAT. HDL also prohibits oxidation of phospholipids in LDL through apoA-1 and paraoxonase 1, and inhibits inflammatory cytokine and adhesion molecule expression. In this manner, both oxidation of LDL and uptake by macrophages are limited as is oxLDL-mediated O2•− generation [493495, 507514]. The importance of HDL in modulating inflammation and atherosclerosis may be ascertained by studies of patients treated with recombinant HDL. A single infusion of recombinant HDL in 7 hypercholesterolemic men improved endothelial function and brachial artery flow-mediated dilation [515]. In 36 patients with acute coronary syndromes and established atherosclerosis, treatment with apoA-1Milano, an anti-atherogenic apoA-1 variant, weekly for 5 weeks resulted in a significant decrease in total coronary artery atheroma volume compared to that observed in 11 placebo-treated individuals [516].

In contrast, in a pro-atherogenic milieu, HDL transition to a proinflammatory phenotype is characterized by several structural changes: there is a decrease in apoA-1 (or it may form dimers, trimers, or aggregates with other apolipoproteins), paraoxonase-1, and LCAT content, and the particle becomes enriched in apolipoprotein J and serum amyloid A [488, 491, 493, 494, 497, 498, 517520].

Notably, the pro-atherogenic environment is characterized by an influx of inflammatory macrophages that generate O2•−, H2O2, ONOO, and, via MPO, HOCl and NO2 [68, 521]. Both MPO and lipoproteins modified by HOCl have been detected in atherosclerotic lesions [498, 522]; oxidative modification of protein tyrosyl residues to form 3-chlorotyrosine and 3-nitrotyrosine has been detected in HDL isolated from atherosclerotic plaques [522]. In fact, HDL particles isolated from patients with established cardiovascular disease demonstrated 13-fold higher levels of protein-bound 3-chlorotyrosine as well as higher levels of 3-nitrotyrosine compared to control subjects, indicating that MPO-derived species oxidized HDL in vivo [76, 523].

The functional consequences of MPO-mediated oxidatively modified HDL were determined by examining the effect of oxidation of apoA-1 on cholesterol efflux from macrophages. Here, chlorination of apoA-1 resulted in a marked decrease in cholesterol efflux, even greater than that observed with nitration of apoA-1 [523, 524]. Mass spectrometry revealed that Tyr192 of apoA-1 was the predominant chlorination site in apoA-1, and that chlorination of this residue correlated with loss of (ABC)A1 transport activity [523525]. As apoA-1 Tyr192 is located near a lysine residue and HOCl reacts with lysine ε--amino groups to form chloramines, the mechanism by which HOCl chlorinates Tyr192 likely requires participation of the lysine residue, which was confirmed in site-directed mutagenesis studies [524, 526]. Interestingly, methionine residues inhibit tyrosine chlorination by scavenging chlorinating intermediates [526, 527]; however, methionine oxidation in the absence of tyrosine chlorination does not inhibit apoA-1 cholesterol efflux activity [528]. Furthermore, site-specific substitution of methionine to valine increased the sensitivity of apoA-1 to MPO-generated oxidants confirming the role of methionine as a local residue that limits tyrosine chlorination [529]. In addition to Tyr192 chlorination, apoA-1 cholesterol efflux is also impaired by acrolein that is generated by MPO and modifies Lys226 [524]. Other studies using hydrogen-deuterium exchange mass spectrometry analysis of apoA-1 have implicated Tyr166 as a residue that preferentially undergoes oxidative modification [530]. This residue interacts with and activates LCAT. Thus, oxidative modification of apoA-1 Tyr 166 may influence cholesterol esterification by modulating LCAT function.

It has been suggested that polymorphisms in the paraoxonase 1 promoter or gene may facilitate oxidative modification of HDL and predispose individuals to atherosclerosis; however, the results from clinical studies have been largely contradictory. Paraoxonase 1 limits oxidation of LDL and HDL and mice deficient in this enzyme have been shown to have increased susceptibility to atherosclerosis [531533]. To date, two coding variants, Q192R and L55M, and five promoter polymorphisms have been identified and a functional decrease in paraoxonase 1 activity has been reported in patients with types 1 and 2 diabetes mellitus, familial hypercholesterolemia, renal disease, and established coronary heart disease [534539]. Despite these observations, the ability to link this decrease in HDL antioxidant capacity with a particular polymorphism has been challenging and has been attributed, in part, to different polymorphism distributions between races and within populations [537]. Moreover, a recent meta-analysis of 43 studies that included 11,212 cases of coronary heart disease and 12,786 control subjects revealed that only the Q192R polymorphism was associated with a slight increase in the risk for coronary heart disease [540]. Furthermore, many of the early genetic studies failed to correlate the polymorphisms with activity. Therefore, clarity about the relationship between paraoxonase 1 polymorphisms, HDL redox status, and their influence on atherogenesis awaits further study [541].

Clinical studies do, however, confirm that HDL, possibly through the aforementioned post-translational modifications, can also mediate atherosclerosis. Patients with established coronary heart disease despite very high levels of HDL cholesterol (≥84 mg/dl) have impaired functional HDL responses. Compared to healthy control subjects with similar HDL levels, HDL isolated from these patients exhibits a proinflammatory response in monocyte chemotactic assays and increases LDL oxidation [542]. Similar findings have been observed in patients with stable coronary heart disease or poorly controlled diabetes mellitus, in whom HDL particles exhibited decreased antioxidant enzyme activity and increased lipid hydroperoxide content [542, 543]. Patients with systemic inflammation attributable to non-coronary heart disease, including chronic kidney disease, rheumatoid arthritis, systemic lupus erythematosus, and solid organ transplant recipients, also demonstrate proinflammatory HDL. Interestingly, these patients are also at higher risk for developing atherosclerosis [544548].

Inflammatory cells, oxidant stress, and atherosclerosis

Neutrophils

In addition to the important role that oxidative modification of lipids and lipid-associated proteins plays in atherogenesis, there is compelling evidence to demonstrate that neutrophils participate in atherosclerosis. Epidemiological studies have demonstrated that the neutrophil-lymphocyte ratio on hospital admission for an acute coronary syndrome has prognostic value. In one study of 422 patients with ischemia and angiographically documented coronary artery disease, the neutrophil-lymphocyte ratio was found to be an independent predictor of cardiac death (HR = 8.13, p=0.02), and those patients with the highest ratio had a 10.2% decrease in event-free survival [549]. Similarly, a study of 2,833 patients with myocardial infarction revealed that patients with the highest neutrophil-lymphocyte ratio had higher in-hospital (8.5% vs. 1.8%) and 6-month (11.5% vs. 2.5%) mortality as compared to patients with the lowest ratios. When adjusted for patient clinical characteristics, individuals with the highest ratios continued to have an increased risk for in-hospital (OR = 2.04, p=0.013) and 6-month mortality (OR = 3.88, p < 0.001) [550]. Furthermore, the admission neutrophil-lymphocyte ratio on admission for acute myocardial infarction was found to predict independently an increased risk of mortality over a 2–3 year follow-up period [551, 552].

Animal models have demonstrated a predilection of neutrophils for atherosclerotic plaques. In apoE−/− mice crossed with mice homozygous for a knock-in mutation of green fluorescent protein in the lysozyme M locus, fluorescent neutrophils and monocytes were detected at the periphery of atherosclerotic plaques after 26 weeks [553]. In LDLR−/− mice, neutrophils were found attached to the plaque cap in intermediate and advanced atherosclerotic lesions after 6 weeks [554]. In human atherosclerotic plaques isolated by atherectomy or at autopsy neutrophil infiltration was also observed, mainly at the sites of plaque erosion or rupture [555].

Neutrophil recruitment to atherosclerotic plaques has been shown to be regulated by the CXC receptor 4/CXC ligand 12 axis; disruption of this axis induces a release of hematopoietic stem cells and leukocytes, including neutrophils from the bone marrow [556, 557]. CXCL 12 has been detected in atherosclerotic plaques and an inverse relationship exists between levels of CXCL 12 and unstable coronary artery disease [558, 559]. In apoE−/− or LDLR−/− mice, blockade of CXC receptor 4 resulted in increased numbers of neutrophils as well as elevated neutrophil content in atherosclerotic plaques [560].

The contribution of neutrophils to atherothrombotic vascular disease is, in part, related to production of reactive free radical species via NAD(P)H oxidase, MPO, and iNOS that increase oxidant stress and promote lipid peroxidation; these mechanisms link inflammation with oxidant stress. Fully activated neutrophils have been shown to increase O2•− production and contribute to systemic oxidant stress in hypertension, diabetes, tobacco use, and hyperlipidemia [561564]. Studies performed with neutrophils isolated from hypercholesterolemic patients demonstrated increased phorbol myristate acetate-stimulated O2•− production and adherence to endothelial cells as compared to those neutrophils isolated from control subjects [565]. Ex vivo studies performed with human neutrophils also revealed that they oxidize LDL thiols by MPO-derived HOCl and N-chloramine-dependent mechanisms [566].

Monocytes/macrophages

Circulating monocytes undergo phenotype transition to macrophages that accumulate lipid and serve as the nidus for atherosclerotic lesion formation (reviewed in [567]). Early studies that implicated monocytes in atherogenesis were performed in cholesterol-fed rabbits where examination of the aorta revealed accumulations of lipid-filled macrophages. Prior to the appearance of visible atherosclerotic plaques, macrophages were adherent to the endothelial surface and had migrated to the subendothelial space. In advanced atherosclerotic lesions, macrophage foam cells resided in the superficial layers of the plaque and within areas of necrosis. After cessation of the high cholesterol diet, the number of macrophages in the vessel wall decreased significantly, implying that monocytes participated in the initial phase of atherogenesis [568]. Monocytes and macrophages were also identified in fibro-fatty lesions and to a lesser extent in fibrous plaques and advanced lesions [569]. Immunohistochemical studies using FOH1a/DLH3, a monoclonal antibody that recognizes oxidized phosphatidylcholine in oxLDL, revealed accumulation of oxLDL in macrophages in human atherosclerotic plaques [570, 571]. Other studies that examined the progression of atherosclerosis in mice deficient in chemokines and their receptors that promote monocyte recruitment, including CCL2, CCR2, CCL5, and CCR5, revealed that genetic deletion of these chemokines or receptors increased atherosclerosis. Similarly, animal models in which monocytes or macrophages were selectively depleted reveal that atherogenesis, but not established atherosclerosis, is decreased implying that monocytes and macrophages play a critical role in early atherogenesis [572, 573]. Furthermore, the degree of monocyte accumulation in the vessel wall was found to correlate with plaque size [574].

Monocytes contribute to atherogenesis by altering the local redox state, thereby providing another link between inflammation and oxidant stress. Monocytes possess an NAD(P)H oxidase that is differentially regulated compared to neutrophil NAD(P)H oxidase, generates O2•− with peak production at 1 hour, and are capable of lipid peroxidation via NAD(P)H oxidase activation in a Ca2+- and phospholipase A2-dependent manner [575579]. In human atheroma isolated by directional atherectomy, macrophage infiltration and O2•− production were increased in plaques isolated from patients with acute coronary syndromes compared to those obtained from patients with stable angina. In these atherosclerotic plaques, O2•− colocalized with NAD(P)H oxidase subunits and oxLDL deposition [580]. The relative contribution of monocyte/macrophage-derived O2•− to atherosclerosis was determined through bone marrow transplantation studies performed with p47phox−/− mice. In these studies, deficiency of NAD(P)H oxidase activity decreased monocyte/macrophage infiltration of the vessel wall, plasma oxLDL levels, aortic O2•− production, and atherosclerotic lesion formation [188]. Monocytes also generate reactive nitrogen species, and studies performed with isolated human monocytes in the presence of NO2 were found to nitrate tyrosine residues of apoB-100 and initiate LDL lipid peroxidation. Under these conditions, both LDL nitration and lipid peroxidation were found to require monocyte activation and NO2 but were inhibited in the presence of catalase and MPO inhibitors. Further study revealed that at low rates of NO flux, monocyte-mediated LDL oxidation occurred via a MPO-H2O2 pathway, while at higher levels of NO flux, this process was more dependent upon ONOO formation [207]. Immunohistochemical studies to identify HOCl-modified epitopes in human atherosclerotic plaque using a monoclonal antibody directed against human HOCl-modified LDL demonstrated abundant staining in fibroatheroma and complex lesions that localized to monocytes/macrophages [581].

Platelets, oxidant stress, and atherothrombosis

Platelets, which are essential for primary hemostasis, promote atherothrombotic vascular disease by contributing to plaque genesis and expansion under conditions that favor increased oxidative or nitrosative stress [582587]. Much experimental evidence supports the role of platelets in atherogenesis. Studies performed in apoE−/− mice demonstrate that platelets are adherent to the endothelium prior to development of visible atherosclerotic plaques [588]. Similarly, mice deficient in von Willebrand factor, which recruits platelets to sites of vascular injury, have less atherosclerosis than wild-type mice [589]. Furthermore, the ablation of platelet-derived thromboxane delays atherogenesis in atherosclerosis-prone LDLR−/− mice [583, 584]. Platelets also facilitate the progression of atherosclerosis through the surface expression and release of P-selectin to stimulate monocytes and macrophages to synthesize and release chemoattractrants or growth factors; increased P-selectin levels have been shown to modulate atherosclerosis in apoE−/− and LDLR−/− mice [586, 587, 590, 591].

Platelet reactivity is regulated by vascular endothelium-derived prostacyclin, which inhibits platelets via increased intracellular cAMP levels; ecto-ADPase, which decreases plasma levels of ADP and ATP to limit platelet recruitment; and NO, which diffuses into platelets and modulates platelet function through cGMP-dependent and –independent processes. Platelets themselves express NOSs and synthesize NO, albeit at lesser amounts than endothelial cells [592]; however, platelet-derived NO has been shown to modulate primary platelet aggregation, contribute to platelet disaggregation, and inhibit platelet recruitment to the growing thrombus [592595]. Increased levels of platelet NO stimulate soluble guanylyl cyclase to elevate cGMP levels, resulting in decreased intracellular Ca2+ stores, phosphorylation and inhibition of the thromboxane A2 receptor, and inhibition of phosphodiesterase type 3 to elevate cAMP levels and limit platelet aggregation [596598]. Elevated cGMP levels also inhibit phosphatidylinositol 3-kinase to prevent glycoprotein IIb/IIIa activation [599]. Interestingly, NO inhibits platelet reactivity in a number of cGMP-independent mechanisms, including decreased ATP-dependent Ca2+ uptake by platelets, and by limiting exocytosis of platelet granules via S-nitrosation of N-ethylmaleimide-sensitive factor [600].

Reactive oxidant species released by vascular cells or generated by platelet themselves directly influence platelet responses, in part, by reacting with NO and inhibiting the redox-sensitive ecto-ADPases [601605]. Ex vivo studies of platelet reactivity have shown that platelets exposed to O2•−-generating systems have a decreased threshold for activation by collagen, thrombin, and ADP [604, 606]. Platelets themselves also produce free radical oxidants as evidenced by a burst of O2 consumption, O2•− production, and GSSG formation during platelet aggregation [607, 608]. There appears to be several platelet sources of ROS as thrombin-stimulated aggregation is accompanied by mitochondrial generation of H2O2, which is believed to mediate thrombin-induced apoptosis [609]. Platelets also express NAD(P)H oxidase, and activation of this enzyme to produce O2•− occurs concomitant with platelet activation [610, 611]. Platelet NAD(P)H oxidase activation stimulates glycoprotein IIb/IIIa and αIIbβ3 integrin activation, but does not influence α-granule or dense granule release [612, 613]. Increased platelet NAD(P)H oxidase-derived O2•− has also been shown to induce oxidative modifications of LDL as demonstrated by increased conjugated diene and lysophosphatidylcholine formation in collagen-stimulated platelets [611]. Enhanced lipid peroxidation, in turn, increases platelet activation and adhesion as observed in platelets exposed to F2-isoprostanes [614]. Activation of platelet NAD(P)H oxidase has also been shown to regulate platelet release of CD40 ligand (CD40L), which initiates an inflammatory response by increasing adhesion molecule expression and chemokine secretion by endothelial cells [615, 616]. Redox sensitive interactions between CD40-CD40L increase the adherence of platelets to the vessel wall [617]. Ex vivo studies performed with washed platelets revealed that uncoupled eNOS may also contribute to platelet O2•− generation, which has pathophysiological implications for atherothrombosis; however, it remains unknown if this observation resulted from depletion of cofactors that occurred during platelet processing [618]. Furthermore, it is now recognized that platelet agonists target either intra- or extracellular O2•−-generating enzymes, and selective activation of these different enzymatic sources influences the downstream effect(s) on platelet signaling. For example, both intra- and extracellular O2•− may modulate CD40L expression and release while studies performed with extracellular antioxidants suggest that only extracellular O2•− stimulates P-selectin expression, and intracellular O2•− appears to regulate αIIbβ3 integrin activation [618].

Studies examining the direct effects of ONOO on platelet reactivity have yielded conflicting results. Early studies suggested that ONOO inhibited platelet aggregation in response to ADP, collagen, or thrombin when performed in the presence of plasma, while more recent studies performed by generating endogenous ONOO at nanomolar concentrations revealed that ONOO formation increased concomitant with prostaglandin endoperoxide H2 synthase-1 activity, thromboxane A2 release, and platelet aggregation [601603, 619]. In these studies, inhibition of either NO or O2•− generation limited platelet aggregation [619]. A number of plausible mechanisms have been advanced to explain these seemingly discordant results, including the use of pharmacological concentrations of ONOO in some studies, the formation of S-nitrosothiols that act as a reservoir of NO, agonist-dependent differences in the relative amount of NO and O2•− formed resulting in non-steady state levels of ONOO, and NO-mediated S-glutathiolation of SERCA to lower intracellular Ca2+ levels [61, 602, 620, 621].

In the setting of hyperlipidemia, biologically active oxidized lipids implicated in atherogenesis have also been shown to promote platelet aggregation. Exogenously oxidized lipoproteins or oxidized LDL and HDL isolated from hypertriglyceridemic subjects increased the ADP-stimulated maximal aggregation rate of platelets compared to nonoxidized lipoproteins [622]. Oxidation of LDL yields a family of oxidized choline glycerophospholipids (oxPCCD36) that function as ligands for the macrophage scavenger receptor CD36, have been demonstrated in vivo, and have been implicated in atherosclerosis [216218]. Platelets also express CD36 and studies performed in hyperlipidemic apoE−/− and LDLR−/− mice as well as with human plasma revealed that oxPCCD36 accumulated in the plasma, bound to platelet CD36, and induced platelet activation [623]. Mechanistically, CD36-mediated platelet activation occurs through JNK phosphorylation [624].

Oxidant stress, fibrinogen, and fibrinolysis

Increased oxidant stress also favors a procoagulant state by influencing the function of key mediators of fibrinolysis. Fibrinogen is subject to a number of posttranslational modifications that result from oxidation, nitration, and homocysteinylation and influence its function. Oxidative modification of fibrinogen results in an increased carbonyl-to-protein molar ratio and decreased α-helical content of the protein. Oxidized fibrinogen forms fibrin at an accelerated rate, supports platelet aggregation, and is less efficient in stimulating plasminogen activation by tissue- plasminogen activator than non-oxidized fibrinogen [625]. Nitration of fibrinogen β-chain at Tyr292 and Tyr422 significantly accelerated thrombus formation with clots demonstrating large bundles of twisted, thin fibrin fibers with distorted clot architecture, and increased fibrin stiffness [626, 627]. Fibrinogen also undergoes posttranslational modification by homocysteine thiolactone, a metabolite of homocysteine, to yield fibrin clots that are composed of thin, densely packed fibrin fibers with increased resistance to fibrinolysis owing to homocysteinylation of twelve lysine residues and possible steric interference with the tissue plasminogen activator and plasminogen binding sites [628]. Oxidation of annexin II, an endothelial cell receptor for tissue plasminogen activator, by homocysteinylation of Cys9 leads to decreased tissue plasminogen activation, binding, and decreased activation of cell-surface plasminogen activation and fibrinolysis [629].

Oxidant stress also increases the transcription of plasminogen activator inhibitor-1 (PAI-1) that limits the effects of tissue plasminogen activator [630]. While clinical studies often find that there are increased levels of tissue plasminogen activator in patients at risk for atherosclerosis, this increase is accompanied by elevated PAI-1 levels that lead to a net inhibition of tissue-plasminogen activator activity and, therefore, explain the prothrombotic phenotype in the setting of elevated levels of tissue-plasminogen activator [631]. Although smokers, who have increased indices of oxidant stress, also have an elevated baseline release of tissue plasminogen activator and PAI-1, stimulated release of tissue plasminogen activator was significantly reduced compared to nonsmokers suggesting that a net imbalance that favored a prothrombotic state existed [9, 632]. Furthermore, in the presence of minimally oxLDL, a proatherogenic lipoprotein that contains oxidized phospholipids, endothelial cell PAI-1 protein levels were increased 2-fold and activity increased by 35% while tissue plasminogen activator protein levels decreased by 45% indicating a prothrombotic phenotype [633].

Oxidant stress and coagulation

Coagulation is supported by tissue factor, which binds to and allosterically activates factor VIIa to generate thrombin for physiological secondary hemostasis. Vascular endothelial cells, smooth muscle cells, monocytes, and macrophages all express tissue factor in response to inflammatory mediators, such as tumor necrosis factor-α, interleukin-1β, CD40L, and oxLDL [634646]. Platelets also express tissue factor, although this occurs via microparticle-bound tissue factor exchange [647]. In addition, a soluble, alternatively spliced form of tissue factor with procoagulant activity has been detected in blood; however, its clot-forming potential remains controversial [648, 649].

Oxidized phospholipids present in minimally oxLDL have been shown to stimulate coagulation by increasing expression of tissue factor via two distinct signaling pathways: activation of PKC/ERK/EGR-1 and Ca2+/calcineurin/NFAT [650]. Oxidized phospholipids have also been shown to decrease the expression of thrombomodulin protein levels by 40% resulting in a 30% reduction in activity. The oxidation products of 1- and/or 2-oleoyl phosphatidylcholine or phosphatidylethanolamine were also found to reduce tissue factor pathway inhibitor (TFPI) activity by interacting directly with the C-terminal basic region of TFPI [651]. In fact, in patients with coronary artery disease, elevated plasma levels of TFPI were found to be higher than in control subjects and associated with higher levels of oxidized lipids [652].

Tissue factor coagulant activity is dependent upon an extracellular Cys186-Cys209 disulfide bond [653]. The redox state of this bond is modulated by protein disulfide isomerase that targets the bond to suppress coagulation via thiol/disulfide exchange; this action is regulated by NO [654]. Thus, in the setting of increased oxidant stress resulting in limited NO, this mechanism will favor the procoagulant effects of tissue factor.

Immune modulation of atherosclerosis and oxidant stress

Atherogenesis involves mediators of the immune system, and studies performed in immunodeficient mice or apoE−/− mice crossed with interferon-γ−/− mice reveal a significant delay in both the onset and progression of atherosclerotic plaque formation [655]. Immunohistochemical analysis of human atherosclerotic plaques, which have been shown to contain polyclonal memory T lymphocytes that are reactive against oxLDL epitopes, further supports these observations. CD4+ lymphocytes and immune cell derived-cytokines have been shown to activate NAD(P)H oxidase, increase O2•− production, and impair vascular reactivity, early findings in atherosclerosis (Fig. 3) [656]. Together, these studies implicate oxidant stress as an integral component of the cellular immune response associated with atherosclerosis.

Figure 3
Reactive oxidant species and the pathogenesis of atherosclerosis

In advanced human atheromas, T cells comprise approximately 10–20% of the total cell population and are of the T helper-1 subset [657]. These T cells recognize antigens in a major histocompatibility complex class II manner, as well as secrete proinflammatory cytokines, including interferon-γ, interleukin-2, and tumor necrosis factor-α, that activate macrophages to increase O2•− production [658]. In a mouse model, it was shown that mice that mount a predominantly T helper-1 subset immune response have increased levels of serum interleukin-6 and develop significantly more atherosclerosis than those that mount a T helper-2 cell response, independent of lipid levels [659].

The role of oxLDL as a candidate autoantigen has been confirmed experimentally and in clinical studies [660, 661]. In apoE−/− mice with atherosclerosis, CD4+ and CD8+ T cells have been identified in the plaques, and the mice have increased levels of circulating antibodies against oxLDL [662]. Patients who present with acute coronary syndromes have been shown to have high serum levels of oxLDL antibodies that are decreased following treatment with a statin [663, 664]. Furthermore, scavenger receptors expressed by macrophages, including CD36, CD68, CXCL16, scavenger receptor-A and –B, and LOX-1, modulate the uptake of oxLDL for presentation to antigen-specific T cells [665671]. This effect, in turn, leads to upregulation of toll-like receptor-2 and toll-like receptor-4, and oxidized derivatives of LDL have been shown to bind toll-like receptor-4-CD14 complexes on monocytes/macrophages to augment the immune response [464]. Antibodies to oxLDL also bind to other oxidatively modified targets, including oxidized phosphatidylcholine generated on the surface of bacteria or endothelial cells as well as oxidation-specific epitopes on apoptotic cells [672].

In addition to oxLDL, other ROS-related candidate antigens include lipoprotein(a), advanced glycation end products, heat shock proteins, and bacterial-derived antigens. Lipoprotein(a) has been shown to be the preferential carrier of oxidized phospholipids in human plasma, and in vitro transfer studies revealed that oxLDL donates these oxidatively modified phospholipids to lipoprotein(a) in a time- and concentration-dependent manner [673]. Cross-reactivity between these candidate antigens with antibodies that recognize oxLDL epitopes augments immune activation [673]. Advanced glycation end products facilitate antigenic stimulation in atherosclerosis by increasing ROS levels to induce maturation of dendritic cells that stimulate T cell proliferation and cytokine secretion [674]. Advanced glycation end products stimulate the immune response further by signaling through toll-like receptors to propagate an immune-inflammatory response [675]. Oxidant stress has also been shown to increase expression of lymphocyte Hsp60 and members of the heat shock protein (Hsp) family, including mycobacterial Hsp65 and chlamydial Hsp60 that resemble human Hsp60 and exist in atherosclerotic lesions in experimental animal models [676680]. Furthermore, immunization with Hsp65 or Hsp60 augments atherosclerosis in both mice and rabbits [677, 681]. Interestingly, the antioxidant capacity of macrophages may regulate the chronicity of Chlamydophila pneumoniae infection. Macrophages with decreased antioxidant enzyme activity resulting in elevated levels of oxidant stress have a significant increase in the levels and duration of Hsp60 protein expression [682].

The relationship between bacterial-derived antigens and atherosclerosis is exceedingly complex. Although early studies focused on a select group of pathogens, namely Chlamydophila pneumoniae and Porphyromonas gingivalis, analysis of human coronary artery atherosclerotic plaque excised from patients by directional atherectomy revealed a high bacterial diversity with DNA from more than 50 species present that was absent from postmortem patients without heart disease [683]. Collectively, components of these bacterial pathogens may induce an immune inflammatory response through molecular mimicry, serve as ligands for toll-like receptors, and upregulate the ROS-responsive transcription factor NF-KB to promote a cascade of inflammatory events [684, 685].

Cell-free hemoglobin has also been proposed as a candidate antigen. Intraplaque hemorrhage with accumulation of erythrocyte cholesterol-containing membranes and release of hemoglobin is a frequent finding in advanced atherosclerosis [686]. Elevated levels of oxidant stress within the plaque lead to oxidative modification of cell-free hemoglobin generating targets that are identified as autoantigenic epitopes. In patients with carotid atheromas, these novel epitopes were shown to increase the population of T cells that secrete interferon-γ as well as promote maturation of human monocyte-derived dendritic cells. As such, ROS-mediated modification of cell-free hemoglobin likely contributes to the local immune-inflammatory response within the atheroma [687].

Free radical species may also provide a mechanistic link between the innate and adaptive immune responses to atherosclerosis. These radicals influence T cell expression of CD40L implying that oxidant stress may importantly modulate B cell antibody formation to putative target epitopes and antigens [688]. In fact, it has been demonstrated that activated T cells that express CD40L bind to CD40 on B cells to yield circulating antibodies to oxLDL [689, 690]. Increased oxidant stress also perpetuates the immune response by rendering T cells refractory to deactivation [691]. These observations suggest that immunomodulation of atherosclerosis as a targeted therapy may also benefit from a concomitant reduction in oxidant stress.

Oxidant stress and hemodynamic forces

Local and systemic alterations of ambient biomechanical forces inherent to the flow of blood through the vascular system also promote free radical formation and increase the predilection for atherosclerotic lesion formation. In vivo, blood vessels are subject to shear stress, a longitudinal frictional force at the blood-endothelial surface that varies between 15–75 dyne/cm2 over the cardiac cycle, as well as mechanical strain, a tangential force on the vessel wall related to blood pressure [692694]. Under basal conditions, these forces are atheroprotective and serve to limit deleterious free radical formation within physiological parameters; however, once perturbed, these protective effects are lost, flow becomes bidirectional with a time-average near 0, and free radicals may engage in local oxidation reactions more efficiently [692694]. The relationship between these hemodynamic forces, oxidant stress, and atherosclerosis is best recognized at arterial bifurcations where alternating turbulent and stagnant blood flow creates a complex flow profile and increases the susceptibility to atherothrombogenesis [695697].

Experimental evidence demonstrates the atheroprotective effects of laminar or unidirectional shear stress on the vascular endothelium. Laminar shear stress increases eNOS activity by elevating intracellular Ca2+, increases eNOS phosphorylation at Ser1177, and upregulates eNOS expression to increase NO production, as well as stimulates prostacyclin synthesis, all limiting endothelial oxidant stress [698706]. Interestingly, only steady-state pulsatile shear stress may maintain redox homeostasis. Using human coronary arteries, an abrupt increase in shear stress was shown to stimulate mitochondrial H2O2 production, and carotid arteries exposed to abnormally elevated laminar flow exhibit NAD(P)H oxidase activation and persistent O2•− production [707, 708]. Pulsatile shear stress modulates the redox environment further by increasing the antioxidant capacity of the vascular endothelium. Studies performed in vitro and using ex vivo arterial specimens have shown that pulsatile shear stress increases the expression of Cu,Zn-SOD, Mn-SOD, GPx-1, thioredoxin-1, peroxiredoxins, HO-1, NADPH:quinine oxidoreductase 1, ferritin, microsomal expoxide hydrolase, glutathione-S-transferase, gamma-glutamylcysteine synthase, and intracellular GSH stores [709716].

By contrast, oscillatory shear stress and its characteristic pattern of turbulent blood flow renders segments of the vasculature prone to atherosclerosis (Fig. 4). In vivo, low shear stress (< 0.5 Pa) predicts the development of atherosclerotic plaques characterized by abundant lipid accumulation, inflammatory cells, and a thin fibrous cap with evidence of vascular remodeling [710]. Furthermore, in a clinical study, alterations in shear stress patterns in human coronary arteries were found to correlate with areas of high strain, implying that these forces may act in concert to modulate net vascular oxidant stress [717].

Figure 4
Oscillatory shear stress increases vascular oxidant stress

Oscillatory shear stress increases oxidant stress by activating O2•−-generating enzymes and shifting mechanical-transcriptional coupling to downregulate the expression of atheroprotective mediators [718]. In vitro and in vivo, oscillatory shear stress increases vascular endothelial oxidant stress owing to increased activation and expression of the O2•−-generating enzymes NAD(P)H oxidase and xanthine oxidase with a concomitant and prolonged increase in O2•−, H2O2, and ONOO levels [719]. Turbulent flow also diminishes antioxidant capacity by downregulating antioxidant enzymes, including Mn- SOD, and decreasing GSH levels and eNOS expression [719, 720]. In this redox active environment, O2•−-sensitive transcription factors such as NF-kB are activated to induce the expression of the endothelial adhesion molecules VCAM-1, ICAM-1, and E-selectin, as well as chemokines and inflammatory cytokines that are important for leukocyte recruitment and extravasation [721].

Loss of atheroprotective hemodynamic forces, as occurs at arterial bifurcations, has further implications for the retention and oxidation of LDL. Immunostaining for 3-nitrotyrosine of explanted human coronary arteries from patients with ischemic cardiomyopathy at transplant revealed increased staining at arterial branch points characterized by oscillatory shear stress [719]. In vitro studies confirmed that under conditions of oscillatory shear stress, increased endothelial cell O2•− and ONOO production allowed for tyrosyl nitration of apoB-100 [719]. Using 2-photon microscopy of porcine or murine coronary arteries, it was determined that the vascular architecture, in fact, is permissive for atherosclerotic plaque formation at arterial branch points. Here, it was shown that the absence of the luminal surface elastin layer at arterial branch points facilitates extensive binding of LDL at these sites, while the presence of elastin throughout the remainder of the vessel lumen retarded LDL retention [722]. Taken together, these studies provide evidence for the link among flow disturbances, oxidant stress, and the inciting events of atherosclerosis.

Conclusion

In the vasculature, an increase in oxidant species, including reactive oxygen, nitrogen, or halogenating species, and free radical species such as thiyl, tyrosyl, or protein radicals defines the pathobiological state of oxidant stress. Oxidant stress can arise from pathophysiological stimulation of enzymatic sources, decreased antioxidant capacity, or both increased production and decreased antioxidant capacity. This redox imbalance in the vessel wall mediates a transition to a vascular phenotype that facilitates oxidative modification of lipids and proteins, infiltration of inflammatory and immune cells, platelet activation, and altered local hemodynamic forces. In this perturbed redox environment, oxLDL particles are engulfed by macrophages and transited to the vessel wall to serve as the nidus for atherosclerotic plaque formation. Dysregulation of antiatherogenic HDL and immune mediators by increased oxidant stress augment this response. Moreover, aberrant lipid deposition and disruption of atheroprotective laminar flow results in a pattern of alternating turbulent flow and stasis. Taken together, these findings demonstrate that free radical and redox reactive non-radical species play an integral, mechanistic role in all aspects of atherogenesis, and that adverse modification of the factors that govern the vascular redox state increase the oxidative risk of atherothrombotic cardiovascular disease.

ACKNOWLEDGEMENTS

The authors wish to thank Ms. Stephanie Tribuna for expert secretarial assistance. This work was supported by grants HL81110, HL70819, HL61795, HL81857, and HV28178.

ABBREVIATIONS

5-LO
5-lipoxygenase
AA
arachidonic acid
Ab
antibodies
ABC(A1)
ATP-binding cassette
apoA-1
apolipoprotein A-1
apoB-100
apolipoprotein B-100
apoE
apolipoprotein E
BH2
dihydrobiopterin
BH4
5,6,7,8-tetrahydrobiopterin
BR
biliverdin reductase
Cu,Zn-SOD
copper,zinc-superoxide dismutase
EC-SOD
extracellular superoxide dismutase
eIF2α
eukaryotic initiation factor 2α
eNOS
endothelial nitric oxide synthase
ERK
extracellular signal-regulated kinase
FAD
flavin adenine dinucleotide
FMN
flavin adenine mononucleotide; FLAP, 5-lipoxygenase activating protein
GSH
reduced glutathione
GSSG
oxidized glutathione
GPx
glutathione peroxidase
GST
glutathione-S-transferase
G-6-P
glucose-6-phosphate
G6PD
glucose-6-phosphate dehydrogenase
HDL
high-density lipoprotein
HETE
hydroxyl-eicosatetraenoic acid
HODE
hydroxy-octadecadienoic acid
HO-1
heme oxygenase-1
HO-2
heme oxygenase-2
Hsp
heat shock protein
ICAM-1
intercellular adhesion molecule-1
iNOS
inducible nitric oxide synthase
LCAT
lecithin:cholesterol acyltransferase
LDL
low-density lipoprotein
LSS
laminar shear stress
oxLDL
oxidized low-density lipoprotein
LOX-1
lectin-like oxidized low-density lipoprotein receptor-1
Mn-SOD
manganese-superoxide dismutase
MPO
myeloperoxidase
OSS
oscillatory shear stress
PLA2
phospholipase A2
6-PG
6-phosphogluconate
PUFA
polyunsaturated fatty acid
SOD
superoxide dismutase
NO
nitric oxide
RLP-C
remnant-like lipoprotein particle-cholesterol
ROS
reactive oxidant species
VCAM-1
vascular cell adhesion molecule-1
XO
xanthine oxidase.

Footnotes

Disclaimer: The project described was supported by Grant Numbers HL81110, HL70819, HL61795, HL81857, and HV28178 and its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

REFERENCES

1. Organization WH. Cardiovascular diseases. 2007
2. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJ., 2nd Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci U S A. 1992;89:10721–10725. [PubMed]
3. Morrow JD, Minton TA, Badr KF, Roberts LJ., 2nd Evidence that the F2-isoprostane, 8-epi-prostaglandin F2 alpha, is formed in vivo. Biochim Biophys Acta. 1994;1210:244–248. [PubMed]
4. Awad JA, Morrow JD, Takahashi K, Roberts LJ., 2nd Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. J Biol Chem. 1993;268:4161–4169. [PubMed]
5. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99:224–229. [PubMed]
6. Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R, Seta F, Capone ML, Tacconelli S, Palatresi S, Bencini C, Del Vecchio C, Mansueto G, Arosio E, Santonastaso CL, Lechi A, Morganti A, Patrono C. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation. 2002;106:2800–2805. [PubMed]
7. Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bon GB, Ciabattoni G, Patrono C. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17:3230–3235. [PubMed]
8. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002;288:2008–2014. [PubMed]
9. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ., 2nd Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 1995;332:1198–1203. [PubMed]
10. Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brummer J, Gutzki FM, Berger J, Frolich JC, Boger RH. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation. 2004;109:843–848. [PubMed]
11. Wang B, Pan J, Wang L, Zhu H, Yu R, Zou Y. Associations of plasma 8-isoprostane levels with the presence and extent of coronary stenosis in patients with coronary artery disease. Atherosclerosis. 2006;184:425–430. [PubMed]
12. Shishehbor MH, Zhang R, Medina H, Brennan ML, Brennan DM, Ellis SG, Topol EJ, Hazen SL. Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med. 2006;41:1678–1683. [PMC free article] [PubMed]
13. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF, Jr, Penn MS, Sprecher DL, Vita JA, Hazen SL. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA. 2003;289:1675–1680. [PubMed]
14. Walter MF, Jacob RF, Bjork RE, Jeffers B, Buch J, Mizuno Y, Mason RP. Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study. J Am Coll Cardiol. 2008;51:1196–1202. [PubMed]
15. Bielski BH, Shiue GG. Reaction rates of superoxide radicals with the essential amino acids. Ciba Found Symp. 1978:43–56. [PubMed]
16. Gebicki JM, Bielski BH. Comparison of the capacities of the perhydroxyl and the superoxide radicals to initiate chain oxidation of linoleic acid. J Am Chem Soc. 1981;103:7020–7022.
17. Aikens J, Dix TA. Perhydroxyl radical (HOO.) initiated lipid peroxidation. The role of fatty acid hydroperoxides. J Biol Chem. 1991;266:15091–15098. [PubMed]
18. Bielski BH, Arudi RL, Sutherland MW. A study of the reactivity of HO2/O2- with unsaturated fatty acids. J Biol Chem. 1983;258:4759–4761. [PubMed]
19. Rabani J, Nielsen J. Absorption spectrum and decay kinetics of O2 and HO2 in aqueous solutiions by pulse radiolysis. J Phys Chem. 1969;73:3736–3744.
20. Fridovich I. Superoxide dismutases. Annu Rev Biochem. 1975;44:147–159. [PubMed]
21. Rotilio G, Bray RC, Fielden EM. A pulse radiolysis study of superoxide dismutase. Biochim Biophys Acta. 1972;268:605–609. [PubMed]
22. Klug D, Rabani J, Fridovich I. A direct demonstration of the catalytic action of superoxide dismutase through the use of pulse radiolysis. J Biol Chem. 1972;247:4839–4842. [PubMed]
23. Ozawa T, Hanaki A, Matsumoto S, Matsuo M. Electron spin resonance studies of radicals obtained by the reaction of alpha-tocopherol and its model compound with superoxide ion. Biochim Biophys Acta. 1978;531:72–78. [PubMed]
24. Yim MB, Berlett BS, Chock PB, Stadtman ER. Manganese(II)-bicarbonate-mediated catalytic activity for hydrogen peroxide dismutation and amino acid oxidation: detection of free radical intermediates. Proc Natl Acad Sci U S A. 1990;87:394–398. [PubMed]
25. Rees MD, Hawkins CL, Davies MJ. Hypochlorite and superoxide radicals can act synergistically to induce fragmentation of hyaluronan and chondroitin sulphates. Biochem J. 2004;381:175–184. [PubMed]
26. Gutteridge JM, Beard AP, Quinlan GJ. Superoxide-dependent lipid peroxidation. Problems with the use of catalase as a specific probe for fenton-derived hydroxyl radicals. Biochem Biophys Res Commun. 1983;117:901–907. [PubMed]
27. Liochev SI, Fridovich I. The role of O2.- in the production of HO.: in vitro and in vivo. Free Radic Biol Med. 1994;16:29–33. [PubMed]
28. Keyer K, Gort AS, Imlay JA. Superoxide and the production of oxidative DNA damage. J Bacteriol. 1995;177:6782–6790. [PMC free article] [PubMed]
29. Keyer K, Imlay JA. Superoxide accelerates DNA damage by elevating free-iron levels. Proc Natl Acad Sci U S A. 1996;93:13635–13640. [PubMed]
30. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 1992;286(Pt 3):901–905. [PubMed]
31. Farhataziz A, Ross AB. Natl. Bur. Standards. 1977 NSRDS No. 59.
32. Dorfman LM, Adams GE. Natl. Bur. Standards. 1973 NSRDS No. 46.
33. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys. 1991;288:481–487. [PubMed]
34. Moore KP, Darley-Usmar V, Morrow J, Roberts LJ., 2nd Formation of F2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite. Circ Res. 1995;77:335–341. [PubMed]
35. Darley-Usmar VM, Hogg N, O'Leary VJ, Wilson MT, Moncada S. The simultaneous generation of superoxide and nitric oxide can initiate lipid peroxidation in human low density lipoprotein. Free Radic Res Commun. 1992;17:9–20. [PubMed]
36. Field L, Dilts RV, Ravichandran R, Lenhert PG, Carnahan GE. An unusually stable thionitrite from N-acetyl-D,L-penicillamine; X-ray crystal and molecular structure of 2-(acetylamino)-2-carboxy-1,1-dimethylethyl thionitrite. J Am Chem Soc, Chem Commun. 1978:249–250.
37. Padmaja S, Huie RE. The reaction of nitric oxide with organic peroxyl radicals. Biochem Biophys Res Commun. 1993;195:539–544. [PubMed]
38. Beckman JS, Ischiropoulos H, Zhu L, van der Woerd M, Smith C, Chen J, Harrison J, Martin JC, Tsai M. Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch Biochem Biophys. 1992;298:438–445. [PubMed]
39. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, Beckman JS. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys. 1992;298:431–437. [PubMed]
40. Schulz U, McCalla DR. Reactions of cysteine with N-methyl-N-nitroso-p-toluenesulfonamide and N-methyl-N′-nitro-N-nitrosoguanidine. Can J Chem. 1969;47:2021–2027.
41. Koppenol WH. Thermodynamics of reactions involving nitrogen-oxygen compounds. Methods Enzymol. 1996;268:7–12. [PubMed]
42. Grisham MB, Miles AM. Effects of aminosalicylates and immunosuppressive agents on nitric oxide-dependent N-nitrosation reactions. Biochem Pharmacol. 1994;47:1897–1902. [PubMed]
43. Ignarro LJ, Fukuto JM, Griscavage JM, Rogers NE, Byrns RE. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: comparison with enzymatically formed nitric oxide from L-arginine. Proc Natl Acad Sci U S A. 1993;90:8103–8107. [PubMed]
44. Lewis RS, Deen WM. Kinetics of the reaction of nitric oxide with oxygen in aqueous solutions. Chem Res Toxicol. 1994;7:568–574. [PubMed]
45. Ford PC, Wink DA, Stanbury DM. Autoxidation kinetics of aqueous nitric oxide. FEBS Lett. 1993;326:1–3. [PubMed]
46. Wink DA, Darbyshire JF, Nims RW, Saavedra JE, Ford PC. Reactions of the bioregulatory agent nitric oxide in oxygenated aqueous media: determination of the kinetics for oxidation and nitrosation by intermediates generated in the NO/O2 reaction. Chem Res Toxicol. 1993;6:23–27. [PubMed]
47. Kharitonov VG, Sundquist AR, Sharma VS. Kinetics of nitric oxide autoxidation in aqueous solution. J Biol Chem. 1994;269:5881–5883. [PubMed]
48. Brennan ML, Wu W, Fu X, Shen Z, Song W, Frost H, Vadseth C, Narine L, Lenkiewicz E, Borchers MT, Lusis AJ, Lee JJ, Lee NA, Abu-Soud HM, Ischiropoulos H, Hazen SL. A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. J Biol Chem. 2002;277:17415–17427. [PubMed]
49. Gallon AA, Pryor WA. The reaction of low levels of nitrogen dioxide with methyl linoleate in the presence and absence of oxygen. Lipids. 1994;29:171–176. [PubMed]
50. Pryor WA, Lightsey JW. Mechanisms of Nitrogen Dioxide Reactions: Initiation of Lipid Peroxidation and the Production of Nitrous Acid. Science. 1981;214:435–437. [PubMed]
51. Halliwell B, Hu ML, Louie S, Duvall TR, Tarkington BK, Motchnik P, Cross CE. Interaction of nitrogen dioxide with human plasma. Antioxidant depletion and oxidative damage. FEBS Lett. 1992;313:62–66. [PubMed]
52. Thomas HV, Mueller PK, Lyman RL. Lipoperoxidation of lung lipids in rats exposed to nitrogen dioxide. Science. 1968;159:532–534. [PubMed]
53. Huie RE, Padmaja S. The reaction of no with superoxide. Free Radic Res Commun. 1993;18:195–199. [PubMed]
54. Koppenol WH, Moreno JJ, Pryor WA, Ischiropoulos H, Beckman JS. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem Res Toxicol. 1992;5:834–842. [PubMed]
55. Kissner R, Nauser T, Bugnon P, Lye PG, Koppenol WH. Formation and properties of peroxynitrite as studied by laser flash photolysis, high-pressure stopped-flow technique, and pulse radiolysis. Chem Res Toxicol. 1997;10:1285–1292. [PubMed]
56. Radi R, Denicola A, Alvarez B, Ferrer B, Rubbo H. The biological chemistry of peroxynitrite. San Diego: Academic Press; 2000.
57. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990;87:1620–1624. [PubMed]
58. Uppu RM, Pryor WA. Carbon dioxide catalysis of the reaction of peroxynitrite with ethyl acetoacetate: an example of aliphatic nitration by peroxynitrite. Biochem Biophys Res Commun. 1996;229:764–769. [PubMed]
59. Denicola A, Freeman BA, Trujillo M, Radi R. Peroxynitrite reaction with carbon dioxide/bicarbonate: kinetics and influence on peroxynitrite-mediated oxidations. Arch Biochem Biophys. 1996;333:49–58. [PubMed]
60. Beckman JS, Chen J, Ischiropoulos H, Crow JP. Oxidative chemistry of peroxynitrite. Methods Enzymol. 1994;233:229–240. [PubMed]
61. Jourd'heuil D, Jourd'heuil FL, Kutchukian PS, Musah RA, Wink DA, Grisham MB. Reaction of superoxide and nitric oxide with peroxynitrite. Implications for peroxynitrite-mediated oxidation reactions in vivo. J Biol Chem. 2001;276:28799–28805. [PubMed]
62. Lehnig M, Kirsch M. 15N CIDNP investigations of the peroxynitric acid nitration of L-tyrosine and of related compounds. Org Biomol Chem. 2006;4:721–729. [PubMed]
63. Alvarez B, Denicola A, Radi R. Reaction between peroxynitrite and hydrogen peroxide: formation of oxygen and slowing of peroxynitrite decomposition. Chem Res Toxicol. 1995;8:859–864. [PubMed]
64. Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, Kirk M, Freeman BA. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem. 1994;269:26066–26075. [PubMed]
65. Nappi AJ, Vass E. Hydroxyl radical formation resulting from the interaction of nitric oxide and hydrogen peroxide. Biochim Biophys Acta. 1998;1380:55–63. [PubMed]
66. Buxton BF, Greenstock CL, Helman WP, Ross AB. Critical review of rate constants for reactions of hydrated electrons. Hydrogen atoms and hydroxyl radicals in aqueous solution. J Phys Chem Ref Data. 1988;17:513–886.
67. Eiserich JP, Cross CE, Jones AD, Halliwell B, van der Vliet A. Formation of nitrating and chlorinating species by reaction of nitrite with hypochlorous acid. A novel mechanism for nitric oxide-mediated protein modification. J Biol Chem. 1996;271:19199–19208. [PubMed]
68. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, van der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature. 1998;391:393–397. [PubMed]
69. Eiserich JP, Vossen V, O'Neill CA, Halliwell B, Cross CE, van der Vliet A. Molecular mechanisms of damage by excess nitrogen oxides: nitration of tyrosine by gas-phase cigarette smoke. FEBS Lett. 1994;353:53–56. [PubMed]
70. Thomas DD, Espey MG, Vitek MP, Miranda KM, Wink DA. Protein nitration is mediated by heme and free metals through Fenton-type chemistry: an alternative to the NO/O2- reaction. Proc Natl Acad Sci U S A. 2002;99:12691–12696. [PubMed]
71. Souza JM, Peluffo G, Radi R. Protein tyrosine nitration--functional alteration or just a biomarker? Free Radic Biol Med. 2008;45:357–366. [PubMed]
72. Beckmann JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, White CR. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler. 1994;375:81–88. [PubMed]
73. Leeuwenburgh C, Hardy MM, Hazen SL, Wagner P, Oh-ishi S, Steinbrecher UP, Heinecke JW. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem. 1997;272:1433–1436. [PubMed]
74. Hunter GC, Henderson AM, Westerband A, Kobayashi H, Suzuki F, Yan ZQ, Sirsjo A, Putnam CW, Hansson GK. The contribution of inducible nitric oxide and cytomegalovirus to the stability of complex carotid plaque. J Vasc Surg. 1999;30:36–49. discussion 50. [PubMed]
75. Sucu N, Unlu A, Tamer L, Aytacoglu B, Ercan B, Dikmengil M, Atik U. 3-Nitrotyrosine in atherosclerotic blood vessels. Clin Chem Lab Med. 2003;41:23–25. [PubMed]
76. Pennathur S, Bergt C, Shao B, Byun J, Kassim SY, Singh P, Green PS, McDonald TO, Brunzell J, Chait A, Oram JF, O'Brien K, Geary RL, Heinecke JW. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem. 2004;279:42977–42983. [PubMed]
77. Troxler M, Naseem KM, Homer-Vanniasinkam S. Increased nitrotyrosine production in patients undergoing abdominal aortic aneurysm repair. Br J Surg. 2004;91:1146–1151. [PubMed]
78. Nanetti L, Taffi R, Vignini A, Moroni C, Raffaelli F, Bacchetti T, Silvestrini M, Provinciali L, Mazzanti L. Reactive oxygen species plasmatic levels in ischemic stroke. Mol Cell Biochem. 2007;303:19–25. [PubMed]
79. Baker PR, Lin Y, Schopfer FJ, Woodcock SR, Groeger AL, Batthyany C, Sweeney S, Long MH, Iles KE, Baker LM, Branchaud BP, Chen YE, Freeman BA. Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J Biol Chem. 2005;280:42464–42475. [PMC free article] [PubMed]
80. Lima ES, Di Mascio P, Abdalla DS. Cholesteryl nitrolinoleate, a nitrated lipid present in human blood plasma and lipoproteins. J Lipid Res. 2003;44:1660–1666. [PubMed]
81. Balazy M, Iesaki T, Park JL, Jiang H, Kaminski PM, Wolin MS. Vicinal nitrohydroxyeicosatrienoic acids: vasodilator lipids formed by reaction of nitrogen dioxide with arachidonic acid. J Pharmacol Exp Ther. 2001;299:611–619. [PubMed]
82. Napolitano A, Camera E, Picardo M, d'Ischia M. Acid-promoted reactions of ethyl linoleate with nitrite ions: formation and structural characterization of isomeric nitroalkene, nitrohydroxy, and novel 3-nitro-1,5-hexadiene and 1,5-dinitro-1, 3-pentadiene products. J Org Chem. 2000;65:4853–4860. [PubMed]
83. Castro L, Eiserich JP, Sweeney S, Radi R, Freeman BA. Cytochrome c: a catalyst and target of nitrite-hydrogen peroxide-dependent protein nitration. Arch Biochem Biophys. 2004;421:99–107. [PubMed]
84. O'Donnell VB, Eiserich JP, Chumley PH, Jablonsky MJ, Krishna NR, Kirk M, Barnes S, Darley-Usmar VM, Freeman BA. Nitration of unsaturated fatty acids by nitric oxide-derived reactive nitrogen species peroxynitrite, nitrous acid, nitrogen dioxide, and nitronium ion. Chem Res Toxicol. 1999;12:83–92. [PubMed]
85. O'Donnell VB, Freeman BA. Interactions between nitric oxide and lipid oxidation pathways: implications for vascular disease. Circ Res. 2001;88:12–21. [PubMed]
86. Lima ES, Bonini MG, Augusto O, Barbeiro HV, Souza HP, Abdalla DS. Nitrated lipids decompose to nitric oxide and lipid radicals and cause vasorelaxation. Free Radic Biol Med. 2005;39:532–539. [PubMed]
87. Gorczynski MJ, Huang J, King SB. Regio- and stereospecific syntheses and nitric oxide donor properties of (E)-9- and (E)-10-nitrooctadec-9-enoic acids. Org Lett. 2006;8:2305–2308. [PMC free article] [PubMed]
88. Batthyany C, Schopfer FJ, Baker PR, Duran R, Baker LM, Huang Y, Cervenansky C, Branchaud BP, Freeman BA. Reversible post-translational modification of proteins by nitrated fatty acids in vivo. J Biol Chem. 2006;281:20450–20463. [PMC free article] [PubMed]
89. Baker LM, Baker PR, Golin-Bisello F, Schopfer FJ, Fink M, Woodcock SR, Branchaud BP, Radi R, Freeman BA. Nitro-fatty acid reaction with glutathione and cysteine. Kinetic analysis of thiol alkylation by a Michael addition reaction. J Biol Chem. 2007;282:31085–31093. [PMC free article] [PubMed]
90. Freeman BA, Baker PR, Schopfer FJ, Woodcock SR, Napolitano A. d'Ischia, M. Nitro-fatty acid formation and signaling. J Biol Chem. 2008;283:15515–15519. [PMC free article] [PubMed]
91. Rudolph V, Schopfer FJ, Khoo NK, Rudolph TK, Cole MP, Woodcock SR, Bonacci G, Groeger AL, Golin-Bisello F, Chen CS, Baker PR, Freeman BA. Nitro-fatty acid metabolome: saturation, desaturation, beta-oxidation, and protein adduction. J Biol Chem. 2009;284:1461–1473. [PMC free article] [PubMed]
92. Cui T, Schopfer FJ, Zhang J, Chen K, Ichikawa T, Baker PR, Batthyany C, Chacko BK, Feng X, Patel RP, Agarwal A, Freeman BA, Chen YE. Nitrated fatty acids: Endogenous anti-inflammatory signaling mediators. J Biol Chem. 2006;281:35686–35698. [PMC free article] [PubMed]
93. Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, Chen K, Chen YE, Freeman BA. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci U S A. 2005;102:2340–2345. [PubMed]
94. Lim DG, Sweeney S, Bloodsworth A, White CR, Chumley PH, Krishna NR, Schopfer F, O'Donnell VB, Eiserich JP, Freeman BA. Nitrolinoleate, a nitric oxide-derived mediator of cell function: synthesis, characterization, and vasomotor activity. Proc Natl Acad Sci U S A. 2002;99:15941–15946. [PubMed]
95. Coles B, Bloodsworth A, Clark SR, Lewis MJ, Cross AR, Freeman BA, O'Donnell VB. Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel antiinflammatory properties of nitric oxide-derived reactive species in vascular cells. Circ Res. 2002;91:375–381. [PubMed]
96. Ichikawa T, Zhang J, Chen K, Liu Y, Schopfer FJ, Baker PR, Freeman BA, Chen YE, Cui T. Nitroalkenes suppress lipopolysaccharide-induced signal transducer and activator of transcription signaling in macrophages: a critical role of mitogen-activated protein kinase phosphatase 1. Endocrinology. 2008;149:4086–4094. [PubMed]
97. Trostchansky A, Souza JM, Ferreira A, Ferrari M, Blanco F, Trujillo M, Castro D, Cerecetto H, Baker PR, O'Donnell VB, Rubbo H. Synthesis, isomer characterization, and anti-inflammatory properties of nitroarachidonate. Biochemistry. 2007;46:4645–4653. [PubMed]
98. Wanikiat P, Woodward DF, Armstrong RA. Investigation of the role of nitric oxide and cyclic GMP in both the activation and inhibition of human neutrophils. Br J Pharmacol. 1997;122:1135–1145. [PMC free article] [PubMed]
99. Iles KE, Wright MM, Cole MP, Welty NE, Ware LB, Matthay MA, Schopfer FJ, Baker PR, Agarwal A, Freeman BA. Fatty acid transduction of nitric oxide signaling: nitrolinoleic acid mediates protective effects through regulation of the ERK pathway. Free Radic Biol Med. 2009;46:866–875. [PMC free article] [PubMed]
100. Wright MM, Schopfer FJ, Baker PR, Vidyasagar V, Powell P, Chumley P, Iles KE, Freeman BA, Agarwal A. Fatty acid transduction of nitric oxide signaling: nitrolinoleic acid potently activates endothelial heme oxygenase 1 expression. Proc Natl Acad Sci U S A. 2006;103:4299–4304. [PubMed]
101. Villacorta L, Zhang J, Garcia-Barrio MT, Chen XL, Freeman BA, Chen YE, Cui T. Nitro-linoleic acid inhibits vascular smooth muscle cell proliferation via the Keap1/Nrf2 signaling pathway. Am J Physiol Heart Circ Physiol. 2007;293:H770–H776. [PMC free article] [PubMed]
102. Buettner GR. Thiyl free radical production with hematoporphyrin derivative, cysteine and light: a spin-trapping study. FEBS Lett. 1984;177:295–299. [PubMed]
103. Augusto O, Gatti RM, Radi R. Spin-trapping studies of peroxynitrite decomposition and of 3-morpholinosydnonimine N-ethylcarbamide autooxidation: direct evidence for metal-independent formation of free radical intermediates. Arch Biochem Biophys. 1994;310:118–125. [PubMed]
104. Antholine WE, Kalyanaraman B, Templin JA, Byrnes RW, Petering DH. Spin-trapping studies of the oxidation-reduction reactions of iron bleomycin in the presence of thiols and buffer. Free Radic Biol Med. 1991;10:119–123. [PubMed]
105. Wefers H, Sies H. Oxidation of glutathione by the superoxide radical to the disulfide and the sulfonate yielding singlet oxygen. Eur J Biochem. 1983;137:29–36. [PubMed]
106. Cakir S, Bicer E. The interaction of cysteine with chromium(VI) ions under UV irradiation. Bioelectrochemistry. 2005;67:75–80. [PubMed]
107. Akhlaq MS, Schuchmann HP, von Sonntag C. The reverse of the 'repair' reaction of thiols: H-abstraction at carbon by thiyl radicals. Int J Radiat Biol Relat Stud Phys Chem Med. 1987;51:91–102. [PubMed]
108. Schaefer K, Bonifacic M, Bahnemann K, Asmus K-D. Addition of oxygen to organic sulfur radicals. J Phys Chem. 1978;82:2777–2780.
109. Forni LG, Monig J, Mora-Arellano V, Willson RL. Thiyl free radicals: direct observations of electron transfer reactions with phenothiazines and ascorbate. J Am Chem Soc, Perkin Trans 2. 1983;2:961–966.
110. Forni LG, Willson RL. Thiyl and phenoxyl free radicals and NADH. Direct observation of one-electron oxidation. Biochem J. 1986;240:897–903. [PubMed]
111. Forni LG, Willson RL. Thiyl free radicals and the oxidation of ferrocytochrome c. Direct observation of coupled hydrogen-atom-and electron-transfer reactions. Biochem J. 1986;240:905–907. [PubMed]
112. Chatgilialoglu C, Zambonin L, Altieri A, Ferreri C, Mulazzani QG, Landi L. Geometrical isomerism of monounsaturated fatty acids: thiyl radical catalysis and influence of antioxidant vitamins. Free Radic Biol Med. 2002;33:1681–1692. [PubMed]
113. Ito O, Matsuda M. Kinetic study for addition rates of phenylthio radicals to cis- and trans-β-methylstyrenes. J Org Chem. 1983;48:2748–2751.
114. Chamulitrat W, Jordan SJ, Mason RP. Fatty acid radical formation in rats administered oxidized fatty acids: in vivo spin trapping investigation. Arch Biochem Biophys. 1992;299:361–367. [PubMed]
115. Gatti RM, Radi R, Augusto O. Peroxynitrite-mediated oxidation of albumin to the protein-thiyl free radical. FEBS Lett. 1994;348:287–290. [PubMed]
116. Vasquez-Vivar J, Santos AM, Junqueira VB, Augusto O. Peroxynitrite-mediated formation of free radicals in human plasma: EPR detection of ascorbyl, albumin-thiyl and uric acid-derived free radicals. Biochem J. 1996;314(Pt 3):869–876. [PubMed]
117. Ferreri C, Constantino C, Landi L, Mulazzani QG, Chatgilialoglu C. The thiyl radical-mediated isomerization of cis-monounsaturated fatty acid residues in phospholipids: a novel path of membrane damage? Chem Commun. 1999;5:407–408.
118. Ferreri C, Costantino C, Perrotta L, Landi L, Mulazzani QG, Chatgilialoglu C. Cis-trans isomerization of polyunsaturated fatty acid residues in phospholipids catalyzed by thiyl radicals. J Am Chem Soc. 2001;123:4459–4468. [PubMed]
119. Ferreri C, Faraone Mennella MR, Formisano C, Landi L, Chatgilialoglu C. Arachidonate geometrical isomers generated by thiyl radicals: the relationship with trans lipids detected in biological samples. Free Radic Biol Med. 2002;33:1516–1526. [PubMed]
120. Jiang H, Kruger N, Lahiri DR, Wang D, Vatele JM, Balazy M. Nitrogen dioxide induces cis-trans-isomerization of arachidonic acid within cellular phospholipids. Detection of trans-arachidonic acids in vivo. J Biol Chem. 1999;274:16235–16241. [PubMed]
121. Sprinz H, Schwinn J, Naumov S, Brede O. Mechanism of thiyl radical-catalyzed isomerization of unsaturated fatty acid residues in homogeneous solution and in liposomes. Biochim Biophys Acta. 2000;1483:91–100. [PubMed]
122. Chatgilialoglu C, Altieri A, Fischer H. The kinetics of thiyl radical-induced reactions of monounsaturated fatty acid esters. J Am Chem Soc. 2002;124:12816–12823. [PubMed]
123. Sprinz H, Adhikari S, Brede O. Transformation of phospholipid membranes by thiyl radicals via cis-trans isomerization of fatty acid residues. Adv Colloid Interface Sci. 2001;89(90):313–325. [PubMed]
124. Ferreri C, Samadi A, Sassatelli F, Landi L, Chatgilialoglu C. Regioselective cis-trans isomerization of arachidonic double bonds by thiyl radicals: the influence of phospholipid supramolecular organization. J Am Chem Soc. 2004;126:1063–1072. [PubMed]
125. Roach C, Feller SE, Ward JA, Shaikh SR, Zerouga M, Stillwell W. Comparison of cis and trans fatty acid containing phosphatidylcholines on membrane properties. Biochemistry. 2004;43:6344–6351. [PubMed]
126. Sebedio JL, Vermunt SH, Chardigny JM, Beaufrere B, Mensink RP, Armstrong RA, Christie WW, Niemela J, Henon G, Riemersma RA. The effect of dietary trans alpha-linolenic acid on plasma lipids and platelet fatty acid composition: the TransLinE study. Eur J Clin Nutr. 2000;54:104–113. [PubMed]
127. Beyers EC, Emken EA. Metabolites of cis,trans, and trans,cis isomers of linoleic acid in mice and incorporation into tissue lipids. Biochim Biophys Acta. 1991;1082:275–284. [PubMed]
128. Grandgirard A, Piconneaux A, Sebedio JL, O'Keefe SF, Semon E, Le Quere JL. Occurrence of geometrical isomers of eicosapentaenoic and docosahexaenoic acids in liver lipids of rats fed heated linseed oil. Lipids. 1989;24:799–804. [PubMed]
129. Zambonin L, Ferreri C, Cabrini L, Prata C, Chatgilialoglu C, Landi L. Occurrence of trans fatty acids in rats fed a trans-free diet: a free radical-mediated formation? Free Radic Biol Med. 2006;40:1549–1556. [PubMed]
130. Zambonin L, Prata C, Cabrini L, Maraldi T, Fiorentini D, Vieceli Dalla Sega F, Hakim G, Landi L. Effect of radical stress and ageing on the occurrence of trans fatty acids in rats fed a trans-free diet. Free Radic Biol Med. 2008;44:594–601. [PubMed]
131. Ascherio A. Epidemiologic studies on dietary fats and coronary heart disease. Am J Med. 2002;113 Suppl 9B:9S–12S. [PubMed]
132. Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med. 1990;323:439–445. [PubMed]
133. Vermunt SH, Beaufrere B, Riemersma RA, Sebedio JL, Chardigny JM, Mensink RP. TransLin EI a. Dietary trans alpha-linolenic acid from deodorized rapeseed oil and plasma lipids and lipoproteins in healthy men: the TransLinE Study. Br J Nutr. 2001;85:387–392. [PubMed]
134. Ascherio A, Katan MB, Zock PL, Stampfer MJ, Willett WC. Trans fatty acids and coronary heart disease. N Engl J Med. 1999;340:1994–1998. [PubMed]
135. Lopez-Garcia E, Schulze MB, Meigs JB, Manson JE, Rifai N, Stampfer MJ, Willett WC, Hu FB. Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr. 2005;135:562–566. [PubMed]
136. Mozaffarian D, Rimm EB, King IB, Lawler RL, McDonald GB, Levy WC. trans fatty acids and systemic inflammation in heart failure. Am J Clin Nutr. 2004;80:1521–1525. [PMC free article] [PubMed]
137. Moens AL, Goovaerts I, Claeys MJ, Vrints CJ. Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool? Chest. 2005;127:2254–2263. [PubMed]
138. Schoneich C, Asmus KD, Dillinger U, von Bruchhausen F. Thiyl radical attack on polyunsaturated fatty acids: a possible route to lipid peroxidation. Biochem Biophys Res Commun. 1989;161:113–120. [PubMed]
139. Schoneich C, Dillinger U, von Bruchhausen F, Asmus KD. Oxidation of polyunsaturated fatty acids and lipids through thiyl and sulfonyl radicals: reaction kinetics, and influence of oxygen and structure of thiyl radicals. Arch Biochem Biophys. 1992;292:456–467. [PubMed]
140. Wagner BA, Buettner GR, Burns CP. Free radical-mediated lipid peroxidation in cells: oxidizability is a function of cell lipid bis-allylic hydrogen content. Biochemistry. 1994;33:4449–4453. [PubMed]
141. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem. 1987;262:10098–10103. [PubMed]
142. Ferreri C, Kratzsch S, Brede O, Marciniak B, Chatgilialoglu C. Trans lipid formation induced by thiols in human monocytic leukemia cells. Free Radic Biol Med. 2005;38:1180–1187. [PubMed]
143. Heinecke JW, Li W, Francis GA, Goldstein JA. Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins. J Clin Invest. 1993;91:2866–2872. [PMC free article] [PubMed]
144. Davies KJ, Delsignore ME, Lin SW. Protein damage and degradation by oxygen radicals. II. Modification of amino acids. J Biol Chem. 1987;262:9902–9907. [PubMed]
145. van der Vliet A, Eiserich JP, O'Neill CA, Halliwell B, Cross CE. Tyrosine modification by reactive nitrogen species: a closer look. Arch Biochem Biophys. 1995;319:341–349. [PubMed]
146. Hunter EP, Desrosiers MF, Simic MG. The effect of oxygen, antioxidants, and superoxide radical on tyrosine phenoxyl radical dimerization. Free Radic Biol Med. 1989;6:581–585. [PubMed]
147. Jin F, Leitich J, von Sonntag c. The superoxide radical reacts with tyrosine-derived phenoxyl radicals by addition rather than electron transfer. J Am Chem Soc Perkins Trans 2. 1993;9:1583–1588.
148. Heinecke JW, Li W, Daehnke HL, 3rd, Goldstein JA. Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem. 1993;268:4069–4077. [PubMed]
149. Hazen SL, Hsu FF, Heinecke JW. p-Hydroxyphenylacetaldehyde is the major product of L-tyrosine oxidation by activated human phagocytes. A chloride-dependent mechanism for the conversion of free amino acids into reactive aldehydes by myeloperoxidase. J Biol Chem. 1996;271:1861–1867. [PubMed]
150. Hazen SL, Gaut JP, Hsu FF, Crowley JR, d'Avignon A, Heinecke JW. p-Hydroxyphenylacetaldehyde, the major product of L-tyrosine oxidation by the myeloperoxidase-H2O2-chloride system of phagocytes, covalently modifies epsilon-amino groups of protein lysine residues. J Biol Chem. 1997;272:16990–16998. [PubMed]
151. Savenkova ML, Mueller DM, Heinecke JW. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem. 1994;269:20394–20400. [PubMed]
152. Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller DM, Pennathur S, Heinecke JW. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem. 1997;272:3520–3526. [PubMed]
153. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, Jones OT. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol. 1996;271:H1626–H1634. [PubMed]
154. Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C, Ballinger CA, Brasier AR, Bode C, Runge MS. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem. 1999;274:19814–19822. [PubMed]
155. Bayraktutan U, Draper N, Lang D, Shah AM. Expression of functional neutrophil-type NADPH oxidase in cultured rat coronary microvascular endothelial cells. Cardiovasc Res. 1998;38:256–262. [PubMed]
156. Jones SA, Hancock JT, Jones OT, Neubauer A, Topley N. The expression of NADPH oxidase components in human glomerular mesangial cells: detection of protein and mRNA for p47phox, p67phox, and p22phox. J Am Soc Nephrol. 1995;5:1483–1491. [PubMed]
157. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem. 1996;271:23317–23321. [PubMed]
158. Chen XL, Zhang Q, Zhao R, Ding X, Tummala PE, Medford RM. Rac1 and superoxide are required for the expression of cell adhesion molecules induced by tumor necrosis factor-alpha in endothelial cells. J Pharmacol Exp Ther. 2003;305:573–580. [PubMed]
159. Segal AW, West I, Wientjes F, Nugent JH, Chavan AJ, Haley B, Garcia RC, Rosen H, Scrace G. Cytochrome b-245 is a flavocytochrome containing FAD and the NADPH-binding site of the microbicidal oxidase of phagocytes. Biochem J. 1992;284(Pt 3):781–788. [PubMed]
160. Burritt JB, DeLeo FR, McDonald CL, Prigge JR, Dinauer MC, Nakamura M, Nauseef WM, Jesaitis AJ. Phage display epitope mapping of human neutrophil flavocytochrome b558. Identification of two juxtaposed extracellular domains. J Biol Chem. 2001;276:2053–2061. [PubMed]
161. Burritt JB, Foubert TR, Baniulis D, Lord CI, Taylor RM, Mills JS, Baughan TD, Roos D, Parkos CA, Jesaitis AJ. Functional epitope on human neutrophil flavocytochrome b558. J Immunol. 2003;170:6082–6089. [PubMed]
162. Imajoh-Ohmi S, Tokita K, Ochiai H, Nakamura M, Kanegasaki S. Topology of cytochrome b558 in neutrophil membrane analyzed by anti-peptide antibodies and proteolysis. J Biol Chem. 1992;267:180–184. [PubMed]
163. Rotrosen D, Kleinberg ME, Nunoi H, Leto T, Gallin JI, Malech HL. Evidence for a functional cytoplasmic domain of phagocyte oxidase cytochrome b558. J Biol Chem. 1990;265:8745–8750. [PubMed]
164. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285:R277–R297. [PubMed]
165. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, Griendling KK. Novel gp91(phox) homologues in vascular smooth muscle cells : nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res. 2001;88:888–894. [PubMed]
166. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, Schiffrin EL. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res. 2002;90:1205–1213. [PubMed]
167. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation. 2002;105:1429–1435. [PubMed]
168. Groemping Y, Lapouge K, Smerdon SJ, Rittinger K. Molecular basis of phosphorylation-induced activation of the NADPH oxidase. Cell. 2003;113:343–355. [PubMed]
169. Clark RA, Leidal KG, Pearson DW, Nauseef WM. NADPH oxidase of human neutrophils. Subcellular localization and characterization of an arachidonate-activatable superoxide-generating system. J Biol Chem. 1987;262:4065–4074. [PubMed]
170. Gertzberg N, Neumann P, Rizzo V, Johnson A. NAD(P)H oxidase mediates the endothelial barrier dysfunction induced by TNF-alpha. Am J Physiol Lung Cell Mol Physiol. 2004;286:L37–L48. [PubMed]
171. Li JM, Fan LM, Christie MR, Shah AM. Acute tumor necrosis factor alpha signaling via NADPH oxidase in microvascular endothelial cells: role of p47phox phosphorylation and binding to TRAF4. Mol Cell Biol. 2005;25:2320–2330. [PMC free article] [PubMed]
172. Li JM, Shah AM. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem. 2002;277:19952–19960. [PubMed]
173. Hashikabe Y, Suzuki K, Jojima T, Uchida K, Hattori Y. Aldosterone impairs vascular endothelial cell function. J Cardiovasc Pharmacol. 2006;47:609–613. [PubMed]
174. Hwang J, Saha A, Boo YC, Sorescu GP, McNally JS, Holland SM, Dikalov S, Giddens DP, Griendling KK, Harrison DG, Jo H. Oscillatory shear stress stimulates endothelial production of O2- from p47phox-dependent NAD(P)H oxidases, leading to monocyte adhesion. J Biol Chem. 2003;278:47291–47298. [PubMed]
175. Sorescu GP, Song H, Tressel SL, Hwang J, Dikalov S, Smith DA, Boyd NL, Platt MO, Lassegue B, Griendling KK, Jo H. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res. 2004;95:773–779. [PubMed]
176. Csiszar A, Ahmad M, Smith KE, Labinskyy N, Gao Q, Kaley G, Edwards JG, Wolin MS, Ungvari Z. Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype. Am J Pathol. 2006;168:629–638. [PubMed]
177. Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H, Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation. 1998;97:135–137. [PubMed]
178. Shimokata K, Yamada Y, Kondo T, Ichihara S, Izawa H, Nagata K, Murohara T, Ohno M, Yokota M. Association of gene polymorphisms with coronary artery disease in individuals with or without nonfamilial hypercholesterolemia. Atherosclerosis. 2004;172:167–173. [PubMed]
179. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation. 2000;102:1744–1747. [PubMed]
180. Moreno MU, San Jose G, Fortuno A, Beloqui O, Redon J, Chaves FJ, Corella D, Diez J, Zalba G. A novel CYBA variant, the -675A/T polymorphism, is associated with essential hypertension. J Hypertens. 2007;25:1620–1626. [PubMed]
181. Fan M, Raitakari OT, Kahonen M, Juonala M, Hutri-Kahonen N, Porsti I, Viikari J, Lehtimaki T. The association between cigarette smoking and carotid intima-media thickness is influenced by the -930A/G CYBA gene polymorphism: the Cardiovascular Risk in Young Finns Study. Am J Hypertens. 2009;22:281–287. [PubMed]
182. Guzik TJ, Chen W, Gongora MC, Guzik B, Lob HE, Mangalat D, Hoch N, Dikalov S, Rudzinski P, Kapelak B, Sadowski J, Harrison DG. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol. 2008;52:1803–1809. [PMC free article] [PubMed]
183. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation. 2002;105:1656–1662. [PubMed]
184. Guzik TJ, Sadowski J, Guzik B, Jopek A, Kapelak B, Przybylowski P, Wierzbicki K, Korbut R, Harrison DG, Channon KM. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol. 2006;26:333–339. [PubMed]
185. Terashima M, Inoue N, Ohashi Y, Yokoyama M. Relationship between coronary plaque formation and NAD(P)H oxidase-derived reactive oxygen species - comparison of intravascular ultrasound finding of atherosclerotic lesions with histochemical characteristics. Kobe J Med Sci. 2007;53:107–117. [PubMed]
186. Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke JW, LeBoeuf RC. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2000;20:1529–1535. [PubMed]
187. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, Runge MS. p47phox is required for atherosclerotic lesion progression in ApoE(−/−) mice. J Clin Invest. 2001;108:1513–1522. [PMC free article] [PubMed]
188. Vendrov AE, Hakim ZS, Madamanchi NR, Rojas M, Madamanchi C, Runge MS. Atherosclerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells. Arterioscler Thromb Vasc Biol. 2007;27:2714–2721. [PubMed]
189. Nauseef WM. Myeloperoxidase biosynthesis by a human promyelocytic leukemia cell line: insight into myeloperoxidase deficiency. Blood. 1986;67:865–872. [PubMed]
190. Nauseef WM, Malech HL. Analysis of the peptide subunits of human neutrophil myeloperoxidase. Blood. 1986;67:1504–1507. [PubMed]
191. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 1994;94:437–444. [PMC free article] [PubMed]
192. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997;99:2075–2081. [PMC free article] [PubMed]
193. Harrison JE, Schultz J. Studies on the chlorinating activity of myeloperoxidase. J Biol Chem. 1976;251:1371–1374. [PubMed]
194. Weiss SJ, Test ST, Eckmann CM, Roos D, Regiani S. Brominating oxidants generated by human eosinophils. Science. 1986;234:200–203. [PubMed]
195. van der Vliet A, Eiserich JP, Halliwell B, Cross CE. Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity. J Biol Chem. 1997;272:7617–7625. [PubMed]
196. Marquez LA, Dunford HB. Reaction of compound III of myeloperoxidase with ascorbic acid. J Biol Chem. 1990;265:6074–6078. [PubMed]
197. Metodiewa D, Dunford HB. The role of myeloperoxidase in the oxidation of biologically active polyhydroxyphenols (substituted catechols) Eur J Biochem. 1990;193:445–448. [PubMed]
198. Klebanoff SJ. Estrogen binding by leukocytes during phagocytosis. J Exp Med. 1977;145:983–998. [PMC free article] [PubMed]
199. Svensson BE. Involvement of cysteine, serotonin and their analogues in peroxidase-oxidase reactions. Chem Biol Interact. 1989;70:305–321. [PubMed]
200. Abu-Soud HM, Hazen SL. Nitric oxide modulates the catalytic activity of myeloperoxidase. J Biol Chem. 2000;275:5425–5430. [PubMed]
201. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem. 2000;275:37524–37532. [PubMed]
202. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, Castro L, Lusis AJ, Nauseef WM, White CR, Freeman BA. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002;296:2391–2394. [PubMed]
203. Kettle AJ, van Dalen CJ, Winterbourn CC. Peroxynitrite and myeloperoxidase leave the same footprint in protein nitration. Redox Rep. 1997;3:257–258. [PubMed]
204. Albrich JM, McCarthy CA, Hurst JK. Biological reactivity of hypochlorous acid: implications for microbicidal mechanisms of leukocyte myeloperoxidase. Proc Natl Acad Sci U S A. 1981;78:210–214. [PubMed]
205. Thomas EL, Jefferson MM, Grisham MB. Myeloperoxidase-catalyzed incorporation of amines into proteins: role of hypochlorous acid and dichloramines. Biochemistry. 1982;21:6299–6308. [PubMed]
206. Heinecke JW, Li W, Mueller DM, Bohrer A, Turk J. Cholesterol chlorohydrin synthesis by the myeloperoxidase-hydrogen peroxide-chloride system: potential markers for lipoproteins oxidatively damaged by phagocytes. Biochemistry. 1994;33:10127–10136. [PubMed]
207. Hazen SL, Zhang R, Shen Z, Wu W, Podrez EA, MacPherson JC, Schmitt D, Mitra SN, Mukhopadhyay C, Chen Y, Cohen PA, Hoff HF, Abu-Soud HM. Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation In vivo. Circ Res. 1999;85:950–958. [PubMed]
208. Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y, Suzuki D, Miyata T, Noguchi N, Niki E, Osawa T. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci U S A. 1998;95:4882–4887. [PubMed]
209. Anderson MM, Hazen SL, Hsu FF, Heinecke JW. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxyamino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest. 1997;99:424–432. [PMC free article] [PubMed]
210. Hazen SL, Gaut JP, Crowley JR, Hsu FF, Heinecke JW. Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions. Biochem J. 2000;352(Pt 3):693–699. [PubMed]
211. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest. 1996;97:1535–1544. [PMC free article] [PubMed]
212. Hazell LJ, Stocker R. Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem J. 1993;290(Pt 1):165–172. [PubMed]
213. Schmidt H, Grune T, Muller R, Siems WG, Wauer RR. Increased levels of lipid peroxidation products malondialdehyde and 4-hydroxynonenal after perinatal hypoxia. Pediatr Res. 1996;40:15–20. [PubMed]
214. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103:1547–1560. [PMC free article] [PubMed]
215. Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, Hajjar DP, Cohen PA, Frazier WA, Hoff HF, Hazen SL. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000;105:1095–1108. [PMC free article] [PubMed]
216. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105:1049–1056. [PMC free article] [PubMed]
217. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Febbraio M, Hajjar DP, Silverstein RL, Hoff HF, Salomon RG, Hazen SL. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem. 2002;277:38517–38523. [PubMed]
218. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Gugiu B, Fox PL, Hoff HF, Salomon RG, Hazen SL. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem. 2002;277:38503–38516. [PubMed]
219. Kersten HW, Moorer WR, Wever R. Thiocyanate as a cofactor in myeloperoxidase activity against Streptococcus mutans. J Dent Res. 1981;60:831–837. [PubMed]
220. Arlandson M, Decker T, Roongta VA, Bonilla L, Mayo KH, MacPherson JC, Hazen SL, Slungaard A. Eosinophil peroxidase oxidation of thiocyanate. Characterization of major reaction products and a potential sulfhydryl-targeted cytotoxicity system. J Biol Chem. 2001;276:215–224. [PubMed]
221. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007;13:1176–1184. [PubMed]
222. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol. 2004;24:1309–1314. [PubMed]
223. Thukkani AK, McHowat J, Hsu FF, Brennan ML, Hazen SL, Ford D. A. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation. 2003;108:3128–3133. [PubMed]
224. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem. 276:41279–41287. [PubMed]
225. Kumar AP, Reynolds WF. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun. 2005;331:442–451. [PubMed]
226. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003;108:426–431. [PubMed]
227. Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol. 2000;104:10–15. [PubMed]
228. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J. 2001;142:336–339. [PubMed]
229. Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, Jessurun GA, Tio RA. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med. 2004;116:429–430. [PubMed]
230. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136–2142. [PubMed]
231. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF, Jr, Hazen SL. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004;110:1134–1139. [PMC free article] [PubMed]
232. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;50:159–165. [PubMed]
233. Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SL. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J. 2008;29:1096–1102. [PMC free article] [PubMed]
234. Olson JS, Ballou DP, Palmer G, Massey V. The mechanism of action of xanthine oxidase. J Biol Chem. 1974;249:4363–4382. [PubMed]
235. Olson JS, Ballow DP, Palmer G, Massey V. The reaction of xanthine oxidase with molecular oxygen. J Biol Chem. 1974;249:4350–4362. [PubMed]
236. Hille R, Massey V. Studies on the oxidative half-reaction of xanthine oxidase. J Biol Chem. 1981;256:9090–9095. [PubMed]
237. Porras AG, Olson JS, Palmer G. The reaction of reduced xanthine oxidase with oxygen. Kinetics of peroxide and superoxide formation. J Biol Chem. 1981;256:9006–9103. [PubMed]
238. Harris CM, Massey V. The oxidative half-reaction of xanthine dehydrogenase with NAD; reaction kinetics and steady-state mechanism. J Biol Chem. 1997;272:28335–28341. [PubMed]
239. Sanders SA, Eisenthal R, Harrison R. NADH oxidase activity of human xanthine oxidoreductase--generation of superoxide anion. Eur J Biochem. 1997;245:541–548. [PubMed]
240. Zhang Z, Blake DR, Stevens CR, Kanczler JM, Winyard PG, Symons MC, Benboubetra M, Harrison R. A reappraisal of xanthine dehydrogenase and oxidase in hypoxic reperfusion injury: the role of NADH as an electron donor. Free Radic Res. 1998;28:151–164. [PubMed]
241. Xia M, Dempski R, Hille R. The reductive half-reaction of xanthine oxidase. Reaction with aldehyde substrates and identification of the catalytically labile oxygen. J Biol Chem. 1999;274:3323–3330. [PubMed]
242. Krenitsky TA, Spector T, Hall WW. Xanthine oxidase from human liver: purification and characterization. Arch Biochem Biophys. 1986;247:108–119. [PubMed]
243. Enroth C, Eger BT, Okamoto K, Nishino T, Pai EF. Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion. Proc Natl Acad Sci U S A. 2000;97:10723–10728. [PubMed]
244. Marti R, Varela E, Pascual C, Segura RM. Determination of xanthine oxidoreductase forms: influence of reaction conditions. Clin Chim Acta. 2001;303:117–125. [PubMed]
245. Linder N, Rapola J, Raivio KO. Cellular expression of xanthine oxidoreductase protein in normal human tissues. Lab Invest. 1999;79:967–974. [PubMed]
246. Hellsten-Westing Y. Immunohistochemical localization of xanthine oxidase in human cardiac and skeletal muscle. Histochemistry. 1993;100:215–222. [PubMed]
247. Stirpe F, Della Corte E. The regulation of rat liver xanthine oxidase. Conversion in vitro of the enzyme activity from dehydrogenase (type D) to oxidase (type O) J Biol Chem. 1969;244:3855–3863. [PubMed]
248. Nishino T. The conversion from the dehydrogenase type to the oxidase type of rat liver xanthine dehydrogenase by modification of cysteine residues with fluorodinitrobenzene. J Biol Chem. 1997;272:29859–29864. [PubMed]
249. Della Corte E, Stirpe F. The regulation of xanthine oxidase. Inhibition by reduced nicotinamide-adenine dinucleotide of rat liver xanthine oxidase type D and of chick liver xanthine dehydrogenase. Biochem J. 1970;117:97–100. [PubMed]
250. Poss WB, Huecksteadt TP, Panus PC, Freeman BA, Hoidal JR. Regulation of xanthine dehydrogenase and xanthine oxidase activity by hypoxia. Am J Physiol. 1996;270:L941–L946. [PubMed]
251. Della Corte E, Gozzetti G, Novello F, Stirpe F. Properties of the xanthine oxidase from human liver. Biochim Biophys Acta. 1969;191:164–166. [PubMed]
252. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164:1546–1551. [PubMed]
253. Spiekermann S, Landmesser U, Dikalov S, Bredt M, Gamez G, Tatge H, Reepschlager N, Hornig B, Drexler H, Harrison DG. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. 2003;107:1383–1389. [PubMed]
254. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks DA, Tarpey MM, Freeman BA. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A. 1996;93:8745–8749. [PubMed]
255. Gimpel JA, Lahpor JR, van der Molen AJ, Damen J, Hitchcock JF. Reduction of reperfusion injury of human myocardium by allopurinol: a clinical study. Free Radic Biol Med. 1995;19:251–255. [PubMed]
256. Guan W, Osanai T, Kamada T, Hanada H, Ishizaka H, Onodera H, Iwasa A, Fujita N, Kudo S, Ohkubo T, Okumura K. Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol. 2003;41:699–705. [PubMed]
257. Schroder K, Vecchione C, Jung O, Schreiber JG, Shiri-Sverdlov R, van Gorp PJ, Busse R, Brandes RP. Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet. Free Radic Biol Med. 2006;41:1353–1360. [PubMed]
258. Millar TM, Stevens CR, Benjamin N, Eisenthal R, Harrison R, Blake DR. Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS Lett. 1998;427:225–228. [PubMed]
259. Li H, Samouilov A, Liu X, Zweier JL. Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrate reduction: evaluation of its role in nitrite and nitric oxide generation in anoxic tissues. Biochemistry. 2003;42:1150–1159. [PubMed]
260. Zhang Z, Naughton D, Winyard PG, Benjamin N, Blake DR, Symons MC. Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. Biochem Biophys Res Commun. 1998;249:767–772. [PubMed]
261. Godber BL, Doel JJ, Sapkota GP, Blake DR, Stevens CR, Eisenthal R, Harrison R. Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase. J Biol Chem. 2000;275:7757–7763. [PubMed]
262. Li H, Samouilov A, Liu X, Zweier JL. Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrite reduction. Evaluation of its role in nitric oxide generation in anoxic tissues. J Biol Chem. 2001;276:24482–24489. [PubMed]
263. Kudo M, Moteki T, Sasaki T, Konno Y, Ujiie S, Onose A, Mizugaki M, Ishikawa M, Hiratsuka M. Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet Genomics. 2008;18:243–251. [PubMed]
264. Yang J, Kamide K, Kokubo Y, Takiuchi S, Horio T, Matayoshi T, Yasuda H, Miwa Y, Yoshii M, Yoshihara F, Nakamura S, Nakahama H, Tomoike H, Miyata T, Kawano Y. Associations of hypertension and its complications with variations in the xanthine dehydrogenase gene. Hypertens Res. 2008;31:931–940. [PubMed]
265. Landmesser U, Spiekermann S, Preuss C, Sorrentino S, Fischer D, Manes C, Mueller M, Drexler H. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol. 2007;27:943–948. [PubMed]
266. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987;237:1171–1176. [PubMed]
267. Nelson MJ, Seitz SP, Cowling RA. Enzyme-bound pentadienyl and peroxyl radicals in purple lipoxygenase. Biochemistry. 1990;29:6897–6903. [PubMed]
268. Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J Clin Invest. 1995;96:504–510. [PMC free article] [PubMed]
269. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, Glass CK, Sigal E, Witztum JL, Steinberg D. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci U S A. 1990;87:6959–6963. [PubMed]
270. Kuhn H, Heydeck D, Hugou I, Gniwotta C. In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J Clin Invest. 1997;99:888–893. [PMC free article] [PubMed]
271. Cyrus T, Pratico D, Zhao L, Witztum JL, Rader DJ, Rokach J, FitzGerald GA, Funk CD. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation. 2001;103:2277–2282. [PubMed]
272. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest. 1999;103:1597–1604. [PMC free article] [PubMed]
273. George J, Afek A, Shaish A, Levkovitz H, Bloom N, Cyrus T, Zhao L, Funk CD, Sigal E, Harats D. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation. 2001;104:1646–1650. [PubMed]
274. Bolick DT, Srinivasan S, Whetzel A, Fuller LC, Hedrick CC. 12/15 lipoxygenase mediates monocyte adhesion to aortic endothelium in apolipoprotein E-deficient mice through activation of RhoA and NF-kappaB. Arterioscler Thromb Vasc Biol. 2006;26:1260–1266. [PubMed]
275. Huo Y, Zhao L, Hyman MC, Shashkin P, Harry BL, Burcin T, Forlow SB, Stark MA, Smith DF, Clarke S, Srinivasan S, Hedrick CC, Pratico D, Witztum JL, Nadler JL, Funk CD, Ley K. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004;110:2024–2031. [PubMed]
276. Assimes TL, Knowles JW, Priest JR, Basu A, Borchert A, Volcik KA, Grove ML, Tabor HK, Southwick A, Tabibiazar R, Sidney S, Boerwinkle E, Go AS, Iribarren C, Hlatky MA, Fortmann SP, Myers RM, Kuhn H, Risch N, Quertermous T. A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease. Atherosclerosis. 2008;198:136–144. [PMC free article] [PubMed]
277. McCaskie PA, Beilby JP, Hung J, Chapman CM, McQuillan BM, Powell BL, Thompson PL, Palmer LJ. 15-Lipoxygenase gene variants are associated with carotid plaque but not carotid intima-media thickness. Hum Genet. 2008;123:445–453. [PubMed]
278. McIntyre TM, Zimmerman GA, Prescott SM. Leukotrienes C4 and D4 stimulate human endothelial cells to synthesize platelet-activating factor and bind neutrophils. Proc Natl Acad Sci U S A. 1986;83:2204–2208. [PubMed]
279. Porreca E, Conti P, Feliciani C, Di Febbo C, Reale M, Mincione G, Neri M, Amerio P, Cuccurullo F. Cysteinyl-leukotriene D4 induced IL-1 beta expression and release in rat vascular smooth muscle cells. Atherosclerosis. 1995;115:181–189. [PubMed]
280. Allen S, Dashwood M, Morrison K, Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation. 1998;97:2406–2413. [PubMed]
281. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol. 2002;22:443–449. [PubMed]
282. Friedrich EB, Tager AM, Liu E, Pettersson A, Owman C, Munn L, Luster AD, Gerszten RE. Mechanisms of leukotriene B4--triggered monocyte adhesion. Arterioscler Thromb Vasc Biol. 2003;23:1761–1767. [PubMed]
283. Subbarao K, Jala VR, Mathis S, Suttles J, Zacharias W, Ahamed J, Ali H, Tseng MT, Haribabu B. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol. 2004;24:369–375. [PubMed]
284. Heller EA, Liu E, Tager AM, Sinha S, Roberts JD, Koehn SL, Libby P, Aikawa ER, Chen JQ, Huang P, Freeman MW, Moore KJ, Luster AD, Gerszten RE. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation. 2005;112:578–586. [PubMed]
285. Back M, Bu DX, Branstrom R, Sheikine Y, Yan ZQ, Hansson GK. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A. 2005;102:17501–17506. [PubMed]
286. Qiu H, Gabrielsen A, Agardh HE, Wan M, Wetterholm A, Wong CH, Hedin U, Swedenborg J, Hansson GK, Samuelsson B, Paulsson-Berne G, Haeggstrom JZ. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci U S A. 2006;103:8161–8166. [PubMed]
287. Zhou YJ, Wang JH, Li L, Yang HW, Wen de L, He QC. Expanding expression of the 5-lipoxygenase/leukotriene B4 pathway in atherosclerotic lesions of diabetic patients promotes plaque instability. Biochem Biophys Res Commun. 2007;363:30–36. [PubMed]
288. Mehrabian M, Wong J, Wang X, Jiang Z, Shi W, Fogelman AM, Lusis AJ. Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res. 2001;89:125–130. [PubMed]
289. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002;91:120–126. [PubMed]
290. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, Moos MP, Kaiser B, Cohnert TU, Wahlers T, Zieske A, Plenz G, Robenek H, Salbach P, Kuhn H, Radmark O, Samuelsson B, Habenicht AJ. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A. 2003;100:1238–1243. [PubMed]
291. Cipollone F, Mezzetti A, Fazia ML, Cuccurullo C, Iezzi A, Ucchino S, Spigonardo F, Bucci M, Cuccurullo F, Prescott SM, Stafforini DM. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol. 2005;25:1665–1670. [PubMed]
292. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004;350:29–37. [PubMed]
293. Oosterveer DM, Versmissen J, Yazdanpanah M, van der Net JB, Defesche JC, Kastelein JJ, Sijbrands EJ. 5-Lipoxygenase activating protein (ALOX5AP) gene variants associate with the presence of xanthomas in familial hypercholesterolemia. Atherosclerosis. 2009 [PubMed]
294. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, Samani NJ, Gudmundsson G, Grant SF, Thorgeirsson G, Sveinbjornsdottir S, Valdimarsson EM, Matthiasson SE, Johannsson H, Gudmundsdottir O, Gurney ME, Sainz J, Thorhallsdottir M, Andresdottir M, Frigge ML, Topol EJ, Kong A, Gudnason V, Hakonarson H, Gulcher JR, Stefansson K. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233–239. [PubMed]
295. Helgadottir A, Gretarsdottir S, St Clair D, Manolescu A, Cheung J, Thorleifsson G, Pasdar A, Grant SF, Whalley LJ, Hakonarson H, Thorsteinsdottir U, Kong A, Gulcher J, Stefansson K, MacLeod MJ. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet. 2005;76:505–509. [PubMed]
296. Helgadottir A, Manolescu A, Helgason A, Thorleifsson G, Thorsteinsdottir U, Gudbjartsson DF, Gretarsdottir S, Magnusson KP, Gudmundsson G, Hicks A, Jonsson T, Grant SF, Sainz J, O'Brien SJ, Sveinbjornsdottir S, Valdimarsson EM, Matthiasson SE, Levey AI, Abramson JL, Reilly MP, Vaccarino V, Wolfe ML, Gudnason V, Quyyumi AA, Topol EJ, Rader DJ, Thorgeirsson G, Gulcher JR, Hakonarson H, Kong A, Stefansson K. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet. 2006;38:68–74. [PubMed]
297. Jawien J, Gajda M, Rudling M, Mateuszuk L, Olszanecki R, Guzik TJ, Cichocki T, Chlopicki S, Korbut R. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest. 2006;36:141–146. [PubMed]
298. Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D, Zink F, Andresdottir M, Manolescu A, Arnar DO, Andersen K, Sigurdsson A, Thorgeirsson G, Jonsson A, Agnarsson U, Bjornsdottir H, Gottskalksson G, Einarsson A, Gudmundsdottir H, Adalsteinsdottir AE, Gudmundsson K, Kristjansson K, Hardarson T, Kristinsson A, Topol EJ, Gulcher J, Kong A, Gurney M, Stefansson K. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA. 2005;293:2245–2256. [PubMed]
299. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA., Jr Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A. 1998;95:9220–9225. [PubMed]
300. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest. 2002;109:817–826. [PMC free article] [PubMed]
301. Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, Hirata K, Yasui H, Sakurai H, Yoshida Y, Masada M, Yokoyama M. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest. 2002;110:331–340. [PMC free article] [PubMed]
302. Bendall JK, Alp NJ, Warrick N, Cai S, Adlam D, Rockett K, Yokoyama M, Kawashima S, Channon KM. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. Circ Res. 2005;97:864–871. [PubMed]
303. Alp NJ, McAteer MA, Khoo J, Choudhury RP, Channon KM. Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 2004;24:445–450. [PubMed]
304. Takaya T, Hirata K, Yamashita T, Shinohara M, Sasaki N, Inoue N, Yada T, Goto M, Fukatsu A, Hayashi T, Alp NJ, Channon KM, Yokoyama M, Kawashima S. A specific role for eNOS-derived reactive oxygen species in atherosclerosis progression. Arterioscler Thromb Vasc Biol. 2007;27:1632–1637. [PubMed]
305. Tegeder I, Costigan M, Griffin RS, Abele A, Belfer I, Schmidt H, Ehnert C, Nejim J, Marian C, Scholz J, Wu T, Allchorne A, Diatchenko L, Binshtok AM, Goldman D, Adolph J, Sama S, Atlas SJ, Carlezon WA, Parsegian A, Lotsch J, Fillingim RB, Maixner W, Geisslinger G, Max MB, Woolf CJ. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med. 2006;12:1269–1277. [PubMed]
306. Lotsch J, Belfer I, Kirchhof A, Mishra BK, Max MB, Doehring A, Costigan M, Woolf CJ, Geisslinger G, Tegeder I. Reliable screening for a pain-protective haplotype in the GTP cyclohydrolase 1 gene (GCH1) through the use of 3 or fewer single nucleotide polymorphisms. Clin Chem. 2007;53:1010–1015. [PubMed]
307. Antoniades C, Shirodaria C, Van Assche T, Cunnington C, Tegeder I, Lotsch J, Guzik TJ, Leeson P, Diesch J, Tousoulis D, Stefanadis C, Costigan M, Woolf CJ, Alp NJ, Channon KM. GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function. J Am Coll Cardiol. 2008;52:158–165. [PMC free article] [PubMed]
308. Zhang L, Rao F, Zhang K, Khandrika S, Das M, Vaingankar SM, Bao X, Rana BK, Smith DW, Wessel J, Salem RM, Rodriguez-Flores JL, Mahata SK, Schork NJ, Ziegler MG, O'Connor DT. Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk. J Clin Invest. 2007;117:2658–2671. [PubMed]
309. Singh U, Devaraj S, Vasquez-Vivar J, Jialal I. C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol. 2007;43:780–791. [PMC free article] [PubMed]
310. Wohlfart P, Xu H, Endlich A, Habermeier A, Closs EI, Hubschle T, Mang C, Strobel H, Suzuki T, Kleinert H, Forstermann U, Ruetten H, Li H. Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther. 2008;325:370–379. [PubMed]
311. Pritchard KA, Jr, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, Wolin MS, Stemerman MB. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res. 1995;77:510–518. [PubMed]
312. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001;88:E14–E22. [PubMed]
313. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111:1201–1209. [PMC free article] [PubMed]
314. Vasquez-Vivar J, Duquaine D, Whitsett J, Kalyanaraman B, Rajagopalan S. Altered tetrahydrobiopterin metabolism in atherosclerosis: implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants. Arterioscler Thromb Vasc Biol. 2002;22:1655–1661. [PubMed]
315. Antoniades C, Shirodaria C, Crabtree M, Rinze R, Alp N, Cunnington C, Diesch J, Tousoulis D, Stefanadis C, Leeson P, Ratnatunga C, Pillai R, Channon KM. Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation. 2007;116:2851–2859. [PubMed]
316. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, Leeson P, Neubauer S, Ratnatunga C, Pillai R, Refsum H, Channon KM. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation. 2006;114:1193–1201. [PubMed]
317. Xie QW, Cho HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TD, Ding A, Troso T, Nathan C. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science. 1992;256:225–228. [PubMed]
318. Buttery LD, Springall DR, Chester AH, Evans TJ, Standfield EN, Parums DV, Yacoub MH, Polak JM. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest. 1996;75:77–85. [PubMed]
319. Luoma JS, Yla-Herttuala S. Expression of inducible nitric oxide synthase in macrophages and smooth muscle cells in various types of human atherosclerotic lesions. Virchows Arch. 1999;434:561–568. [PubMed]
320. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG, Marsden PA. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol. 1997;17:2479–2488. [PubMed]
321. Cromheeke KM, Kockx MM, De Meyer GR, Bosmans JM, Bult H, Beelaerts WJ, Vrints CJ, Herman AG. Inducible nitric oxide synthase colocalizes with signs of lipid oxidation/peroxidation in human atherosclerotic plaques. Cardiovasc Res. 1999;43:744–754. [PubMed]
322. Miyoshi T, Li Y, Shih DM, Wang X, Laubach VE, Matsumoto AH, Helm GA, Lusis AJ, Shi W. Deficiency of inducible NO synthase reduces advanced but not early atherosclerosis in apolipoprotein E-deficient mice. Life Sci. 2006;79:525–531. [PubMed]
323. Niu XL, Yang X, Hoshiai K, Tanaka K, Sawamura S, Koga Y, Nakazawa H. Inducible nitric oxide synthase deficiency does not affect the susceptibility of mice to atherosclerosis but increases collagen content in lesions. Circulation. 2001;103:1115–1120. [PubMed]
324. Chen J, Kuhlencordt P, Urano F, Ichinose H, Astern J, Huang PL. Effects of chronic treatment with L-arginine on atherosclerosis in apoE knockout and apoE/inducible NO synthase double-knockout mice. Arterioscler Thromb Vasc Biol. 2003;23:97–103. [PubMed]
325. Detmers PA, Hernandez M, Mudgett J, Hassing H, Burton C, Mundt S, Chun S, Fletcher D, Card DJ, Lisnock J, Weikel R, Bergstrom JD, Shevell DE, Hermanowski-Vosatka A, Sparrow CP, Chao YS, Rader DJ, Wright SD, Pure E. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol. 2000;165:3430–3435. [PubMed]
326. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation. 2001;103:3099–3104. [PubMed]
327. Upmacis RK, Crabtree MJ, Deeb RS, Shen H, Lane PB, Benguigui LE, Maeda N, Hajjar DP, Gross SS. Profound biopterin oxidation and protein tyrosine nitration in tissues of ApoE-null mice on an atherogenic diet: contribution of inducible nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2007;293:H2878–H2887. [PubMed]
328. Stadler K, Bonini MG, Dallas S, Jiang J, Radi R, Mason RP, Kadiiska MB. Involvement of inducible nitric oxide synthase in hydroxyl radical-mediated lipid peroxidation in streptozotocin-induced diabetes. Free Radic Biol Med. 2008;45:866–874. [PMC free article] [PubMed]
329. Staniek K, Nohl H. H(2)O(2) detection from intact mitochondria as a measure for one-electron reduction of dioxygen requires a non-invasive assay system. Biochim Biophys Acta. 1999;1413:70–80. [PubMed]
330. Boveris A, Oshino N, Chance B. The cellular production of hydrogen peroxide. Biochem J. 1972;128:617–630. [PubMed]
331. Tyler DD. Polarographic assay and intracellular distribution of superoxide dismutase in rat liver. Biochem J. 1975;147:493–504. [PubMed]
332. Ballinger SW, Patterson C, Knight-Lozano CA, Burow DL, Conklin CA, Hu Z, Reuf J, Horaist C, Lebovitz R, Hunter GC, McIntyre K, Runge MS. Mitochondrial integrity and function in atherogenesis. Circulation. 2002;106:544–549. [PubMed]
333. Zmijewski JW, Moellering DR, Le Goffe C, Landar A, Ramachandran A, Darley-Usmar VM. Oxidized LDL induces mitochondrially associated reactive oxygen/nitrogen species formation in endothelial cells. Am J Physiol Heart Circ Physiol. 2005;289:H852–H861. [PubMed]
334. Landar A, Zmijewski JW, Dickinson DA, Le Goffe C, Johnson MS, Milne GL, Zanoni G, Vidari G, Morrow JD, Darley-Usmar VM. Interaction of electrophilic lipid oxidation products with mitochondria in endothelial cells and formation of reactive oxygen species. Am J Physiol Heart Circ Physiol. 2006;290:H1777–H1787. [PubMed]
335. Verkaart S, Koopman WJ, van Emst-de Vries SE, Nijtmans LG, van den Heuvel LW, Smeitink JA, Willems PH. Superoxide production is inversely related to complex I activity in inherited complex I deficiency. Biochim Biophys Acta. 2007;1772:373–381. [PubMed]
336. McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein) J Biol Chem. 1969;244:6049–6055. [PubMed]
337. McCord JM, Fridovich I. The utility of superoxide dismutase in studying free radical reactions. I. Radicals generated by the interaction of sulfite, dimethyl sulfoxide, and oxygen. J Biol Chem. 1969;244:6056–6063. [PubMed]
338. Marklund SL. Human copper-containing superoxide dismutase of high molecular weight. Proc Natl Acad Sci U S A. 1982;79:7634–7638. [PubMed]
339. Marklund SL. Extracellular superoxide dismutase in human tissues and human cell lines. J Clin Invest. 1984;74:1398–1403. [PMC free article] [PubMed]
340. Zipper H, Person P, O'Connell DJ. Redox interactions between cytochrome components and transition ions and metals. Biochemistry. 1972;11:4686–4691. [PubMed]
341. Weisiger RA, Fridovich I. Mitochondrial superoxide simutase. Site of synthesis and intramitochondrial localization. J Biol Chem. 1973;248:4793–4796. [PubMed]
342. Weisiger RA, Fridovich I. Superoxide dismutase. Organelle specificity. J Biol Chem. 1973;248:3582–3592. [PubMed]
343. Oury TD, Crapo JD, Valnickova Z, Enghild JJ. Human extracellular superoxide dismutase is a tetramer composed of two disulphide-linked dimers: a simplified, high-yield purification of extracellular superoxide dismutase. Biochem J. 1996;317(Pt 1):51–57. [PubMed]
344. Petersen SV, Oury TD, Valnickova Z, Thogersen IB, Hojrup P, Crapo JD, Enghild JJ. The dual nature of human extracellular superoxide dismutase: one sequence and two structures. Proc Natl Acad Sci U S A. 2003;100:13875–13880. [PubMed]
345. Yamada H, Yamada Y, Adachi T, Fukatsu A, Sakuma M, Futenma A, Kakumu S. Protective role of extracellular superoxide dismutase in hemodialysis patients. Nephron. 2000;84:218–223. [PubMed]
346. Marklund SL, Nilsson P, Israelsson K, Schampi I, Peltonen M, Asplund K. Two variants of extracellular-superoxide dismutase: relationship to cardiovascular risk factors in an unselected middle-aged population. J Intern Med. 1997;242:5–14. [PubMed]
347. Juul K, Tybjaerg-Hansen A, Marklund S, Heegaard NH, Steffensen R, Sillesen H, Jensen G, Nordestgaard BG. Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study. Circulation. 2004;109:59–65. [PubMed]
348. Chu Y, Alwahdani A, Iida S, Lund DD, Faraci FM, Heistad DD. Vascular effects of the human extracellular superoxide dismutase R213G variant. Circulation. 2005;112:1047–1053. [PubMed]
349. Lund DD, Chu Y, Brooks RM, Faraci FM, Heistad DD. Effects of a common human gene variant of extracellular superoxide dismutase on endothelial function after endotoxin in mice. J Physiol. 2007;584:583–590. [PubMed]
350. Zhou L, Xiang W, Potts J, Floyd M, Sharan C, Yang H, Ross J, Nyanda AM, Guo Z. Reduction in extracellular superoxide dismutase activity in African-American patients with hypertension. Free Radic Biol Med. 2006;41:1384–1391. [PubMed]
351. Yamashita K, Takahiro K, Kamezaki F, Adachi T, Tasaki H. Decreased plasma extracellular superoxide dismutase level in patients with vasospastic angina. Atherosclerosis. 2007;191:147–152. [PubMed]
352. Di Massimo C, Scarpelli P, Di Lorenzo N, Caimi G, di Orio F, Ciancarelli MG. Impaired plasma nitric oxide availability and extracellular superoxide dismutase activity in healthy humans with advancing age. Life Sci. 2006;78:1163–1167. [PubMed]
353. Liao M, Liu Z, Bao J, Zhao Z, Hu J, Feng X, Feng R, Lu Q, Mei Z, Liu Y, Wu Q, Jing Z. A proteomic study of the aortic media in human thoracic aortic dissection: implication for oxidative stress. J Thorac Cardiovasc Surg. 2008;136:65–72. 72, e61–e63. [PubMed]
354. Miller JD, Chu Y, Brooks RM, Richenbacher WE, Pena-Silva R, Heistad DD. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol. 2008;52:843–850. [PMC free article] [PubMed]
355. Kakko S, Paivansalo M, Koistinen P, Kesaniemi YA, Kinnula VL, Savolainen MJ. The signal sequence polymorphism of the MnSOD gene is associated with the degree of carotid atherosclerosis. Atherosclerosis. 2003;168:147–152. [PubMed]
356. Fujimoto H, Taguchi J, Imai Y, Ayabe S, Hashimoto H, Kobayashi H, Ogasawara K, Aizawa T, Yamakado M, Nagai R, Ohno M. Manganese superoxide dismutase polymorphism affects the oxidized low-density lipoprotein-induced apoptosis of macrophages and coronary artery disease. Eur Heart J. 2008;29:1267–1274. [PubMed]
357. Guo W, Adachi T, Matsui R, Xu S, Jiang B, Zou MH, Kirber M, Lieberthal W, Cohen RA. Quantitative assessment of tyrosine nitration of manganese superoxide dismutase in angiotensin II-infused rat kidney. Am J Physiol Heart Circ Physiol. 2003;285:H1396–H1403. [PubMed]
358. Xu S, Ying J, Jiang B, Guo W, Adachi T, Sharov V, Lazar H, Menzoian J, Knyushko TV, Bigelow D, Schoneich C, Cohen RA. Detection of sequence-specific tyrosine nitration of manganese SOD and SERCA in cardiovascular disease and aging. Am J Physiol Heart Circ Physiol. 2006;290:H2220–H2227. [PubMed]
359. MacMillan-Crow LA, Crow JP, Thompson JA. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry. 1998;37:1613–1622. [PubMed]
360. Yamakura F, Matsumoto T, Ikeda K, Taka H, Fujimura T, Murayama K, Watanabe E, Tamaki M, Imai T, Takamori K. Nitrated and oxidized products of a single tryptophan residue in human Cu,Zn-superoxide dismutase treated with either peroxynitrite-carbon dioxide or myeloperoxidase-hydrogen peroxide-nitrite. J Biochem. 2005;138:57–69. [PubMed]
361. Yamakura F, Matsumoto T, Fujimura T, Taka H, Murayama K, Imai T, Uchida K. Modification of a single tryptophan residue in human Cu,Zn-superoxide dismutase by peroxynitrite in the presence of bicarbonate. Biochim Biophys Acta. 2001;1548:38–46. [PubMed]
362. May DW, Catalase a New Enzym of General Occurrence. Science. 1901;14:815–816. [PubMed]
363. Evans CA. On the Catalytic Decomposition of Hydrogen Peroxide by the Catalase of Blood. Biochem J. 1907;2:133–155. [PubMed]
364. Kirkman HN, Gaetani GF. Mammalian catalase: a venerable enzyme with new mysteries. Trends Biochem Sci. 2007;32:44–50. [PubMed]
365. Gaetani GF, Ferraris AM, Sanna P, Kirkman HN. A novel NADPH:(bound) NADP+ reductase and NADH:(bound) NADP+ transhydrogenase function in bovine liver catalase. Biochem J. 2005;385:763–768. [PubMed]
366. Rovira C. Structure, protonation state and dynamics of catalase compound II. Chemphyschem. 2005;6:1820–1826. [PubMed]
367. Putnam CD, Arvai AS, Bourne Y, Tainer JA. Active and inhibited human catalase structures: ligand and NADPH binding and catalytic mechanism. J Mol Biol. 2000;296:295–309. [PubMed]
368. Hirono A, Sasaya-Hamada F, Kanno H, Fujii H, Yoshida T, Miwa S. A novel human catalase mutation (358 T-->del) causing Japanese-type acatalasemia. Blood Cells Mol Dis. 1995;21:232–234. [PubMed]
369. Goth L, Vitai M. The effects of hydrogen peroxide promoted by homocysteine and inherited catalase deficiency on human hypocatalasemic patients. Free Radic Biol Med. 2003;35:882–888. [PubMed]
370. Flekac M, Skrha J, Hilgertova J, Lacinova Z, Jarolimkova M. Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus. BMC Med Genet. 2008;9:30. [PMC free article] [PubMed]
371. Tyther R, Ahmeda A, Johns E, Sheehan D. Proteomic identification of tyrosine nitration targets in kidney of spontaneously hypertensive rats. Proteomics. 2007;7:4555–4564. [PubMed]
372. Ghosh S, Janocha AJ, Aronica MA, Swaidani S, Comhair SA, Xu W, Zheng L, Kaveti S, Kinter M, Hazen SL, Erzurum SC. Nitrotyrosine proteome survey in asthma identifies oxidative mechanism of catalase inactivation. J Immunol. 2006;176:5587–5597. [PubMed]
373. Nguyen AT, Donaldson RP. Metal-catalyzed oxidation induces carbonylation of peroxisomal proteins and loss of enzymatic activities. Arch Biochem Biophys. 2005;439:25–31. [PubMed]
374. Mills GC. Hemoglobin catabolism. I. Glutathione peroxidase, an erythrocyte enzyme which protects hemoglobin from oxidative breakdown. J Biol Chem. 1957;229:189–197. [PubMed]
375. Mills GC. The purification and properties of glutathione peroxidase of erythrocytes. J Biol Chem. 1959;234:502–506. [PubMed]
376. Mills GC. Glutathione peroxidase and the destruction of hydrogen peroxide in animal tissues. Arch Biochem Biophys. 1960;86:1–5. [PubMed]
377. Christophersen BO. Reduction of linolenic acid hydroperoxide by a glutathione peroxidase. Biochim Biophys Acta. 1969;176:463–470. [PubMed]
378. Sies H, Sharov VS, Klotz LO, Briviba K. Glutathione peroxidase protects against peroxynitrite-mediated oxidations. A new function for selenoproteins as peroxynitrite reductase. J Biol Chem. 1997;272:27812–27817. [PubMed]
379. Prabhakar R, Morokuma K, Musaev DG. Peroxynitrite reductase activity of selenoprotein glutathione peroxidase: a computational study. Biochemistry. 2006;45:6967–6977. [PubMed]
380. Forgione MA, Cap A, Liao R, Moldovan NI, Eberhardt RT, Lim CC, Jones J, Goldschmidt-Clermont PJ, Loscalzo J. Heterozygous cellular glutathione peroxidase deficiency in the mouse: abnormalities in vascular and cardiac function and structure. Circulation. 2002;106:1154–1158. [PubMed]
381. Forgione MA, Weiss N, Heydrick S, Cap A, Klings ES, Bierl C, Eberhardt RT, Farber HW, Loscalzo J. Cellular glutathione peroxidase deficiency and endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2002;282:H1255–H1261. [PubMed]
382. Torzewski M, Ochsenhirt V, Kleschyov AL, Oelze M, Daiber A, Li H, Rossmann H, Tsimikas S, Reifenberg K, Cheng F, Lehr HA, Blankenberg S, Forstermann U, Munzel T, Lackner KJ. Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:850–857. [PubMed]
383. Lewis P, Stefanovic N, Pete J, Calkin AC, Giunti S, Thallas-Bonke V, Jandeleit-Dahm KA, Allen TJ, Kola I, Cooper ME, de Haan JB. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation. 2007;115:2178–2187. [PubMed]
384. Guo Z, Ran Q, Roberts LJ, 2nd, Zhou L, Richardson A, Sharan C, Wu D, Yang H. Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice. Free Radic Biol Med. 2008;44:343–352. [PMC free article] [PubMed]
385. Seiler A, Schneider M, Forster H, Roth S, Wirth EK, Culmsee C, Plesnila N, Kremmer E, Radmark O, Wurst W, Bornkamm GW, Schweizer U, Conrad M. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 2008;8:237–248. [PubMed]
386. Loscalzo J. Membrane redox state and apoptosis: death by peroxide. Cell Metab. 2008;8:182–183. [PubMed]
387. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, Smieja M, Cambien F, Meyer J, Lackner KJ. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med. 2003;349:1605–1613. [PubMed]
388. Espinola-Klein C, Rupprecht HJ, Bickel C, Schnabel R, Genth-Zotz S, Torzewski M, Lackner K, Munzel T, Blankenberg S. Glutathione peroxidase-1 activity, atherosclerotic burden, and cardiovascular prognosis. Am J Cardiol. 2007;99:808–812. [PubMed]
389. Handy DE, Zhang Y, Loscalzo J. Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J Biol Chem. 2005;280:15518–15525. [PubMed]
390. Weiss N, Zhang YY, Heydrick S, Bierl C, Loscalzo J. Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction. Proc Natl Acad Sci U S A. 2001;98:12503–12508. [PubMed]
391. Hamanishi T, Furuta H, Kato H, Doi A, Tamai M, Shimomura H, Sakagashira S, Nishi M, Sasaki H, Sanke T, Nanjo K. Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in japanese type 2 diabetic patients. Diabetes. 2004;53:2455–2460. [PubMed]
392. Nemoto M, Nishimura R, Sasaki T, Hiki Y, Miyashita Y, Nishioka M, Fujimoto K, Sakuma T, Ohashi T, Fukuda K, Eto Y, Tajima N. Genetic association of glutathione peroxidase-1 with coronary artery calcification in type 2 diabetes: a case control study with multi-slice computed tomography. Cardiovasc Diabetol. 2007;6:23. [PMC free article] [PubMed]
393. Tang NP, Wang LS, Yang L, Gu HJ, Sun QM, Cong RH, Zhou B, Zhu HJ, Wang B. Genetic variant in glutathione peroxidase 1 gene is associated with an increased risk of coronary artery disease in a Chinese population. Clin Chim Acta. 2008;395:89–93. [PubMed]
394. Kato K, Oguri M, Kato N, Hibino T, Yajima K, Yoshida T, Metoki N, Yoshida H, Satoh K, Watanabe S, Yokoi K, Murohara T, Yamada Y. Assessment of genetic risk factors for thoracic aortic aneurysm in hypertensive patients. Am J Hypertens. 2008;21:1023–1027. [PubMed]
395. Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, Michelson AD. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest. 1996;97:979–987. [PMC free article] [PubMed]
396. Voetsch B, Jin RC, Bierl C, Benke KS, Kenet G, Simioni P, Ottaviano F, Damasceno BP, Annichino-Bizacchi JM, Handy DE, Loscalzo J. Promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene: a novel risk factor for arterial ischemic stroke among young adults and children. Stroke. 2007;38:41–49. [PMC free article] [PubMed]
397. Voetsch B, Jin RC, Bierl C, Deus-Silva L, Camargo EC, Annichino-Bizacchi JM, Handy DE, Loscalzo J. Role of promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene as a risk factor for cerebral venous thrombosis. Stroke. 2008;39:303–307. [PubMed]
398. Danielson UH, Mannervik B. Kinetic independence of the subunits of cytosolic glutathione transferase from the rat. Biochem J. 1985;231:263–267. [PubMed]
399. Liu S, Zhang P, Ji X, Johnson WW, Gilliland GL, Armstrong RN. Contribution of tyrosine 6 to the catalytic mechanism of isoenzyme 3-3 of glutathione S-transferase. J Biol Chem. 1992:4296–4299. [PubMed]
400. Atkins WM, Wang RW, Bird AW, Newton DJ, Lu AY. The catalytic mechanism of glutathione S-transferase (GST). Spectroscopic determination of the pKa of Tyr-9 in rat alpha 1-1 GST. J Biol Chem. 1993;268:19188–19191. [PubMed]
401. Hayes JD, McLellan LI. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res. 1999;31:273–300. [PubMed]
402. Wilce MC, Parker MW. Structure and function of glutathione S-transferases. Biochim Biophys Acta. 1994;1205:1–18. [PubMed]
403. Ishikawa T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci. 1992;17:463–468. [PubMed]
404. Heijn M, Oude Elferink RP, Jansen PL. ATP-dependent multispecific organic anion transport system in rat erythrocyte membrane vesicles. Am J Physiol. 1992;262:C104–C110. [PubMed]
405. Saxena M, Singhal SS, Awasthi S, Singh SV, Labelle EF, Zimniak P, Awasthi YC. Dinitrophenyl S-glutathione ATPase purified from human muscle catalyzes ATP hydrolysis in the presence of leukotrienes. Arch Biochem Biophys. 1992;298:231–237. [PubMed]
406. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427. [PubMed]
407. Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res. 1994;54:4833–4836. [PubMed]
408. Kavallaris M. The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anticancer Drugs. 1997;8:17–25. [PubMed]
409. Listowsky I, Abramovitz M, Homma H, Niitsu Y. Intracellular binding and transport of hormones and xenobiotics by glutathione-S-transferases. Drug Metab Rev. 1988;19:305–318. [PubMed]
410. Ketley JN, Habig WH, Jakoby WB. Binding of nonsubstrate ligands to the glutathione S-transferases. J Biol Chem. 1975;250:8670–8673. [PubMed]
411. Barycki JJ, Colman RF. Identification of the nonsubstrate steroid binding site of rat liver glutathione S-transferase, isozyme 1-1, by the steroid affinity label, 3beta-(iodoacetoxy)dehydroisoandrosterone. Arch Biochem Biophys. 1997;345:16–31. [PubMed]
412. Izzotti A, Cartiglia C, Lewtas J, De Flora S. Increased DNA alterations in atherosclerotic lesions of individuals lacking the GSTM1 genotype. FASEB J. 2001;15:752–757. [PubMed]
413. Miller EA, Pankow JS, Millikan RC, Bray MS, Ballantyne CM, Bell DA, Heiss G, Li R. Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis. 2003;171:265–272. [PubMed]
414. Li R, Folsom AR, Sharrett AR, Couper D, Bray M, Tyroler HA. Interaction of the glutathione S-transferase genes and cigarette smoking on risk of lower extremity arterial disease: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2001;154:729–738. [PubMed]
415. Li R, Boerwinkle E, Olshan AF, Chambless LE, Pankow JS, Tyroler HA, Bray M, Pittman GS, Bell DA, Heiss G. Glutathione S-transferase genotype as a susceptibility factor in smoking-related coronary heart disease. Atherosclerosis. 2000;149:451–462. [PubMed]
416. Manfredi S, Federici C, Picano E, Botto N, Rizza A, Andreassi MG. GSTM1, GSTT1 and CYP1A1 detoxification gene polymorphisms and susceptibility to smoking-related coronary artery disease: a case-only study. Mutat Res. 2007;621:106–112. [PubMed]
417. Turowski SG, Jank KE, Fung HL. Inactivation of hepatic enzymes by inhalant nitrite--in vivo and in vitro studies. AAPS J. 2007;9:E298–E305. [PMC free article] [PubMed]
418. Grimsrud PA, Picklo MJ, Sr, Griffin TJ, Bernlohr DA. Carbonylation of adipose proteins in obesity and insulin resistance: identification of adipocyte fatty acid-binding protein as a cellular target of 4-hydroxynonenal. Mol Cell Proteomics. 2007;6:624–637. [PubMed]
419. McCoubrey WK, Jr, Huang TJ, Maines MD. Heme oxygenase-2 is a hemoprotein and binds heme through heme regulatory motifs that are not involved in heme catalysis. J Biol Chem. 1997;272:12568–12574. [PubMed]
420. Yoshida T, Kikuchi G. Reaction of the microsomal heme oxygenase with cobaltic protoporphyrin IX, and extremely poor substrate. J Biol Chem. 1978;253:8479–8482. [PubMed]
421. Yoshida T, Biro P, Cohen T, Muller RM, Shibahara S. Human heme oxygenase cDNA and induction of its mRNA by hemin. Eur J Biochem. 1988;171:457–461. [PubMed]
422. Poss KD, Tonegawa S. Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci U S A. 1997;94:10925–10930. [PubMed]
423. Jeney V, Balla J, Yachie A, Varga Z, Vercellotti GM, Eaton JW, Balla G. Pro-oxidant and cytotoxic effects of circulating heme. Blood. 2002;100:879–887. [PubMed]
424. Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis RJ, Flavell RA, Choi AM. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med. 2000;6:422–428. [PubMed]
425. Otterbein LE, Zuckerbraun BS, Haga M, Liu F, Song R, Usheva A, Stachulak C, Bodyak N, Smith RN, Csizmadia E, Tyagi S, Akamatsu Y, Flavell RJ, Billiar TR, Tzeng E, Bach FH, Choi AM, Soares MP. Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat Med. 2003;9:183–190. [PubMed]
426. Kaide JI, Zhang F, Wei Y, Jiang H, Yu C, Wang WH, Balazy M, Abraham NG, Nasjletti A. Carbon monoxide of vascular origin attenuates the sensitivity of renal arterial vessels to vasoconstrictors. J Clin Invest. 2001;107:1163–1171. [PMC free article] [PubMed]
427. Wang R, Wu L. The chemical modification of KCa channels by carbon monoxide in vascular smooth muscle cells. J Biol Chem. 1997;272:8222–8226. [PubMed]
428. Kwak JY, Takeshige K, Cheung BS, Minakami S. Bilirubin inhibits the activation of superoxide-producing NADPH oxidase in a neutrophil cell-free system. Biochim Biophys Acta. 1991;1076:369–373. [PubMed]
429. Taille C, El-Benna J, Lanone S, Dang MC, Ogier-Denis E, Aubier M, Boczkowski J. Induction of heme oxygenase-1 inhibits NAD(P)H oxidase activity by down-regulating cytochrome b558 expression via the reduction of heme availability. J Biol Chem. 2004;279:28681–28688. [PubMed]
430. Wang LJ, Lee TS, Lee FY, Pai RC, Chau LY. Expression of heme oxygenase-1 in atherosclerotic lesions. Am J Pathol. 1998;152:711–720. [PubMed]
431. Ishikawa K, Navab M, Leitinger N, Fogelman AM, Lusis AJ. Induction of heme oxygenase-1 inhibits the monocyte transmigration induced by mildly oxidized LDL. J Clin Invest. 1997;100:1209–1216. [PMC free article] [PubMed]
432. Yamaguchi M, Sato H, Bannai S. Induction of stress proteins in mouse peritoneal macrophages by oxidized low-density lipoprotein. Biochem Biophys Res Commun. 1993;193:1198–1201. [PubMed]
433. Agarwal A, Shiraishi F, Visner GA, Nick HS. Linoleyl hydroperoxide transcriptionally upregulates heme oxygenase-1 gene expression in human renal epithelial and aortic endothelial cells. J Am Soc Nephrol. 1998;9:1990–1997. [PubMed]
434. Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, Cook JL. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem. 1999;274:26071–26078. [PubMed]
435. Juan SH, Lee TS, Tseng KW, Liou JY, Shyue SK, Wu KK, Chau LY. Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2001;104:1519–1525. [PubMed]
436. Yet SF, Layne MD, Liu X, Chen YH, Ith B, Sibinga NE, Perrella MA. Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling. FASEB J. 2003;17:1759–1761. [PubMed]
437. Yamada N, Yamaya M, Okinaga S, Nakayama K, Sekizawa K, Shibahara S, Sasaki H. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet. 2000;66:187–195. [PubMed]
438. Brydun A, Watari Y, Yamamoto Y, Okuhara K, Teragawa H, Kono F, Chayama K, Oshima T, Ozono R. Reduced expression of heme oxygenase-1 in patients with coronary atherosclerosis. Hypertens Res. 2007;30:341–348. [PubMed]
439. Chen YH, Chau LY, Lin MW, Chen LC, Yo MH, Chen JW, Lin SJ. Heme oxygenase-1 gene promotor microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. Eur Heart J. 2004;25:39–47. [PubMed]
440. Dick P, Schillinger M, Minar E, Mlekusch W, Amighi J, Sabeti S, Schlager O, Raith M, Endler G, Mannhalter C, Wagner O, Exner M. Haem oxygenase-1 genotype and cardiovascular adverse events in patients with peripheral artery disease. Eur J Clin Invest. 2005;35:731–737. [PubMed]
441. Chen YH, Chau LY, Chen JW, Lin SJ. Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care. 2008;31:1615–1620. [PMC free article] [PubMed]
442. Kinobe R, Ji Y, Nakatsu K. Peroxynitrite-mediated inactivation of heme oxygenases. BMC Pharmacol. 2004;4:26. [PMC free article] [PubMed]
443. Yi L, Ragsdale SW. Evidence that the heme regulatory motifs in heme oxygenase-2 serve as a thiol/disulfide redox switch regulating heme binding. J Biol Chem. 2007;282:21056–21067. [PMC free article] [PubMed]
444. Naylor CE, Rowland P, Basak AK, Gover S, Mason PJ, Bautista JM, Vulliamy TJ, Luzzatto L, Adams MJ. Glucose 6-phosphate dehydrogenase mutations causing enzyme deficiency in a model of the tertiary structure of the human enzyme. Blood. 1996;87:2974–2982. [PubMed]
445. Vulliamy T, Beutler E, Luzzatto L. Variants of glucose-6-phosphate dehydrogenase are due to missense mutations spread throughout the coding region of the gene. Hum Mutat. 1993;2:159–167. [PubMed]
446. Cappadoro M, Giribaldi G, O'Brien E, Turrini F, Mannu F, Ulliers D, Simula G, Luzzatto L, Arese P. Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood. 1998;92:2527–2534. [PubMed]
447. Leopold JA, Cap A, Scribner AW, Stanton RC, Loscalzo J. Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability. FASEB J. 2001;15:1771–1773. [PubMed]
448. Leopold JA, Loscalzo J. Cyclic strain modulates resistance to oxidant stress by increasing G6PDH expression in smooth muscle cells. Am J Physiol Heart Circ Physiol. 2000;279:H2477–H2485. [PubMed]
449. Leopold JA, Walker J, Scribner AW, Voetsch B, Zhang YY, Loscalzo AJ, Stanton RC, Loscalzo J. Glucose-6-phosphate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis. J Biol Chem. 2003;278:32100–32106. [PubMed]
450. Jain M, Cui L, Brenner DA, Wang B, Handy DE, Leopold JA, Loscalzo J, Apstein CS, Liao R. Increased myocardial dysfunction after ischemia-reperfusion in mice lacking glucose-6-phosphate dehydrogenase. Circulation. 2004;109:898–903. [PubMed]
451. Xu Y, Osborne BW, Stanton RC. Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex. Am J Physiol Renal Physiol. 2005;289:F1040–F1047. [PubMed]
452. Stabile LP, Hodge DL, Klautky SA, Salati LM. Posttranscriptional regulation of glucose-6-phosphate dehydrogenase by dietary polyunsaturated fat. Arch Biochem Biophys. 1996;332:269–279. [PubMed]
453. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007;13:189–197. [PMC free article] [PubMed]
454. Gaskin RS, Estwick D, Peddi R. G6PD deficiency: its role in the high prevalence of hypertension and diabetes mellitus. Ethn Dis. 2001;11:749–754. [PubMed]
455. Nemeth I, Orvos H, Boda D. Blood glutathione redox status in gestational hypertension. Free Radic Biol Med. 2001;30:715–721. [PubMed]
456. Afzal-Ahmed I, Mann GE, Shennan AH, Poston L, Naftalin RJ. Preeclampsia inactivates glucose-6-phosphate dehydrogenase and impairs the redox status of erythrocytes and fetal endothelial cells. Free Radic Biol Med. 2007;42:1781–1790. [PubMed]
457. Wan GH, Tsai SC, Chiu DT. Decreased blood activity of glucose-6-phosphate dehydrogenase associates with increased risk for diabetes mellitus. Endocrine. 2002;19:191–195. [PubMed]
458. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979;76:333–337. [PubMed]
459. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915–924. [PubMed]
460. Lankin VZ, Tikhaze AK, Kapel'ko VI, Shepel'kova GS, Shumaev KB, Panasenko OM, Konovalova GG, Belenkov YN. Mechanisms of oxidative modification of low density lipoproteins under conditions of oxidative and carbonyl stress. Biochemistry (Mosc) 2007;72:1081–1090. [PubMed]
461. Obama T, Kato R, Masuda Y, Takahashi K, Aiuchi T, Itabe H. Analysis of modified apolipoprotein B-100 structures formed in oxidized low-density lipoprotein using LC-MS/MS. Proteomics. 2007;7:2132–2141. [PubMed]
462. Harkewicz R, Hartvigsen K, Almazan F, Dennis EA, Witztum JL, Miller YI. Cholesteryl ester hydroperoxides are biologically active components of minimally oxidized low density lipoprotein. J Biol Chem. 2008;283:10241–10251. [PMC free article] [PubMed]
463. Miller YI, Worrall DS, Funk CD, Feramisco JR, Witztum JL. Actin polymerization in macrophages in response to oxidized LDL and apoptotic cells: role of 12/15-lipoxygenase and phosphoinositide 3-kinase. Mol Biol Cell. 2003;14:4196–4206. [PMC free article] [PubMed]
464. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem. 2003;278:1561–1568. [PubMed]
465. Siess W. Platelet interaction with bioactive lipids formed by mild oxidation of low-density lipoprotein. Pathophysiol Haemost Thromb. 2006;35:292–304. [PubMed]
466. Mehta JL, Li DY. Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells. Biochem Biophys Res Commun. 1998;248:511–514. [PubMed]
467. Tanner FC, Noll G, Boulanger CM, Luscher TF. Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. Circulation. 1991;83:2012–2020. [PubMed]
468. Ananyeva NM, Tjurmin AV, Berliner JA, Chisolm GM, Liau G, Winkles JA, Haudenschild CC. Oxidized LDL mediates the release of fibroblast growth factor-1. Arterioscler Thromb Vasc Biol. 1997;17:445–453. [PubMed]
469. Steffen Y, Jung T, Klotz LO, Schewe T, Grune T, Sies H. Protein modification elicited by oxidized low-density lipoprotein (LDL) in endothelial cells: protection by (-)-epicatechin. Free Radic Biol Med. 2007;42:955–970. [PubMed]
470. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086–1095. [PMC free article] [PubMed]
471. Ishigaki Y, Katagiri H, Gao J, Yamada T, Imai J, Uno K, Hasegawa Y, Kaneko K, Ogihara T, Ishihara H, Sato Y, Takikawa K, Nishimichi N, Matsuda H, Sawamura T, Oka Y. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation. 2008;118:75–83. [PubMed]
472. Wen Y, Leake DS. Low density lipoprotein undergoes oxidation within lysosomes in cells. Circ Res. 2007;100:1337–1343. [PubMed]
473. Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J, Kanda H, Emoto M, Kawagishi T, Morii H. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis. 2000;148:171–177. [PubMed]
474. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955–1960. [PubMed]
475. Holvoet P, Collen D, Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA. 1999;281:1718–1721. [PubMed]
476. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998;98:1487–1494. [PubMed]
477. Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest. 1995;95:2611–2619. [PMC free article] [PubMed]
478. Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. 1996;98:800–814. [PMC free article] [PubMed]
479. Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med. 2000;247:371–380. [PubMed]
480. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR., Jr Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA. 2008;299:2287–2293. [PMC free article] [PubMed]
481. Andican G, Seven A, Uncu M, Cantasdemir M, Numan F, Burcak G. Oxidized LDL and anti-oxLDL antibody levels in peripheral atherosclerotic disease. Scand J Clin Lab Invest. 2008:1–7. [PubMed]
482. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353:46–57. [PubMed]
483. Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, Arikan E, Tugrul A. The roles of oxidized low-density lipoprotein and interleukin-6 levels in acute atherothrombotic and lacunar ischemic stroke. Angiology. 2008;59:224–229. [PubMed]
484. Francis GA. High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochim Biophys Acta. 2000;1483:217–235. [PubMed]
485. Panzenboeck U, Raitmayer S, Reicher H, Lindner H, Glatter O, Malle E, Sattler W. Effects of reagent and enzymatically generated hypochlorite on physicochemical and metabolic properties of high density lipoproteins. J Biol Chem. 1997;272:29711–29720. [PubMed]
486. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 1992;13:341–390. [PubMed]
487. Girona J, La Ville AE, Heras M, Olive S, Masana L. Oxidized lipoproteins including HDL and their lipid peroxidation products inhibit TNF-alpha secretion by THP-1 human macrophages. Free Radic Biol Med. 1997;23:658–667. [PubMed]
488. Nagano Y, Arai H, Kita T. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci U S A. 1991;88:6457–6461. [PubMed]
489. Salmon S, Maziere C, Auclair M, Theron L, Santus R, Maziere JC. Malondialdehyde modification and copper-induced autooxidation of high-density lipoprotein decrease cholesterol efflux from human cultured fibroblasts. Biochim Biophys Acta. 1992;1125:230–235. [PubMed]
490. Guertin F, Brunet S, Lairon D, Levy E. Oxidative tyrosylation of high density lipoprotein impairs biliary sterol secretion in rats. Atherosclerosis. 1997;131:35–41. [PubMed]
491. McCall MR, Tang JY, Bielicki JK, Forte TM. Inhibition of lecithin-cholesterol acyltransferase and modification of HDL apolipoproteins by aldehydes. Arterioscler Thromb Vasc Biol. 1995;15:1599–1606. [PubMed]
492. Francis GA, Oram JF, Heinecke JW, Bierman EL. Oxidative tyrosylation of HDL enhances the depletion of cellular cholesteryl esters by a mechanism independent of passive sterol desorption. Biochemistry. 1996;35:15188–15197. [PubMed]
493. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem. 1998;273:6088–6095. [PubMed]
494. Garner B, Witting PK, Waldeck AR, Christison JK, Raftery M, Stocker R. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J Biol Chem. 1998;273:6080–6087. [PubMed]
495. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A. 1992;89:10316–10320. [PubMed]
496. Bonnefont-Rousselot D, Motta C, Khalil AO, Sola R, La Ville AE, Delattre J, Gardes-Albert M. Physicochemical changes in human high-density lipoproteins (HDL) oxidized by gamma radiolysis-generated oxyradicals. Effect on their cholesterol effluxing capacity. Biochim Biophys Acta. 1995;1255:23–30. [PubMed]
497. Maziere JC, Myara I, Salmon S, Auclair M, Haigle J, Santus R, Maziere C. Copper- and malondialdehyde-induced modification of high density lipoprotein and parallel loss of lecithin cholesterol acyltransferase activation. Atherosclerosis. 1993;104:213–219. [PubMed]
498. Ferretti G, Bacchetti T, Busni D, Rabini RA, Curatola G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab. 2004;89:2957–2962. [PubMed]
499. Morel DW. Reduced cholesterol efflux to mildly oxidized high density lipoprotein. Biochem Biophys Res Commun. 1994;200:408–416. [PubMed]
500. Rifici VA, Khachadurian AK. Oxidation of high density lipoproteins: characterization and effects on cholesterol efflux from J774 macrophages. Biochim Biophys Acta. 1996;1299:87–94. [PubMed]
501. Cogny A, Atger V, Paul JL, Soni T, Moatti N. High-density lipoprotein 3 physicochemical modifications induced by interaction with human polymorphonuclear leucocytes affect their ability to remove cholesterol from cells. Biochem J. 1996;314(Pt 1):285–292. [PubMed]
502. Hurtado I, Fiol C, Gracia V, Caldu P. In vitro oxidised HDL exerts a cytotoxic effect on macrophages. Atherosclerosis. 1996;125:39–46. [PubMed]
503. Alomar Y, Negre-Salvayre A, Levade T, Valdiguie P, Salvayre R. Oxidized HDL are much less cytotoxic to lymphoblastoid cells than oxidized LDL. Biochim Biophys Acta. 1992;1128:163–166. [PubMed]
504. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882–2891. [PMC free article] [PubMed]
505. Vohl MC, Neville TA, Kumarathasan R, Braschi S, Sparks DL. A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation. Biochemistry. 1999;38:5976–5981. [PubMed]
506. Forte TM, Oda MN, Knoff L, Frei B, Suh J, Harmony JA, Stuart WD, Rubin EM, Ng DS. Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration. J Lipid Res. 1999;40:1276–1283. [PubMed]
507. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000;41:1495–1508. [PubMed]
508. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, Subbanagounder G, Faull KF, Reddy ST, Miller NE, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res. 2000;41:1481–1494. [PubMed]
509. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481–488. [PubMed]
510. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun. 2004;318:680–683. [PubMed]
511. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987–1994. [PubMed]
512. Calabresi L, Franceschini G, Sirtori CR, De Palma A, Saresella M, Ferrante P, Taramelli D. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun. 1997;238:61–65. [PubMed]
513. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155–167. [PubMed]
514. Lee CM, Chien CT, Chang PY, Hsieh MY, Jui HY, Liau CS, Hsu SM, Lee YT. High-density lipoprotein antagonizes oxidized low-density lipoprotein by suppressing oxygen free-radical formation and preserving nitric oxide bioactivity. Atherosclerosis. 2005;183:251–258. [PubMed]
515. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Luscher TF, Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399–1402. [PubMed]
516. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–2300. [PubMed]
517. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis. 2000;181 Suppl 3:S462–S472. [PubMed]
518. Marcel YL, Jewer D, Leblond L, Weech PK, Milne RW. Lipid peroxidation changes the expression of specific epitopes of apolipoprotein A-I. J Biol Chem. 1989;264:19942–19950. [PubMed]
519. Ueyama K, Yokode M, Arai H, Nagano Y, Li ZX, Cho M, Kita T. Cholesterol efflux effect of high density lipoprotein is impaired by whole cigarette smoke extracts through lipid peroxidation. Free Radic Biol Med. 1998;24:182–190. [PubMed]
520. Jaouad L, Milochevitch C, Khalil A. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic Res. 2003;37:77–83. [PubMed]
521. Gaut JP, Byun J, Tran HD, Lauber WM, Carroll JA, Hotchkiss RS, Belaaouaj A, Heinecke JW. Myeloperoxidase produces nitrating oxidants in vivo. J Clin Invest. 2002;109:1311–1319. [PMC free article] [PubMed]
522. Heinecke JW. Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall. FASEB J. 1999;13:1113–1120. [PubMed]
523. Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, McDonald TO, Singh P, Anantharamaiah GM, Chait A, Brunzell J, Geary RL, Oram JF, Heinecke JW. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A. 2004;101:13032–13037. [PubMed]
524. Shao B, Fu X, McDonald TO, Green PS, Uchida K, O'Brien KD, Oram JF, Heinecke JW. Acrolein impairs ATP binding cassette transporter A1-dependent cholesterol export from cells through site-specific modification of apolipoprotein A-I. J Biol Chem. 2005;280:36386–36396. [PubMed]
525. Bergt C, Fu X, Huq NP, Kao J, Heinecke JW. Lysine residues direct the chlorination of tyrosines in YXXK motifs of apolipoprotein A-I when hypochlorous acid oxidizes high density lipoprotein. J Biol Chem. 2004;279:7856–7866. [PubMed]
526. Shao B, Oda MN, Bergt C, Fu X, Green PS, Brot N, Oram JF, Heinecke JW. Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J Biol Chem. 2006;281:9001–9004. [PubMed]
527. Hawkins CL, Pattison DI, Davies MJ. Hypochlorite-induced oxidation of amino acids, peptides and proteins. Amino Acids. 2003;25:259–274. [PubMed]
528. Panzenbock U, Kritharides L, Raftery M, Rye KA, Stocker R. Oxidation of methionine residues to methionine sulfoxides does not decrease potential antiatherogenic properties of apolipoprotein A-I. J Biol Chem. 2000;275:19536–19544. [PubMed]
529. Peng DQ, Brubaker G, Wu Z, Zheng L, Willard B, Kinter M, Hazen SL, Smith JD. Apolipoprotein A-I tryptophan substitution leads to resistance to myeloperoxidase-mediated loss of function. Arterioscler Thromb Vasc Biol. 2008;28:2063–2070. [PMC free article] [PubMed]
530. Wu Z, Wagner MA, Zheng L, Parks JS, Shy JM, 3rd, Smith JD, Gogonea V, Hazen SL. The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat Struct Mol Biol. 2007;14:861–868. [PubMed]
531. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581–1590. [PMC free article] [PubMed]
532. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284–287. [PubMed]
533. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H, Faull KF, Berliner JA, Witztum JL, Lusis AJ. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000;275:17527–17535. [PubMed]
534. Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis. 2001;155:229–235. [PubMed]
535. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond) 2000;98:355–363. [PubMed]
536. Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest. 2002;32:259–264. [PubMed]
537. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol. 1998;31:329–336. [PubMed]
538. Hasselwander O, Savage DA, McMaster D, Loughrey CM, McNamee PT, Middleton D, Nicholls DP, Maxwell AP, Young IS. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int. 1999;56:289–298. [PubMed]
539. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet. 2001;68:1428–1436. [PubMed]
540. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet. 2004;363:689–695. [PubMed]
541. Loscalzo J. Paraoxonase and coronary heart disease risk: language misleads, linkage misinforms, function clarifies. Circulation-Genetics. 2008:79–80. [PubMed]
542. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–2756. [PubMed]
543. Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol. 1999;19:2226–2233. [PubMed]
544. Kaysen GA. Disorders in high-density metabolism with insulin resistance and chronic kidney disease. J Ren Nutr. 2007;17:4–8. [PubMed]
545. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, Badsha H, Kalunian K, Charles C, Navab M, Fogelman AM, Hahn BH. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006;54:2541–2549. [PubMed]
546. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145:408–415. [PubMed]
547. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722–732. [PubMed]
548. Sviridov D, Chin-Dusting J, Nestel P, Kingwell B, Hoang A, Olchawa B, Starr J, Dart A. Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients: evidence for impaired reverse cholesterol transport. Transplantation. 2006;81:361–366. [PubMed]
549. Papa A, Emdin M, Passino C, Michelassi C, Battaglia D, Cocci F. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin Chim Acta. 2008;395:27–31. [PubMed]
550. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102:653–657. [PubMed]
551. Dragu R, Huri S, Zuckerman R, Suleiman M, Mutlak D, Agmon Y, Kapeliovich M, Beyar R, Markiewicz W, Hammerman H, Aronson D. Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction. Atherosclerosis. 2008;196:405–412. [PubMed]
552. Nunez J, Nunez E, Bodi V, Sanchis J, Minana G, Mainar L, Santas E, Merlos P, Rumiz E, Darmofal H, Heatta AM, Llacer A. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol. 2008;101:747–752. [PubMed]
553. Rotzius P, Soehnlein O, Kenne E, Lindbom L, Nystrom K, Thams S, Eriksson EE. ApoE(−/−)/Lysozyme M(EGFP/EGFP) mice as a versatile model to study monocyte and neutrophil trafficking in atherosclerosis. Atherosclerosis. 2008 [PubMed]
554. van Leeuwen M, Gijbels MJ, Duijvestijn A, Smook M, van de Gaar MJ, Heeringa P, de Winther MP, Tervaert JW. Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR−/− mice. Arterioscler Thromb Vasc Biol. 2008;28:84–89. [PubMed]
555. Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, Komatsu R, Ikura Y, Ogami M, Shimada Y, Ehara S, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106:2894–2900. [PubMed]
556. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, Hangoc G, Bridger GJ, Henson GW, Calandra G, Dale DC. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102:2728–2730. [PubMed]
557. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, Liles WC, Li X, Graham-Evans B, Campbell TB, Calandra G, Bridger G, Dale DC, Srour EF. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201:1307–1318. [PMC free article] [PubMed]
558. Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res. 2000;86:131–138. [PubMed]
559. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, Bucala R, Weber C. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation. 2004;109:380–385. [PubMed]
560. Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzhekov K, Meiler S, Krohn R, Schober A, Sperandio M, Soehnlein O, Bornemann J, Tacke F, Biessen EA, Weber C. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res. 2008;102:209–217. [PubMed]
561. Mazor R, Shurtz-Swirski R, Farah R, Kristal B, Shapiro G, Dorlechter F, Cohen-Mazor M, Meilin E, Tamara S, Sela S. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients. Atherosclerosis. 2008;197:937–943. [PubMed]
562. Kristal B, Shurtz-Swirski R, Chezar J, Manaster J, Levy R, Shapiro G, Weissman I, Shasha SM, Sela S. Participation of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation in patients with essential hypertension. Am J Hypertens. 1998;11:921–928. [PubMed]
563. Shurtz-Swirski R, Sela S, Herskovits AT, Shasha SM, Shapiro G, Nasser L, Kristal B. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diabetes Care. 2001;24:104–110. [PubMed]
564. Sela S, Shurtz-Swirski R, Awad J, Shapiro G, Nasser L, Shasha SM, Kristal B. The involvement of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation among cigarette smokers. Isr Med Assoc J. 2002;4:1015–1019. [PubMed]
565. Sugano R, Matsuoka H, Haramaki N, Umei H, Murase E, Fukami K, Iida S, Ikeda H, Imaizumi T. Polymorphonuclear leukocytes may impair endothelial function: results of crossover randomized study of lipid-lowering therapies. Arterioscler Thromb Vasc Biol. 2005;25:1262–1267. [PubMed]
566. Carr AC, Frei B. Human neutrophils oxidize low-density lipoprotein by a hypochlorous acid-dependent mechanism: the role of vitamin C. Biol Chem. 2002;383:627–636. [PubMed]
567. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 2008;8:802–815. [PubMed]
568. Watanabe T, Hirata M, Yoshikawa Y, Nagafuchi Y, Toyoshima H. Role of macrophages in atherosclerosis. Sequential observations of cholesterol-induced rabbit aortic lesion by the immunoperoxidase technique using monoclonal antimacrophage antibody. Lab Invest. 1985;53:80–90. [PubMed]
569. Gown AM, Tsukada T, Ross R. Human atherosclerosis. II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol. 1986;125:191–207. [PubMed]
570. Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T, Takano T. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem. 1994;269:15274–15279. [PubMed]
571. Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, Sanaka T, Hata Y, Takano T. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res. 1996;37:45–53. [PubMed]
572. Ylitalo R, Oksala O, Yla-Herttuala S, Ylitalo P. Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. J Lab Clin Med. 1994;123:769–776. [PubMed]
573. Stoneman V, Braganza D, Figg N, Mercer J, Lang R, Goddard M, Bennett M. Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ Res. 2007;100:884–893. [PMC free article] [PubMed]
574. Swirski FK, Pittet MJ, Kircher MF, Aikawa E, Jaffer FA, Libby P, Weissleder R. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A. 2006;103:10340–10345. [PubMed]
575. Leusen JH, Verhoeven AJ, Roos D. Interactions between the components of the human NADPH oxidase: intrigues in the phox family. J Lab Clin Med. 1996;128:461–476. [PubMed]
576. Cathcart MK, McNally AK, Morel DW, Chisolm GM., 3rd Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein and conversion of low-density lipoprotein to a cytotoxin. J Immunol. 1989;142:1963–1969. [PubMed]
577. Li Q, Tallant A, Cathcart MK. Dual Ca2+ requirement for optimal lipid peroxidation of low density lipoprotein by activated human monocytes. J Clin Invest. 1993;91:1499–1506. [PMC free article] [PubMed]
578. Li F, Hui DY. Modified low density lipoprotein enhances the secretion of bile salt-stimulated cholesterol esterase by human monocyte-macrophages. species-specific difference in macrophage cholesteryl ester hydrolase. J Biol Chem. 1997;272:28666–28671. [PubMed]
579. Bey EA, Cathcart MK. In vitro knockout of human p47phox blocks superoxide anion production and LDL oxidation by activated human monocytes. J Lipid Res. 2000;41:489–495. [PubMed]
580. Azumi H, Inoue N, Ohashi Y, Terashima M, Mori T, Fujita H, Awano K, Kobayashi K, Maeda K, Hata K, Shinke T, Kobayashi S, Hirata K, Kawashima S, Itabe H, Hayashi Y, Imajoh-Ohmi S, Itoh H, Yokoyama M. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol. 2002;22:1838–1844. [PubMed]
581. Malle E, Waeg G, Schreiber R, Grone EF, Sattler W, Grone HJ. Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem. 2000;267:4495–4503. [PubMed]
582. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227–1234. [PubMed]
583. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A. 2001;98:3358–3363. [PubMed]
584. Pratico D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood. 2000;96:3823–3826. [PubMed]
585. Egan KM, Wang M, Fries S, Lucitt MB, Zukas AM, Pure E, Lawson JA, FitzGerald GA. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation. 2005;111:334–342. [PubMed]
586. Dixon DA, Tolley ND, Bemis-Standoli K, Martinez ML, Weyrich AS, Morrow JD, Prescott SM, Zimmerman GA. Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J Clin Invest. 2006;116:2727–2738. [PubMed]
587. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9:61–67. [PubMed]
588. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002;196:887–896. [PMC free article] [PubMed]
589. Methia N, Andre P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood. 2001;98:1424–1428. [PubMed]
590. Johnson RC, Chapman SM, Dong ZM, Ordovas JM, Mayadas TN, Herz J, Hynes RO, Schaefer EJ, Wagner DD. Absence of P-selectin delays fatty streak formation in mice. J Clin Invest. 1997;99:1037–1043. [PMC free article] [PubMed]
591. Johnson RC, Mayadas TN, Frenette PS, Mebius RE, Subramaniam M, Lacasce A, Hynes RO, Wagner DD. Blood cell dynamics in P-selectin-deficient mice. Blood. 1995;86:1106–1114. [PubMed]
592. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A. 1990;87:5193–5197. [PubMed]
593. Radomski MW, Palmer RM, Moncada S. Characterization of the L-arginine: nitric oxide pathway in human platelets. Br J Pharmacol. 1990;101:325–328. [PMC free article] [PubMed]
594. Clutton P, Miermont A, Freedman JE. Regulation of endogenous reactive oxygen species in platelets can reverse aggregation. Arterioscler Thromb Vasc Biol. 2004;24:187–192. [PubMed]
595. Storey RF, Heptinstall S. Laboratory investigation of platelet function. Clin Lab Haematol. 1999;21:317–329. [PubMed]
596. Trepakova ES, Cohen RA, Bolotina VM. Nitric oxide inhibits capacitative cation influx in human platelets by promoting sarcoplasmic/endoplasmic reticulum Ca2+-ATPase-dependent refilling of Ca2+ stores. Circ Res. 1999;84:201–209. [PubMed]
597. Wang GR, Zhu Y, Halushka PV, Lincoln TM, Mendelsohn ME. Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1998;95:4888–4893. [PubMed]
598. Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol. 1990;37:671–681. [PubMed]
599. Zhang Y, Gray RD. Characterization of folded, intermediate, and unfolded states of recombinant human interstitial collagenase. J Biol Chem. 1996;271:8015–8021. [PubMed]
600. Morrell CN, Matsushita K, Chiles K, Scharpf RB, Yamakuchi M, Mason RJ, Bergmeier W, Mankowski JL, Baldwin WM, 3rd, Faraday N, Lowenstein CJ. Regulation of platelet granule exocytosis by S-nitrosylation. Proc Natl Acad Sci U S A. 2005;102:3782–3787. [PubMed]
601. Yin K, Lai PS, Rodriguez A, Spur BW, Wong PY. Antithrombotic effects of peroxynitrite: inhibition and reversal of aggregation in human platelets. Prostaglandins. 1995;50:169–178. [PubMed]
602. Moro MA, Darley-Usmar VM, Goodwin DA, Read NG, Zamora-Pino R, Feelisch M, Radomski MW, Moncada S. Paradoxical fate and biological action of peroxynitrite on human platelets. Proc Natl Acad Sci U S A. 1994;91:6702–6706. [PubMed]
603. Brown AS, Moro MA, Masse JM, Cramer EM, Radomski M, Darley-Usmar V. Nitric oxide-dependent and independent effects on human platelets treated with peroxynitrite. Cardiovasc Res. 1998;40:380–388. [PubMed]
604. Krotz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM, Becker BF, Theisen K, Klauss V, Pohl U. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood. 2002;100:917–924. [PubMed]
605. Krotz F, Sohn HY, Keller M, Gloe T, Bolz SS, Becker BF, Pohl U. Depolarization of endothelial cells enhances platelet aggregation through oxidative inactivation of endothelial NTPDase. Arterioscler Thromb Vasc Biol. 2002;22:2003–2009. [PubMed]
606. Salvemini D, de Nucci G, Sneddon JM, Vane JR. Superoxide anions enhance platelet adhesion and aggregation. Br J Pharmacol. 1989;97:1145–1150. [PMC free article] [PubMed]
607. Bressler NM, Broekman MJ, Marcus AJ. Concurrent studies of oxygen consumption and aggregation in stimulated human platelets. Blood. 1979;53:167–178. [PubMed]
608. Burch JW, Burch PT. Glutathione disulfide production during arachidonic acid oxygenation in human platelets. Prostaglandins. 1990;39:123–134. [PubMed]
609. Lopez JJ, Salido GM, Gomez-Arteta E, Rosado JA, Pariente JA. Thrombin induces apoptotic events through the generation of reactive oxygen species in human platelets. J Thromb Haemost. 2007;5:1283–1291. [PubMed]
610. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P, Violi F. gp91phox-dependent expression of platelet CD40 ligand. Circulation. 2004;110:1326–1329. [PubMed]
611. Carnevale R, Pignatelli P, Lenti L, Buchetti B, Sanguigni V, Di Santo S, Violi F. LDL are oxidatively modified by platelets via GP91(phox) and accumulate in human monocytes. FASEB J. 2007;21:927–934. [PubMed]
612. Stokes KY, Russell JM, Jennings MH, Alexander JS, Granger DN. Platelet-associated NAD(P)H oxidase contributes to the thrombogenic phenotype induced by hypercholesterolemia. Free Radic Biol Med. 2007;43:22–30. [PMC free article] [PubMed]
613. Begonja AJ, Teichmann L, Geiger J, Gambaryan S, Walter U. Platelet regulation by NO/cGMP signaling and NAD(P)H oxidase-generated ROS. Blood Cells Mol Dis. 2006;36:166–170. [PubMed]
614. Pratico D, FitzGerald GA. Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem. 1996;271:8919–8924. [PubMed]
615. Pignatelli P, Sanguigni V, Lenti L, Loffredo L, Carnevale R, Sorge R, Violi F. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. J Thromb Haemost. 2007;5:1170–1178. [PubMed]
616. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591–594. [PubMed]
617. Chakrabarti S, Blair P, Freedman JE. CD40-40L signaling in vascular inflammation. J Biol Chem. 2007;282:18307–18317. [PubMed]
618. Bakdash N, Williams MS. Spatially distinct production of reactive oxygen species regulates platelet activation. Free Radic Biol Med. 2008;45:158–166. [PubMed]
619. Schildknecht S, van der Loo B, Weber K, Tiefenthaler K, Daiber A, Bachschmid MM. Endogenous peroxynitrite modulates PGHS-1-dependent thromboxane A2 formation and aggregation in human platelets. Free Radic Biol Med. 2008;45:512–520. [PubMed]
620. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, Radomski MW, Moncada S. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A. 1996;93:1480–1485. [PubMed]
621. Randriamboavonjy V, Pistrosch F, Bolck B, Schwinger RH, Dixit M, Badenhoop K, Cohen RA, Busse R, Fleming I. Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone. Circulation. 2008;117:52–60. [PubMed]
622. Bai H, Liu BW, Deng ZY, Shen T, Fang DZ, Zhao YH, Liu Y. Plasma very-low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein oxidative modification induces procoagulant profiles in endogenous hypertriglyceridemia. Free Radic Biol Med. 2006;40:1796–1803. [PubMed]
623. Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, Chen J, Zhang R, Silverstein RL, Hazen SL. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13:1086–1095. [PMC free article] [PubMed]
624. Chen K, Febbraio M, Li W, Silverstein RL. A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein. Circ Res. 2008;102:1512–1519. [PMC free article] [PubMed]
625. Upchurch GR, Jr, Ramdev N, Walsh MT, Loscalzo J. Prothrombotic Consequences of the Oxidation of Fibrinogen and their Inhibition by Aspirin. J Thromb Thrombolysis. 1998;5:9–14. [PubMed]
626. Vadseth C, Souza JM, Thomson L, Seagraves A, Nagaswami C, Scheiner T, Torbet J, Vilaire G, Bennett JS, Murciano JC, Muzykantov V, Penn MS, Hazen SL, Weisel JW, Ischiropoulos H. Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species. J Biol Chem. 2004;279:8820–8826. [PubMed]
627. Parastatidis I, Thomson L, Burke A, Chernysh I, Nagaswami C, Visser J, Stamer S, Liebler DC, Koliakos G, Heijnen HF, Fitzgerald G, Weisel JW, Ischiropoulos H. Fibrinogen beta -chain tyrosine nitration is a prothrombotic risk factor. J Biol Chem. 2008 [PMC free article] [PubMed]
628. Sauls DL, Lockhart E, Warren ME, Lenkowski A, Wilhelm SE, Hoffman M. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry. 2006;45:2480–2487. [PubMed]
629. Hajjar KA, Mauri L, Jacovina AT, Zhong F, Mirza UA, Padovan JC, Chait BT. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem. 1998;273:9987–9993. [PubMed]
630. Vulin AI, Stanley FM. Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. J Biol Chem. 2004;279:25172–25178. [PubMed]
631. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation. 1993;88:2030–2034. [PubMed]
632. Kaehler J, Koeke K, Karstens M, Schneppenheim R, Meinertz T, Heitzer T. Impaired capacity for acute endogenous fibrinolysis in smokers is restored by ascorbic acid. Free Radic Biol Med. 2008;44:315–321. [PubMed]
633. Kim JA, Tran ND, Berliner JA, Fisher MJ. Minimally oxidized low-density lipoprotein regulates hemostasis factors of brain capillary endothelial cells. J Neurol Sci. 2004;217:135–141. [PubMed]
634. Steffel J, Akhmedov A, Greutert H, Luscher TF, Tanner FC. Histamine induces tissue factor expression: implications for acute coronary syndromes. Circulation. 2005;112:341–349. [PubMed]
635. Napoleone E, Di Santo A, Lorenzet R. Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk. Blood. 1997;89:541–549. [PubMed]
636. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem. 2002;277:25032–25039. [PubMed]
637. Camera M, Giesen PL, Fallon J, Aufiero BM, Taubman M, Tremoli E, Nemerson Y. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19:531–537. [PubMed]
638. Drake TA, Hannani K, Fei HH, Lavi S, Berliner JA. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am J Pathol. 1991;138:601–607. [PubMed]
639. Schecter AD, Giesen PL, Taby O, Rosenfield CL, Rossikhina M, Fyfe BS, Kohtz DS, Fallon JT, Nemerson Y, Taubman MB. Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J Clin Invest. 1997;100:2276–2285. [PMC free article] [PubMed]
640. Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S, Llampayas O, Badimon L. Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation. 2004;110:452–459. [PubMed]
641. Taubman MB, Marmur JD, Rosenfield CL, Guha A, Nichtberger S, Nemerson Y. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. Role of Ca2+ mobilization and protein kinase C activation. J Clin Invest. 1993;91:547–552. [PMC free article] [PubMed]
642. Herkert O, Diebold I, Brandes RP, Hess J, Busse R, Gorlach A. NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells. Circulation. 2002;105:2030–2036. [PubMed]
643. Schonbeck U, Mach F, Sukhova GK, Herman M, Graber P, Kehry MR, Libby P. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol. 2000;156:7–14. [PubMed]
644. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396–399. [PubMed]
645. He M, He X, Xie Q, Chen F, He S. Angiotensin II induces the expression of tissue factor and its mechanism in human monocytes. Thromb Res. 2006;117:579–590. [PubMed]
646. Wada H, Kaneko T, Wakita Y, Minamikawa K, Nagaya S, Tamaki S, Deguchi K, Shirakawa S. Effect of lipoproteins on tissue factor activity and PAI-II antigen in human monocytes and macrophages. Int J Cardiol. 1994;47:S21–S25. [PubMed]
647. Scholz T, Temmler U, Krause S, Heptinstall S, Losche W. Transfer of tissue factor from platelets to monocytes: role of platelet-derived microvesicles and CD62P. Thromb Haemost. 2002;88:1033–1038. [PubMed]
648. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med. 2003;9:458–462. [PubMed]
649. Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. Tissue factor activity in whole blood. Blood. 2005;105:2764–2770. [PubMed]
650. Bochkov VN, Mechtcheriakova D, Lucerna M, Huber J, Malli R, Graier WF, Hofer E, Binder BR, Leitinger N. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. Blood. 2002;99:199–206. [PubMed]
651. Ohkura N, Hiraishi S, Itabe H, Hamuro T, Kamikubo Y, Takano T, Matsuda J, Horie S. Oxidized phospholipids in oxidized low-density lipoprotein reduce the activity of tissue factor pathway inhibitor through association with its carboxy-terminal region. Antioxid Redox Signal. 2004;6:705–712. [PubMed]
652. Bilgen D, Sonmez H, Ekmekci H, Ulutin T, Ozturk Z, Kokoglu E, Bayram C, Soner A, Domanic N. The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease. Clin Biochem. 2005;38:92–96. [PubMed]
653. Rehemtulla A, Ruf W, Edgington TS. The integrity of the cysteine 186-cysteine 209 bond of the second disulfide loop of tissue factor is required for binding of factor VII. J Biol Chem. 1991;266:10294–10299. [PubMed]
654. Ahamed J, Versteeg HH, Kerver M, Chen VM, Mueller BM, Hogg PJ, Ruf W. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci U S A. 2006;103:13932–13937. [PubMed]
655. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006;12:178–180. [PubMed]
656. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449–2460. [PMC free article] [PubMed]
657. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986;6:131–138. [PubMed]
658. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33–43. [PubMed]
659. Schulte S, Sukhova GK, Libby P. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am J Pathol. 2008;172:1500–1508. [PubMed]
660. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995;92:3893–3897. [PubMed]
661. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994;14:32–40. [PubMed]
662. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb. 1994;14:605–616. [PubMed]
663. Soltesz P, Veres K, Laczik R, Der H, Csipo I, Timar O, Szomjak E, Szegedi G, Szodoray P. Evaluation of antibodies to oxidized low-density lipoprotein and assessment of C-reactive protein in acute coronary syndrome and stable coronary artery disease. Thromb Haemost. 2007;98:413–419. [PubMed]
664. Resch U, Tatzber F, Budinsky A, Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol. 2006;61:262–274. [PMC free article] [PubMed]
665. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108:785–791. [PMC free article] [PubMed]
666. Brown MS, Goldstein JL. Atherosclerosis. Scavenging for receptors. Nature. 1990;343:508–509. [PubMed]
667. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:73–77. [PubMed]
668. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, Murase T, Sawamura T, Masaki T, Hashimoto N, Kita T. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation. 1999;99:3110–3117. [PubMed]
669. Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1996;93:14833–14838. [PubMed]
670. Minami M, Kume N, Shimaoka T, Kataoka H, Hayashida K, Akiyama Y, Nagata I, Ando K, Nobuyoshi M, Hanyuu M, Komeda M, Yonehara S, Kita T. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2001;21:1796–1800. [PubMed]
671. Nicoletti A, Caligiuri G, Tornberg I, Kodama T, Stemme S, Hansson GK. The macrophage scavenger receptor type A directs modified proteins to antigen presentation. Eur J Immunol. 1999;29:512–521. [PubMed]
672. Shaw PX, Goodyear CS, Chang MK, Witztum JL, Silverman GJ. The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neo-antigens and apoptotic cells. J Immunol. 2003;170:6151–6157. [PubMed]
673. Bergmark C, Dewan A, Orsoni A, Merki E, Miller ER, Shin MJ, Binder CJ, Horkko S, Krauss RM, Chapman MJ, Witztum JL, Tsimikas S. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49:2230–2239. [PubMed]
674. Ge J, Jia Q, Liang C, Luo Y, Huang D, Sun A, Wang K, Zou Y, Chen H. Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells. Arterioscler Thromb Vasc Biol. 2005;25:2157–2163. [PubMed]
675. Vasdev S, Gill VD, Singal PK. Modulation of oxidative stress-induced changes in hypertension and atherosclerosis by antioxidants. Exp Clin Cardol. 2006;11:206–216. [PMC free article] [PubMed]
676. Marini M, Frabetti F, Musiani D, Franceschi C. Oxygen radicals induce stress proteins and tolerance to oxidative stress in human lymphocytes. Int J Radiat Biol. 1996;70:337–350. [PubMed]
677. Xu Q, Dietrich H, Steiner HJ, Gown AM, Schoel B, Mikuz G, Kaufmann SH, Wick G. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb. 1992;12:789–799. [PubMed]
678. Xu Q, Luef G, Weimann S, Gupta RS, Wolf H, Wick G. Staining of endothelial cells and macrophages in atherosclerotic lesions with human heat-shock protein-reactive antisera. Arterioscler Thromb. 1993;13:1763–1769. [PubMed]
679. Cohen IR. A heat shock protein, molecular mimicry and autoimmunity. Isr J Med Sci. 1990;26:673–676. [PubMed]
680. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;16:27–33. [PubMed]
681. Shoenfeld Y, Harats D, George J. Heat shock protein 60/65, beta 2-glycoprotein I and oxidized LDL as players in murine atherosclerosis. J Autoimmun. 2000;15:199–202. [PubMed]
682. Azenabor AA, Muili K, Akoachere JF, Chaudhry A. Macrophage antioxidant enzymes regulate Chlamydia pneumoniae chronicity: evidence of the effect of redox balance on host-pathogen relationship. Immunobiology. 2006;211:325–339. [PubMed]
683. Ott SJ, El Mokhtari NE, Musfeldt M, Hellmig S, Freitag S, Rehman A, Kuhbacher T, Nikolaus S, Namsolleck P, Blaut M, Hampe J, Sahly H, Reinecke A, Haake N, Gunther R, Kruger D, Lins M, Herrmann G, Folsch UR, Simon R, Schreiber S. Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation. 2006;113:929–937. [PubMed]
684. Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, Tuckova L, Cukrowska B, Lodinova-Zadnikova R, Kozakova H, Rossmann P, Bartova J, Sokol D, Funda DP, Borovska D, Rehakova Z, Sinkora J, Hofman J, Drastich P, Kokesova A. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett. 2004;93:97–108. [PubMed]
685. Triantafilou M, Uddin A, Maher S, Charalambous N, Hamm TS, Alsumaiti A, Triantafilou K. Anthrax toxin evades Toll-like receptor recognition, whereas its cell wall components trigger activation via TLR2/6 heterodimers. Cell Microbiol. 2007;9:2880–2892. [PubMed]
686. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003;349:2316–2325. [PubMed]
687. Buttari B, Profumo E, Petrone L, Pietraforte D, Siracusano A, Margutti P, Delunardo F, Ortona E, Minetti M, Salvati B, Rigano R. Free hemoglobin: a dangerous signal for the immune system in patients with carotid atherosclerosis? Ann N Y Acad Sci. 2007;1107:42–50. [PubMed]
688. Salmen S, Corte D, Goncalves L, Barboza L, Montes H, Calderon A, Berrueta L. CD40/CD40L expression in leukocytes from chronic granulomatous disease patients. APMIS. 2007;115:939–947. [PubMed]
689. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998;394:200–203. [PubMed]
690. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A. 1997;94:1931–1936. [PubMed]
691. Griffiths HR. ROS as signalling molecules in T cells--evidence for abnormal redox signalling in the autoimmune disease, rheumatoid arthritis. Redox Rep. 2005;10:273–280. [PubMed]
692. Friedman MH, O'Brien V, Ehrlich LW. Calculations of pulsatile flow through a branch: implications for the hemodynamics of atherogenesis. Circ Res. 1975;36:277–285. [PubMed]
693. Karino T. Microscopic structure of disturbed flows in the arterial and venous systems, and its implication in the localization of vascular diseases. Int Angiol. 1986;5:297–313. [PubMed]
694. Giddens DP, Zarins CK, Glagov S. The role of fluid mechanics in the localization and detection of atherosclerosis. J Biomech Eng. 1993;115:588–594. [PubMed]
695. Stone PH, Coskun AU, Kinlay S, Clark ME, Sonka M, Wahle A, Ilegbusi OJ, Yeghiazarians Y, Popma JJ, Orav J, Kuntz RE, Feldman CL. Effect of endothelial shear stress on the progression of coronary artery disease, vascular remodeling, and in-stent restenosis in humans: in vivo 6-month follow-up study. Circulation. 2003;108:438–444. [PubMed]
696. Wentzel JJ, Corti R, Fayad ZA, Wisdom P, Macaluso F, Winkelman MO, Fuster V, Badimon JJ. Does shear stress modulate both plaque progression and regression in the thoracic aorta? Human study using serial magnetic resonance imaging. J Am Coll Cardiol. 2005;45:846–854. [PubMed]
697. Wentzel JJ, Kloet J, Andhyiswara I, Oomen JA, Schuurbiers JC, de Smet BJ, Post MJ, de Kleijn D, Pasterkamp G, Borst C, Slager CJ, Krams R. Shear-stress and wall-stress regulation of vascular remodeling after balloon angioplasty: effect of matrix metalloproteinase inhibition. Circulation. 2001;104:91–96. [PubMed]
698. Frangos JA, Eskin SG, McIntire LV, Ives CL. Flow effects on prostacyclin production by cultured human endothelial cells. Science. 1985;227:1477–1479. [PubMed]
699. Hwang J, Ing MH, Salazar A, Lassegue B, Griendling K, Navab M, Sevanian A, Hsiai TK. Pulsatile versus oscillatory shear stress regulates NADPH oxidase subunit expression: implication for native LDL oxidation. Circ Res. 2003;93:1225–1232. [PMC free article] [PubMed]
700. McNally JS, Davis ME, Giddens DP, Saha A, Hwang J, Dikalov S, Jo H, Harrison DG. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol Heart Circ Physiol. 2003;285:H2290–H2297. [PubMed]
701. Qiu Y, Tarbell JM. Interaction between wall shear stress and circumferential strain affects endothelial cell biochemical production. J Vasc Res. 2000;37:147–157. [PubMed]
702. Corson MA, James NL, Latta SE, Nerem RM, Berk BC, Harrison DG. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ Res. 1996;79:984–991. [PubMed]
703. Boo YC, Jo H. Flow-dependent regulation of endothelial nitric oxide synthase: role of protein kinases. Am J Physiol Cell Physiol. 2003;285:C499–C508. [PubMed]
704. Boo YC, Sorescu G, Boyd N, Shiojima I, Walsh K, Du J, Jo H. Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Ser1179 by Akt-independent mechanisms: role of protein kinase A. J Biol Chem. 2002;277:3388–3396. [PubMed]
705. Nishida K, Harrison DG, Navas JP, Fisher AA, Dockery SP, Uematsu M, Nerem RM, Alexander RW, Murphy TJ. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest. 1992;90:2092–2096. [PMC free article] [PubMed]
706. Uematsu M, Ohara Y, Navas JP, Nishida K, Murphy TJ, Alexander RW, Nerem RM, Harrison DG. Regulation of endothelial cell nitric oxide synthase mRNA expression by shear stress. Am J Physiol. 1995;269:C1371–C1378. [PubMed]
707. Liu Y, Zhao H, Li H, Kalyanaraman B, Nicolosi AC, Gutterman DD. Mitochondrial sources of H2O2 generation play a key role in flow-mediated dilation in human coronary resistance arteries. Circ Res. 2003;93:573–580. [PubMed]
708. Castier Y, Brandes RP, Leseche G, Tedgui A, Lehoux S. p47phox-dependent NADPH oxidase regulates flow-induced vascular remodeling. Circ Res. 2005;97:533–540. [PubMed]
709. Mowbray AL, Kang DH, Rhee SG, Kang SW, Jo H. Laminar shear stress up-regulates peroxiredoxins (PRX) in endothelial cells: PRX 1 as a mechanosensitive antioxidant. J Biol Chem. 2008;283:1622–1627. [PubMed]
710. Chatzizisis YS, Jonas M, Coskun AU, Beigel R, Stone BV, Maynard C, Gerrity RG, Daley W, Rogers C, Edelman ER, Feldman CL, Stone PH. Prediction of the localization of high-risk coronary atherosclerotic plaques on the basis of low endothelial shear stress: an intravascular ultrasound and histopathology natural history study. Circulation. 2008;117:993–1002. [PubMed]
711. Woodman CR, Muller JM, Rush JW, Laughlin MH, Price EM. Flow regulation of ecNOS and Cu/Zn SOD mRNA expression in porcine coronary arterioles. Am J Physiol. 1999;276:H1058–H1063. [PubMed]
712. Topper JN, Cai J, Falb D, Gimbrone MA., Jr Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A. 1996;93:10417–10422. [PubMed]
713. Mueller CF, Widder JD, McNally JS, McCann L, Jones DP, Harrison DG. The role of the multidrug resistance protein-1 in modulation of endothelial cell oxidative stress. Circ Res. 2005;97:637–644. [PubMed]
714. Takeshita S, Inoue N, Ueyama T, Kawashima S, Yokoyama M. Shear stress enhances glutathione peroxidase expression in endothelial cells. Biochem Biophys Res Commun. 2000;273:66–71. [PubMed]
715. Hosoya T, Maruyama A, Kang MI, Kawatani Y, Shibata T, Uchida K, Warabi E, Noguchi N, Itoh K, Yamamoto M. Differential responses of the Nrf2-Keap1 system to laminar and oscillatory shear stresses in endothelial cells. J Biol Chem. 2005;280:27244–27250. [PubMed]
716. Chen XL, Varner SE, Rao AS, Grey JY, Thomas S, Cook CK, Wasserman MA, Medford RM, Jaiswal AK, Kunsch C. Laminar flow induction of antioxidant response element-mediated genes in endothelial cells. A novel anti-inflammatory mechanism. J Biol Chem. 2003;278:703–711. [PubMed]
717. Gijsen FJ, Wentzel JJ, Thury A, Mastik F, Schaar JA, Schuurbiers JC, Slager CJ, van der Giessen WJ, de Feyter PJ, van der Steen AF, Serruys PW. Strain distribution over plaques in human coronary arteries relates to shear stress. Am J Physiol Heart Circ Physiol. 2008 [PubMed]
718. Won D, Zhu SN, Chen M, Teichert AM, Fish JE, Matouk CC, Bonert M, Ojha M, Marsden PA, Cybulsky MI. Relative reduction of endothelial nitric-oxide synthase expression and transcription in atherosclerosis-prone regions of the mouse aorta and in an in vitro model of disturbed flow. Am J Pathol. 2007;171:1691–1704. [PubMed]
719. Hsiai TK, Hwang J, Barr ML, Correa A, Hamilton R, Alavi M, Rouhanizadeh M, Cadenas E, Hazen SL. Hemodynamics influences vascular peroxynitrite formation: Implication for low-density lipoprotein apo-B-100 nitration. Free Radic Biol Med. 2007;42:519–529. [PMC free article] [PubMed]
720. Gambillara V, Chambaz C, Montorzi G, Roy S, Stergiopulos N, Silacci P. Plaque-prone hemodynamics impair endothelial function in pig carotid arteries. Am J Physiol Heart Circ Physiol. 2006;290:H2320–H2328. [PubMed]
721. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 2007;49:2379–2393. [PubMed]
722. Kwon GP, Schroeder JL, Amar MJ, Remaley AT, Balaban RS. Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. Circulation. 2008;117:2919–2927. [PMC free article] [PubMed]